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ABSTRACT 
 Alpha-synuclein (AS) is a natively unfolded protein whose structure is extremely sensitive to 
its environment. The hallmark of Parkinson’s disease (PD) is aggregation and deposition of AS 
in inclusion bodies. Formation of misfolded AS monomers which are partially folded is the first 
and critical stage in fibrillation of AS and is a good target for designing therapeutic strategies. 
Characterization the biochemical properties of partially folded intermediates induced by 
fibrillization and anti- fibrillization agents will help to design drugs as new inhibitors of AS 
misfolding and aggregation. Nanopore analysis is an emerging technique for studying the 
molecular mechanism of protein misfolding. This technique was used to characterize the 
conformational change of AS in the presence of two groups of chemicals; anti-parkinsonian 
small molecules (dopamine and nicotine) and Parkinson’s developing toxin (Cu(II) and 
methamphetamine). Other biophysical techniques such as NMR spectroscopy and isothermal 
titration calorimetry (ITC) were able to confirm the nanopore analysis results and also to study 
other biophysical properties of the partially folded intermediates such as the binding constant of 
the interaction and the secondary structure content. The results from nanopore analysis showed 
that both groups of ligands shifted the blockade current peak of AS (centered at -86 pA) to lower 
blockade currents but in a different manner.  Anti-parkinsonian drugs shifted the blockade 
current of AS to intermediate peaks between -40 to -80 pA but Parkinson developing toxins 
shifted the peak to a lower blockade current centered at -25 pA which suggests a more compact 
conformation. Thus nanopore analysis distinguished the different conformation induced by 
different ligands. Furthermore nanopore analysis with AS fragments showed that these ligands 
bind to different regions of AS. NMR spectroscopy of AS in the presence of dopamine and 
nicotine isomers was in agreement with the nanopore analysis and showed conformational 
changes of AS in a concentration dependent manner. CD spectroscopy results showed that the 
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secondary structure of AS alone and in the presence of ligands was mostly random coil and 
suggests a loop formation model for the interaction of ligands with AS. The results of this thesis 
showed the application of nanopore analysis as a real-time and label-free technique to screen a 
library of ligands for designing misfolding inhibitors for PD treatment. The result of a synergic 
experiment with nicotine and caffeine showed that combination of these anti-parkinsonian small 
molecules would be a promising new drug for treatment of PD.   
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 1 
1 Introduction and Literature Review 
1.1 Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disease that permanently impairs 
movement, with a prevalence of approximately 2% after the age of 65 (Leonard, 2002; Pahwa 
and Lyons, 2007). The characteristic property of PD is the aggregation and deposition of α-
synuclein (AS) in inclusion bodies (Dauer and Przedborski, 2003; Henchcliffe and Beal, 2008; 
Lotharius and Brundin, 2002b; Moore et al., 2005; Ottolini et al., 2013). Aggregated AS 
undergoes degradation by the ubiquitin-proteasome system (UPS) to protect cells from the 
deleterious toxicity of these aggregates. Two of the UPS components are Parkin and Ubiquitin 
carboxyl-terminal hydrolase L1 (UCH-L1) which are important in maintaining the protective 
function of this system against aggregated proteins (Dauer and Przedborski, 2003; Moore et al., 
2005). Loss of function mutations in Parkin and UCH-L1 genes can also cause PD because of the 
accumulation of AS aggregates in dopaminergic neurons (Dauer and Przedborski, 2003; Ottolini 
et al., 2013). This accumulation finally leads to the death of dopaminergic neurons and dopamine 
depletion due to an increase in reactive oxygen species (ROS) production, mitochondrial 
impairment and the unfolded protein response (UPR) in the Endoplasmic Reticulum (ER) 
(Cooper et al., 2006; Franssens et al., 2010; Gorbatyuk et al., 2012). Moreover, misfolding and 
aggregation of AS leads to the loss of function of this unfolded protein which has an important 
role in dopamine homeostasis and metabolism (Kanaan and Manfredsson, 2012; Lashuel et al., 
2013). Aggregates of AS are able to propagate and transfer the PD pathogenicity from cell to cell 
in a prion-like manner (Angot et al., 2012; Braak et al., 2003; Danzer et al., 2012; Masuda-
Suzukake et al., 2013). Thus AS aggregation is a key step in the development of PD pathology 
and highlights the importance of preventing the aggregation process as a therapeutic strategy for 
PD treatment.  The critical stage of AS aggregation is the conformational changes of intrinsically 
disordered AS monomers to form partially folded intermediates (Fink, 2006; Uversky and 
Eliezer, 2009; Uversky et al., 2001a; Uversky et al., 2001c). It is known that there are 
aggregation promoter and inhibitor agents which interact with AS monomers and favor the 
conversion into a partially folded intermediate. The partially folded conformations induced by 
anti-fibrillogenic and fibrillogenic agents are thought to be different due to the many possible 
modes of interaction with the intrinsically disordered protein (Fink, 2006; Uversky et al., 2001b). 
Understanding the initial stages of AS aggregation, is therefore important for designing 
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inhibitors as new therapeutics to prevent the pathogenic process (Trexler and Rhoades, 2010b). 
The focus of this thesis is the use of nanopore analysis and other biophysical methods to study 
the folding of AS and its interaction with small molecules. One promising approach in order to 
develop therapeutics for treatment of PD is to inhibit AS misfolding and aggregation with small 
molecules identified using high-throughput screening (May et al., 2006; Rochet, 2007).  NMR 
spectroscopy (Lendel et al., 2009; Rao et al., 2008) and single molecule biophysics techniques 
such as nanopore analysis have been successfully used to characterize the partially folded 
intermediate or misfolded conformation of AS in the presence of different types of small 
molecules (Asandei et al., 2013; Wang et al., 2011a; Wang et al., 2013).  
1.2 Nanopore analysis 
Nanopores are nm sized openings that ions and macromolecules can pass through. There are 
two types of these nano-scale pores; the biological protein pores and synthetic solid state pores.  
The biological pores are naturally occurring protein complexes such as alpha-hemolysin (αHL) 
toxin from Staphylococcus aureus that interact with lipid bilayers to form a transmembrane pore. 
Synthetic pores are fabricated in solid-state membranes (Iqbal and Bashir, 2011; Ma and 
Cockroft, 2010; Wang et al., 2010a).  
For the first time in 1996, Kasianowicz et al. recruited a biological protein pore as a sensitive 
biosensor to probe individual single stranded DNA and RNA. In this study αHL was  inserted 
into a lipid bilayer which was painted on a 0.1-mm-diameter hole in a 25-mm thick Teflon 
partition separating two compartments filled with 1 M KCl, 5mM HEPES buffer (pH 7.5) 
(Kasianowicz et al., 1996). Each compartment contained an electrode connected to a patch clamp 
amplifier. Upon applying a voltage across the membrane, ions transport through the pore and 
create a stable current (I) (Figure 1.1a). They found that by adding single stranded DNA into the 
compartment with the cathode electrode, the DNA molecules could translocate through the pore 
electrophoretically and cause blockade of the transient ionic current (I) for a certain duration of 
time (T) (Figure 1.1b) (Kasianowicz et al., 1996; Ma and Cockroft, 2010).  
This was the beginning of nanopore-based single molecule spectroscopy for real-time probing 
of macromolecular behavior. Since then, this technique has been used to study conformational 
changes and molecular interactions of biological macromolecules and also has become a 
candidate for developing the next generation sequencing devices (Branton et al., 2008; Carlsen et 
al., 2014; Clarke et al., 2009; Derrington et al., 2010; Ku and Roukos, 2013; Maitra et al., 2012; 
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Scheicher et al., 2012).  As shown by Madampage et al. nanopore analysis can also be used to 
study protein conformation (Madampage et al., 2012). Many serious human diseases have been 
linked to protein misfolding and aggregation (Dawson and Dawson, 2003; Jaikaran and Clark, 
2001; Lotharius and Brundin, 2002b; Prusiner, 2001; Selkoe, 2004; Watanabe et al., 2001). 
Nanopore analysis is an emerging technique for studying the conformational changes of 
misfolded proteins and designing small molecules to prevent their misfolding and aggregation 
(see later) (Madampage et al., 2012; Wang et al., 2013; Wang et al., 2011a). 
 
Figure 1.1 Schematic representation of the first nanopore based detection of single stranded 
DNA translocation through the αHL pore. (A) Shows the free channel state which is the 
experimental set up before adding DNA. A voltage is applied across the membrane which creates 
the transmembrane ionic current. (B) Translocation of individual DNA molecules interrupts the 
transient ionic current and causes blockades of this current which is represented by a drop in 
current (I) for a duration of time (T). Reprinted with permission from (Ma and Cockroft, 2010). 
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. All rights reserved. 
1.2.1 Principles of nanopore analysis 
1.2.1.1 Alpha-hemolysin as a model nanopore 
Alpha-hemolysin is a toxin secreted by Staphylococcus aureus as a water soluble monomer. 
Each monomer has molecular weight of 33 kDa and is composed of 293 amino acids. The 
toxicity of αHL is due to its ability to bind and form transmembrane pores in mammalian cells 
such as erythrocytes and lymphocytes which finally leads to cell lysis and death (Berube and 
Bubeck Wardenburg, 2013; Ma and Cockroft, 2010; Menestrina et al., 2001). To form a channel, 
seven monomers assemble in the phospholipid bilayer and form a mushroom-shaped 
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transmembrane pore (Ma and Cockroft, 2010). The crystal structure of heptameric αHL has been 
determined to 1.89 Å (Song et al., 1996) and 2.30 Å (Tanaka et al., 2011). Figure 1.2 shows the 
cross-sectional model of the channel. The channel diameter is not constant and changes along the 
length. The diameter of the cap opening is 2.6 Å which leads into an inner vestibule with the 
widest diameter of 3.6 nm. The vestibule narrows into a 1.5 nm limiting aperture which connects 
the vestibule to the transmembrane stem with an internal diameter of 2.2 nm. The stem consists 
of 14 antiparallel strands (DeGuzman et al., 2006; Ma and Cockroft, 2010).  
 
Figure 1.2 Cross-sectional model of the alpha-hemolysin channel demonstrating the dimensions 
of the channel of pore. Reprinted with permission from (DeGuzman et al., 2006). Copyright © 
2006 Oxford University Press. All rights reserved. 
The biophysical features of the αHL pore make it ideal for nanopore analysis. Monomers of 
this toxin self-assemble and insert into the lipid bilayer to form the heptamer channel 
spontaneously. The lumen of the channel is hydrophilic which facilitates the transport of ions 
and biological molecules between separated compartments. Furthermore, this pore has thermal 
stability up to 100°C and a wide range of pH tolerance from 2 to 12 (DeGuzman et al., 2006; Ma 
and Cockroft, 2010; Song et al., 1996). It also has stability against urea denaturation and the 
heptamer complex inserted into the lipid bilayer can resist up to 7.8 M urea (Pastoriza-Gallego et 
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al., 2007). It also has a low-noise characteristic and has been used for probing different types of 
macromolecules such as proteins, nucleic acids and carbohydrates but its size limitation (1.5 nm) 
makes it suitable for single stranded nucleic acids and unfolded peptides (Kasianowicz et al., 
2008; Madampage et al., 2012; Mulero et al., 2010; Venkatesan and Bashir, 2011; Wanunu et al., 
2011).  
The interaction of macromolecules with the αHL pore can be categorized into three different 
events (Figure 1.3). Events with the smallest blockade current represent bumping events which 
show the interaction of large or compact macromolecule with the outside of the pore. This 
interaction blocks the ionic flow for a short time (Figure 1.3c). Translocation events occur with 
the highest blockade current and are due to translocation of macromolecules through the pore 
(Figure 1.3a). The third type of events is intercalation which has an intermediate blockade 
current. It is proposed that these events occur when a part of a macromolecule (a loop or a 
domain) enters the vestibule of the pore and is stuck there before diffusing away (Figure 1.3b). 
It’s difficult to distinguish intercalation and translocation events (Meng et al., 2010a). The 
blockade current distribution can be fitted with a Gaussian function to obtain event populations 
in a graph which represents the number of events versus the blockade currents (pA) (Christensen 
et al., 2011; Krasniqi and Lee, 2012; Krasniqi and Lee, 2014; Madampage et al., 2010; Meng et 
al., 2010a; Stefureac et al., 2008; Stefureac and Lee, 2008; Stefureac et al., 2010).  
 
Figure 1.3 Schematic representation of possible interaction of macromolecules with αHL (top) 
and also the corresponding event profiles (bottom). Idea adapted from (Meng et al., 2010a). 
Copyright © 2010 European Peptide Society and John Wiley & Sons, Ltd. All rights reserved. 
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1.2.1.2 Nanopores as biochemical sensors 
In nanopore analysis the parameters, I and T are exquisitely sensitive to the conformation of 
the protein at the moment it interacts with the pore (Christensen et al., 2011). Therefore, it can be 
used as a biosensor to detect conformational changes induced by binding of ligands to the 
individual molecules. Nanopore analysis is a real-time, label-free and sensitive technique which 
requires very low concentrations of ligand and target molecules (Larkin et al., 2013). These 
features make it more efficient than other analytical chemistry techniques especially for studying 
misfolded proteins and short nucleic acids such as aptamers (Arnaut et al.; Madampage et al., 
2012; Wang et al., 2013; Wang et al., 2011a; Ying et al., 2011). 
1.2.1.2.1 Nanopore sensing of peptides and peptide-metal interactions 
The ability of nanopore analysis to detect conformational changes of peptides upon binding to 
a ligand has been used to study the interaction of metal ions with peptides. Under an applied 
voltage each peptide has unique event parameters of blockade current (I) or time (T). Binding of 
a metal ion may cause a conformational change which alters the event parameters (Brucale et al., 
2014; Stefureac and Lee, 2008; Stefureac et al., 2010). The ability of nanopore analysis to detect 
conformational changes of biomacromolecules by monitoring the event parameters has been 
used to study the interaction of metal ions and peptides. For example, nanopore analysis was 
used to detect the folding of a zinc-finger molecule (Zif268) which has 28 amino acids. The 
blockade current histogram of this motif was changed in the presence of Zn(II) with an increase 
in the magnitude of the bumping peak and a simultaneous decrease in the proportion of 
translocation events.  This demonstrated the compaction and folding of this peptide upon adding 
Zn(II) which was not observed with Mg(II) (Stefureac and Lee, 2008). In another study (Mereuta 
et al., 2012), the α-HL pore has been used to investigate the conformational changes of an 
antimicrobial-derived chimera peptide (CAMA) of 20 amino acids which has a His residue as 
part of the Cu(II) binding site. Cu(II) alters the event parameters (I and T) of this peptide. The 
results of nanopore analysis demonstrated an increase in the number of bumping events with 
short blockade current in the presence of various concentrations of copper (II) (Mereuta et al., 
2012). These researchers showed that nanopore analysis can be used as a biosensor to study the 
interaction of metal ions with other peptides such as misfolded proteins (Brucale et al., 2014). 
Most of the misfolded proteins which are important in the pathology of neurodegenerative 
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disease are metal binding peptides. Thus nanopore analysis has the ability to study the 
conformation of these peptides in the presence of metals (Brucale et al., 2014; Lee, 2014). As 
these peptides are unfolded, they can translocate through the pore and result in a large blockade 
current.  Binding of metal ions to these peptides changes their conformations and causes local or 
overall folding and compaction of their structure. The interaction of a more compact 
conformation with the pore results in blockade currents which are shorter than the blockade 
current of the natively unfolded conformation (Baran et al., 2010; Lee, 2014; Madampage et al., 
2012; Stefureac et al., 2010). An example of a misfolding protein is the β-amyloid (Aβ) peptide. 
Interaction of Cu(II) with human and rat amyloid fragments Aβ (1−16) was investigated using 
nanopore analysis. Addition of various concentrations of Cu(II) causes a reduction in the number 
of events with long blockage and a simultaneous increase in the number of events with short 
blockage. The results showed that Cu(II) causes folding and compaction of this peptide (Asandei 
et al., 2013). The prion protein is another example of a misfolded protein which has been studied 
with nanopore analysis. The prion protein has 220 residues and is found in most tissues including 
the brain. Prion proteins are metal binding proteins and it has been shown that metal ions change 
the conformation of this protein by inducing the formation of a local β-sheet conformer. The 
main metal binding region of the prion protein is four tandem repeats of an octapeptide sequence 
(Octa) in the N-terminal of the protein which can bind 4-5 Cu(II) ions with Kd in the range of 
nano to micro molar. Nanopore analysis using α-HL was used to investigate the effect of Cu(II), 
Zn(II), Mg(II) and Mn(II) on a prion peptide with two tandem repeats of the Octa region (Octa2). 
The authors found that Cu(II) and Zn(II) change the event parameters of this peptide but no 
changes were observed with Mg(II) and Mn(II).  Octa2 which is a very short peptide translocates 
through the pore and a single translocation peak with high blockade current centered at -67 pA 
was found. In the presence of Cu(II), the translocation peak shifted to -77 pA and a bumping 
peak was found at -24 pA. In addition, the translocation time was increased from 0.16 ms to 0.46 
ms. Thus, Cu(II) binds to the peptide and causes conformational changes. The effect of Zn(II) on 
the Octa2 structure was less than the effect of Cu(II). Zn(II), at a concentration of 320 μM, 
shifted the translocation peak to -72 pA and made it broaden. A small bumping peak is also 
found in the presence of Zn(II). So the interaction of Zn(II) with Octa2 is weaker than Cu(II) 
(Stefureac et al., 2010). This technique also has been used to study the interaction of Cu(II) and 
Zn(II) with Myelin basic protein (MBP). Blockade current histogram of this intrinsically 
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disordered protein shows a single translocation peak centered at -65 pA. Upon addition of Cu(II) 
or Zn(II) to the experiment the proportion of translocation events decreased and a new peak 
formed at around -25 pA which represents the more compact conformation of MBP bound to the 
metal ions (Baran et al., 2010; Lee, 2014). These studies together showed the sensitivity of 
nanopore analysis to detect subtle conformational changes of misfolded peptides in the presence 
of metal ions and also the potential application to other misfolded peptides such as AS (Lee, 
2014). Since metal ions bind proteins and are able to change their conformation even at very low 
concentrations, it is important to consider any sort of metal contamination in characterizing the 
structure and function of proteins in in vitro experiments. For example Krasniqi et al. 
demonstrated that adding of EDTA as a metal chelator to the nanopore cup containing maltose 
binding protein in HEPES buffer has a large impact on the blockade current histogram of this 
protein. Without EDTA this protein mostly adopted a compact conformation as a bumping peak 
(-25 pA) and also a broader peak with blockade currents higher than -40 pA. In the presence of 
EDTA the proportion of the intermediate peak increased. This peak represents the conformation 
of this protein in the absence of metal contamination. Control experiments with EDTA can be 
helpful to detect any conformational change due to metal contaminations (Krasniqi and Lee, 
2012; Lee, 2014).    
1.2.1.2.2 Nanopore sensing of macromolecule-ligand interactions 
The study of the interaction between biological macromolecules and small molecules is 
important for drug screening and development. Nanopore analysis has been utilized as a high-
throughput tool to investigate the interaction of small molecules and bio-macromolecules such as 
proteins and nucleic acids (Wang et al., 2013; Wang et al., 2011a).  
As a proof of concept, the interaction of A53T-AS with trehalose (Wang et al., 2013) was 
studied using natural nanopore analysis. In this study a voltage of 100 mV was applied and two 
baselines were considered to record the current blockades; the open pore current level (at 100 
pA) as the primary baseline and a secondary baseline which shows the capture of monomers into 
the vestibule of α-HL. They showed that the interaction of AS molecules with the pore is a two 
step process and causes two drops from the first baseline, i.e. the open pore current level. They 
showed that the first drop of current from the primary baseline (Lo) to the secondary baseline 
(Lc) is due to the capture of AS monomers into the vestibule of the pore followed by a second 
drop from Lc to a lower level (Lb). For AS-wild type the total drop was about 85 pA consisting of 
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80 pA for capture events from Lo to Lc and a 5 pA drop from Lc to Lb due to translocation. For 
A53T the total drop from primary baseline is smaller than that of AS-wild type because of a 
reduction in the blockade current of the capture events (Lo-Lc). They showed that trehalose 
causes a significant reduction in the transient blockade events between Lo and Lb. This study 
showed that nanopore analysis detects the conformational changes of AS monomers upon 
binding to a small molecule (Wang et al., 2013).  
This technique also has been used to study the opposite effects of β-cyclodextrin (β-CD) and 
Congo Red (CR) in the aggregation transition of β-amyloid-42 (Aβ42). β-CD and CR are 
aggregation promoter and inhibitor agents, respectively, and their effects on Aβ42 misfolding 
and aggregation has been detected by monitoring the corresponding blockade current and time.  
The blockade current histogram for Aβ42 showed two peaks concentrated at 21.5 pA and 96.25 
pA. In the presence of CR the peak centered at 96.25 pA dramatically decreases and there is an 
increase in the events with the characteristic current concentrated at 29 pA and also 
corresponding long duration times were observed. This profile showed that CR reduces 
formation of the misfolded or compact conformation of Aβ42. In the presence of β-CD a 
significant peak at 23.25 pA was detected which was different from free Aβ42 and Aβ42-CR 
complex (Wang et al., 2011a). 
Nanopores have also been used to study the interaction of small molecules and nucleic acids 
(Arnaut et al.; Larkin et al., 2013; Wanunu et al., 2011; Ying et al., 2011). Most of the nanopore 
experiments in this field are carried out using nucleic acid aptamers. Aptamers are synthetic 
single-stranded fragments of DNA or RNA, usually 20-80 nt long, with very high affinity for 
their targets (Banerjee and Nilsen-Hamilton, 2013; Iliuk et al., 2011; Radom et al., 2013). 
Nanopore analysis has been used as a real-time electrochemical sensor to probe the interaction of 
aptamers with AMP, ADP, ATP (Arnaut et al.; Ying et al., 2011), thrombin (Arnaut et al.) and 
cocaine (Kawano et al., 2011). Ying et al. investigated the interaction of a 33-mer ATP-binding 
DNA aptamer using the αHL nanopore. The aptamer had a folded conformation and was not able 
to translocate completely through the pore, suggesting that aptamers sit in the vestibule without 
transiting the pore. That is why the majority of the events (95%) have lower blockage current (46 
pA). To keep the aptamer unfolded a 10-mer reporter sequence was pre-hybridized to the 
aptamer before adding to the cis side and then ATP was added to the cis compartment. The 
duplex of aptamer/reporter resulted in a translocation peak of lower blockade current, 
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concentrated at 30.35 pA, with a shorter duration time relative to the folded aptamer. Adding 
ATP at equimolar amounts of 0.15 nmol aptamer and 0.15 nmol reporter changes the blockade 
current profile. The authors showed that adding ATP to the duplex of aptamer/reporter causes the 
release of reporter from aptamer and formation of an ATP/aptamer complex which has a 
different conformation (Ying et al., 2011). In another study a modified aptamer was designed to 
detect the interaction of aptamer and ATP. In this study aptamer and ATP were added to cis and 
trans compartments respectively. The general structure of the modified sequence was composed 
of 5ʹ-stopper-spacer-aptamer-thread-3ʹ. A +120 mV voltage was applied which forces the 
aptamer to denature and pass through the pore. A stable hairpin sequence at the 5ʹ end prevented 
complete translocation of the sequence from cis side into the trans side. After detecting a capture 
event by observing a drop in current, the captured sequence was kept inside the pore by reducing 
the applied voltage to +50 mV. Afterward a reverse voltage of -200 mV was applied to force the 
aptamer to denature and re-enter the cis compartment. Upon reversing and increasing the applied 
voltage, the observed rise of current was recorded as the unfolding voltage which represents the 
unfolding and escaping of aptamer from trans side to the cis side. These unfolding voltages have 
been used to calculate the binding constant of ATP. This experiment also has been done for other 
aptamer targets (ADP and AMP) and the results showed that the affinity of aptamer for AMP and 
ADP is more than ATP (Arnaut et al.). Furthermore, Kawano et al. used a cocaine binding 
aptamer for selective detection of cocaine. Rapid and real time detection of recreational drugs 
such as cocaine is important. The sensitivity of this detection was 300 ng/mL in a very short time 
(60 seconds). They designed an ssDNA aptamer with a long tail which facilitated the oligo to 
easily pass through the αHL pore when a 100 mV voltage was applied. In the presence of 
cocaine, the complex of cocaine/aptamer was not able to pass through the pore and was captured 
on the cis side of the pore. This capture results in a drop of current which has been recorded as 
the captured blockade current. The results showed that the cocaine concentration is dependent on 
the captured-interval time which means that the time was increased as the cocaine concentration 
decreased (Kawano et al., 2011).  
1.3 Parkinson’s Disease 
Parkinson disease (PD) is a chronic, progressive neurodegenerative disease. James Parkinson 
described PD as tremor, gait disorder, and bradykinesia for the first time in 1817 (Grosset et al., 
2009; Leonard, 2002; Shulman et al., 2011). This observation was based on six cases. PD is the 
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second most common neurodegenerative disorder with a prevalence of about 1% at age 65. The 
incidence and prevalence of PD are age dependent and increase with age. The onset of symptoms 
is approximately 60 years on average and almost 2% of people over 65 years have PD (Leonard, 
2002; Pahwa and Lyons, 2007). There is an extensive destruction of dopaminergic neurons in the 
substantia nigra (SN). The SN is a small area of cells in the midbrain (Uversky, 2007; Uversky 
and Eliezer, 2009). Defects in energy metabolism, especially a significant reduction in the 
function of complex I of the mitochondrial electron transport chain, is detected in patients with 
PD (Seth and Seth, 2009). Gradual degeneration of the SN causes a reduction in the dopamine 
content (Amer et al., 2006; Uversky, 2007; Uversky and Eliezer, 2009). For extrapyramidal 
motor activity a balance between the excitatory cholinergic and the inhibitory dopaminergic 
components is essential. In PD the degradation of dopaminergic neurons in the SN causes the 
cholinergic component to become dominant.  This imbalance between the two components 
causes movement difficulty in PD (Seth and Seth, 2009). Resting tremor, generalized slowness 
of movement or difficulty initiating movement, stiffness of limbs and balance problems are all 
obvious clinical characteristics of PD (Amer et al., 2006; Uversky and Eliezer, 2009). The 
hallmark of PD is the degeneration of dopaminergic neurons in the SN which leads to the 
depigmentation of this area and the presence of Lewy bodies which are cytoplasmic inclusions of 
aggregated AS (Grosset et al., 2009; Shulman et al., 2011). 
1.3.1 Cell biology of Parkinson’s disease 
PD is a multifactorial neurodegenerative disease which finally leads to the death of 
dopaminergic neurons. Endoplasmic reticulum (ER) stress and mitochondrial dysfunction are the 
main cellular mechanisms that cause the development of PD (Calì et al., 2011). Mitochondria 
have a central role in development of PD and many of the PD genetic factors (see below) are 
involved in the maintenance of mitochondrial integrity. Impairment of mitochondria-related 
metabolic pathways such as the respiratory pathway, fusion and fission are associated with 
Parkinson’s disease pathology (Calì et al., 2011; Exner et al., 2012).  
1.3.1.1 Role of ER stress in Parkinson’s disease 
The activation of endoplasmic reticulum (ER) stress due to accumulation of unfolded proteins 
in the ER lumen is a cellular process which is linked to PD.  The ER is involved in synthesis, 
folding and targeting of secretory proteins in eukaryotic cells. Folding of synthesized proteins 
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into their functional conformation, post-translational modifications and disulfide bond formation 
are the main biochemical roles of the ER in the secretory protein pathway. Secretory proteins 
also undergo a quality-control process in the ER which allows the exportation of correctly folded 
proteins to the Golgi complex whereas proteins with uncompleted folding status either undergo 
another folding process to assure their native conformation or enter the degradation pathway. 
Conditions that alter the ER control system on protein folding leads to ER stress and the 
protective response to overcome this stress is called the unfolded protein response (UPR) 
(Schröder and Kaufman, 2005).  
Under conditions which lead to ER stress, UPR is activated to allow cell survival by 
inhibition of protein translation and recovery of the normal protein folding process but in the 
case of extreme stress it results in cell death through apoptosis (Doyle et al., 2011; Ferri and 
Kroemer, 2001). There are three transmembrane proteins which initiate the major protecting 
pathways in the response of ER stress. These proteins are inositol requiring enzyme 1(IRE1), 
PKR-like endoplasmic reticulum kinase (PERK) and activating transcription factor 6 (ATF6). In 
unstressed cells these proteins are associated with Binding immunoglobulin protein (BiP) also 
known as glucose-regulated protein 78 (GRP78). Upon initiation of ER stress, interaction of 
unfolded proteins with GRP78 leads to its dissociation from PERK, IRE1 and ATF6. This 
dissociation activates these proteins to initiate signalling pathways to relieve the stress and 
protect cells against the harmful effects of ER stress by inhibiting protein translation, increase of 
degradation of malfunction proteins, and up-regulation of chaperone expression (Doyle et al., 
2011).  
In the event of prolonged or unmitigated ER stress, the ER-UPR triggers apoptosis through 
the PERK, ATF6 and IRE1 signaling pathways.  PERK and ATF6 branches of UPR promote 
apoptosis through activation of CCAAT/-enhancer-binding protein homologous protein (CHOP) 
which alters the balance between pro-apoptotic and antiapoptotic BCL-2 family members and 
transits the protective UPR to an apoptotic response. (Bernales et al., 2012; Doyle et al., 2011; 
Mercado et al., 2013; Schonthal, 2012).  
The apoptosis pathway through the IRE1 branch of UPR initiates after activation of tumor-
necrosis- factor-receptor-(TNFR-) associated factor 2 (TRAF2) by IRE1 which finally activates 
the pro-apoptic members of Bcl-2 and inhibits the anti-apoptic members of this protein family 
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and stimulates the apoptosis response (Bernales et al., 2012; Doyle et al., 2011; Schonthal, 
2012).  
The ER has a critical role in the folding of synthetic secretory proteins and any disruption of 
this function leads to accumulation of misfolded proteins and induction of UPR. Misfolded 
proteins and their aggregation are associated with the pathology of neurodegenerative disease 
such as PD. Accumulation of misfolded proteins activates UPR which facilitates normal folding 
by increasing the expression of chaperones. Furthermore, the misfolded proteins undergo 
degradation by the Endoplasmic-reticulum-associated protein degradation (ERAD) system, a 
process which involves retro-translocation of unfolded proteins from the ER lumen to the cytosol 
to be degraded by the polyubiquitination system, which is also activated during UPR (Doyle et 
al., 2011). Up-regulation of some of the signaling proteins involving in UPR such as Grp78, 
XBP1, CHOP, and ATF4  have been reported in the brain of AS transgenic mice (Bellucci et al., 
2011; Colla et al., 2012a; Colla et al., 2012b; Mercado et al., 2013). Smith et al. have shown that 
expressing of the A53T mutant of AS which is prone to adopt the misfolded conformation, 
causes the activation of ER stress in differentiated PC12 cells. (Smith et al., 2005). Furthermore, 
Bellucci et al. demonstrated that accumulation of AS in the ER lumen activates the PERK 
dependent UPR pathway. In vitro and in vivo experiments demonstrated direct interaction of AS 
with GRP78 which causes the dissociation of the PERK-GRP78 complex and activation of 
PERK to initiate the UPR (Bellucci et al., 2011). In another study, wild type AS was over 
expressed in the substantia nigra pars compacta (SNc) of a mouse model of PD. After four weeks 
they found elevated levels of phosphorylated eIf2α, ATF4, and ATF6(N) which are UPR 
markers from PERK and ATF pathways, respectively.   Furthermore, the level of CHOP was 
significantly increased due to activation of ATF4 and PERK pathways. This pro-apoptic protein, 
i.e. CHOP, initiates the apoptosis pathway which finally leads to death of dopaminergic neurons 
(Gorbatyuk et al., 2012).  Gorbatyuk et al. also studied the effects of GRP78 overexpression on 
AS accumulation and toxicity which leads to cell death and apoptosis due to induction of ER 
stress and activation of UPR. This study showed the attenuation of AS accumulation toxicity by 
GRP78 overexpression and proposed GRP78 as a new target for treatment of PD (Gorbatyuk et 
al., 2012). It also has been reported that AS overexpression reduces the degradation of 
malformed proteins by the ERAD pathway in a yeast model of PD and results in accumulation of 
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unfolded proteins in ER which initiates the ER stress (Cooper et al., 2006; Franssens et al., 
2010).     
Other PD proteins which are involved in dealing with unfolded protein stress are Parkin and 
UCHL-1. These proteins are part of the ubiquitin and proteasome system (UPS) which is an 
important element of the ERAD pathway during UPR. Mutation of the genes encoding Parkin 
and UCHL-1 results in loss of their activity in the ERAD pathway which leads to accumulation 
of proteins (Shimura et al., 2000; Tan et al., 2008; Trempe et al., 2013; Tsai et al., 2003; Wauer 
and Komander, 2013) and activation of ER stress (Imai et al., 2000; Ledesma et al., 2002; Tan et 
al., 2008).  
1.3.1.2 Role of mitochondria in Parkinson’s disease 
Mitochondria are eukaryotic intracellular organelles with key functions in metabolism and 
generation of energy. This organelle is surrounded by two membranes, the outer mitochondrial 
membrane (OMM) and the inner mitochondrial membrane (IMM). This compartmentalization 
creates two spaces between the OMM and the IMM, i.e. the intermembrane space (IMS) and the 
space inside the IMM, i.e. matrix. The most important role of this organelle is production of 
energy by the respiratory chain or electron-transport chain (ETC) and the oxidative-
phosphorylation system located in the highly folded regions of IMM. Five protein complexes and 
two electron carriers are responsible for generating energy as ATP through the ETC (DiMauro 
and Schon, 2003; Perier and Vila, 2012). The first complex of the respiratory chain, i.e. complex 
I, is crucial for the maintenance of the mitochondrial role in ATP synthesis and any defect of this 
complex impairs the respiratory chain and the generation of ATP and finally causes disorders of 
the respiratory chain. This multimer complex is composed of 45 subunits encoded by mtDNA 
and the nuclear genome. Mitochondrial DNA encodes seven subunits of this complex (ND1–
ND6 and ND4L) and the other subunits are encoded by nuclear DNA. The catalytic site of this 
complex consists of 14 subunits encoded by both mitochondrial and nuclear genes including 
NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7, NDUFS8, ND1, ND2, ND3, 
ND4, ND5, ND6 and ND4L (Bridges et al., 2011; Dieteren et al., 2008). Dysfunction of the 
respiratory chain especially at the level of complex I has been reported as one of the pathological 
features of PD (Blake et al., 1997; Keane et al., 2011; Keeney et al., 2006; Parker and Swerdlow, 
1998; Perier and Vila, 2012).  
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Using post-mortem human brain samples, Keenay et al. have shown that the dysfunction of 
mitochondrial complex I in PD is due to oxidation of its catalytic subunit (Keeney et al., 2006). 
This study showed up-regulation and oxidation of catalytic subunits of mitochondrial complex I 
of PD samples in comparison with the controls. This might be the reason for the reduced activity 
of this complex in PD patients (Keeney et al., 2006; Perier and Vila, 2012). The consequences of 
complex I dysfunction are the depletion of ATP levels in brain (Chan et al., 1991; Perier and 
Vila, 2012; Scotcher et al., 1990) and increase in ROS production (Perier et al., 2005; Perier and 
Vila, 2012; Ramsay et al., 1987).   
Several studies have found an association between some of the genes involved in familial PD, 
including PINKI and AS, and deficits of the mitochondrial complex I (Abramov et al., 2011; 
Banerjee et al., 2010; Chinta et al., 2010; Devi et al., 2008; Gautier et al., 2008; Hsu et al., 2000; 
Liu et al., 2009; Loeb et al., 2010; Martin et al., 2006; Matsuda et al., 2013; Morais et al., 2014; 
Morais et al., 2009; Plun-Favreau and Hardy, 2008). Morais et al. have shown that PINK1 loss 
of function reduces the normal activity of mitochondrial complex I and finally leads to the 
mitochondrial depolarization and sensitivity to apoptotic stress in fruit fly and mouse models of 
PD. Loss of PINK1 causes a reduction in the mitochondrial membrane potential which is 
required for ATP synthesis in both PD models (Morais et al., 2009). Dysfunction of 
mitochondria also has been reported in PINK1-/- mice which is due to the impaired mitochondrial 
respiration in the striatum and elevated oxidative stress associated with dopamine metabolism 
(Gautier et al., 2008). It also has been shown that the mitochondrial membrane potential is 
decreased in the presence of PINK1 mutations in human fibroblasts (Abramov et al., 2011). It 
has been shown that PINK1 regulates the phosphorylation of NdufA10 subunit of complex I 
which is required for its activity and maintenance of the respiratory chain (Morais et al., 2014).  
AS is another protein involved in PD and has been shown to be associated with mitochondrial 
function (Chinta et al., 2010; Devi et al., 2008; Hsu et al., 2000). It has been reported that 
overexpression of AS causes mitochondrial dysfunction, oxidative stress and cell death (Banerjee 
et al., 2010; Hsu et al., 2000; Martin et al., 2006). Several research groups have reported that the 
overexpression of AS inhibits mitochondrial complex I activity (Liu et al., 2009; Loeb et al., 
2010). Devi et al. (Devi et al., 2008) have identified that AS has a cryptic mitochondrial targeting 
sequence located at the N-terminus of the peptide. They also have found that the transportation 
and accumulation of AS in mitochondria impairs mitochondrial complex I. Direct interaction of 
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AS and mitochondrial complex I also has been reported in the striatum of PD brain samples, 
normal brain samples and dopaminergic primary neuronal (DAN) cells expressing AS using blue 
native electrophoresis (Devi et al., 2008). Another research group has reported that the 
monomers and oligomers of AS are imported and localized in the mitochondria of dopaminergic 
neurons from transgenic mice overexpressing the A53T mutant AS (Chinta et al., 2010). These 
results together showed the association of overexpressed AS and mitochondria dysfunction in the 
pathology of PD. Constitutive expression of AS is important in maintaining the integrity of 
mitochondria especially for the activity of complex I. Pathological conditions such as up-
regulation or mutation of AS gene which cause accumulation of AS inside the mitochondria 
result in impairment of mitochondrial function (Chinta et al., 2010; Devi et al., 2008; Hsu et al., 
2000; Ottolini et al., 2013).    
It also has been reported that genetics and environmental factors involved in PD participate in 
maintenance of mitochondrial dynamics through control of mitochondrial fission, fusion and 
mitophagy (Arduino et al., 2011; Barsoum et al., 2006; Cagalinec et al., 2013; Gomez-Lazaro et 
al., 2008; Meuer et al., 2007; van der Bliek et al., 2013; Youle and van der Bliek, 2012). 
Mitochondria have a dynamic structure and undergo frequent cycles of fission and fusion to 
maintain the quantity and quality of their biological functions such as cellular biogenesis and 
respiratory function (Arduino et al., 2011; Perier and Vila, 2012; van der Bliek et al., 2013). 
During mitochondrial fusion two mitochondria are fused into a single organelle (Figure 1.4b) and 
mitochondrial fission defines the separation of a large mitochondrion into two or more smaller 
organelles (Figure 1.4a). Mitophagy is the selective elimination of mitochondria through the 
autophagic degradation process which is important in removal of damaged mitochondria and 
maintenance of mitochondrion numbers (Figure 1.4c). During the mitophagy process damaged 
mitochondria are sequestrated into an autophagosome which is a double membrane bounded 
structure which is then fused with the lysosome to degrade the targeted mitochondria. Mitophagy 
is associated with the fission and fusion process by involving elimination of the damaged and 
hypopolarized mitochondria resulting from fission processes (Figure 1.4c) (Cagalinec et al., 
2013; Chan, 2012; Imai and Lu, 2011; Youle and van der Bliek, 2012). 
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Figure 1.4 Schematic representation of mitochondrial fission-fusion processes associated with 
mitophagy. (a) The fission or separation of a large mitochondrion into two daughter 
mitochondria (b) The fusion of two mitochondria to form a single mitochondrion (c) The 
elimination of damaged mitochondrion through mitophagy. Parkin and pink1 are involved in this 
process. Reprinted and adopted with permission from (Imai and Lu, 2011; Perier and Vila, 
2012). Copyright © 2011 Elsevier and Copyright © 2012 Cold Spring Harbor Laboratory Press. 
All rights reserved. 
Accumulation of PINK1 on the OMM serves as a signal for initiating mitophagy in damaged 
mitochondria. PINK1 accumulates on the OMM and phosphorylates Mfn2 by its kinase activity. 
Phosphorylated mfn2 serves as a Parkin receptor on damaged mitochondria (Chen and Dorn, 
2013). Parkin then mediates the ubiquitination of a variety of OMM proteins such as Mfn1 and 
Mfn2 and induces autophagic elimination of the damaged mitochondrion. Ubiquitination of 
Mfn1 and Mfn2 prevents the fusion of damaged mitochondria with healthy mitochondria (Deas 
et al., 2011; Grenier et al., 2013; Ivatt and Whitworth, 2014; Jin and Youle, 2012; Springer and 
Kahle, 2011; Vincow et al., 2013).  
Mitochondrial fission and fusion is mediated by a group of GTPases whose function causes 
division and fusion of mitochondrial membranes (Figure 1.4a). Fusion of OMM and IMM 
mediated by mitofusins (Mfn1, Mfn2) and optic atrophy 1 (OPA1), respectively. Dynamin-
related protein 1 (Drp1) is required for the fission process (Figure 1.4b) (Chan, 2012; Ottolini et 
al., 2013; Perier and Vila, 2012; Youle and van der Bliek, 2012). 
In the case of PD, it has been shown that toxins like 6-hydroxydopamine (6-OHDA), 
rotenone, and MPP+ which induce Parkinson disease pathology also cause the fragmentation of 
mitochondria (Barsoum et al., 2006; Gomez-Lazaro et al., 2008; Meuer et al., 2007). Barsoum et 
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al. have shown that treatment of cortical neuronal cultures, derived from embryonic rats, with 
rotenone causes mitochondrial fission in a dose dependent manner, causing up to 80% of 
fragmentation at 100nM. Further investigations revealed that overexpression of Mfn1 and the 
dominant-negative mutant Drp1 prevent mitochondrial fission induced by 100 nM rotenone and 
inhibits cell death (Barsoum et al., 2006). The MPP+ induced fission also has been reduced in rat 
primary midbrain neurons expressing a dominant-negative mutant of Drp1 (Meuer et al., 2007). 
It also has been shown that silencing of Drp1 inhibits mitochondrial fragmentation induced by 6-
OHDA which is another complex I inhibitor (Gomez-Lazaro et al., 2008). These results showed 
the role of Drp1 function in mitochondrial fission and cell death induced by these neurotoxins 
(Barsoum et al., 2006; Gomez-Lazaro et al., 2008; Meuer et al., 2007).  
Besides the effects of PD environmental factors on mitochondrial fission and fusion, it has 
been shown that genetics factors causing familial PD (PINK1 and Parkin) regulate the fission 
and fusion processes in mitochondria. Deng et al. have shown the role of the Pink1-Parkin 
pathway in regulation of mitochondrial fission and fusion in Drosophila. The Pink1/Parkin 
pathway promotes and inhibits the fission and fusion processes respectively. The controlling 
effect of pink1 and parkin on mitochondrial dynamics is through the activation of the fission 
protein Drp1 and inactivation of fusion proteins mfn and opa1 (Deng et al., 2008). Furthermore 
the regulatory role of the pink1-parkin pathway in mitochondrial dynamics also has been 
demonstrated in rat midbrain dopaminergic neurons (Yu et al., 2011).    
1.3.2 Pathophysiology of Parkinson’s disease 
The hallmarks of PD pathology are the loss of dopaminergic (DA) neurons of the substantia 
nigra (or nigrostriatal neurons) which lie at the pars compacta (SNpc) and the presence of Lewy 
body inclusions in the substantia nigra. The cell bodies of nigrostriatal neurons are in the SNpc, 
and they lead out to the putamen. As the normal cells contain noticeable amounts of 
neuromelanin, their loss produces the common neuropathology feature of PD which is the 
depigmentation of the SNpc (Dauer and Przedborski, 2003; Henchcliffe and Beal, 2008; 
Lotharius and Brundin, 2002b; Moore et al., 2005; Ottolini et al., 2013; Zigmond and Burke, 
2002). Cytoplasmic inclusions or Lewy bodies are found in some of the dopaminergic neurons in 
the substantia nigra of PD patients. Electron microscopic imaging showed that compartments of 
Lewy bodies are densely aggregated filaments. Biochemical studies have demonstrated that 
Lewy bodies are composed of a mixture of proteins with aggregated AS as the most significant 
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component. Immunostaining with an antibody against AS is the method that can be used to label 
Lewy bodies. In this immunostained method, a Lewy body is revealed as a strongly 
immunoreactive central zone which is surrounded by a weakly immunoreactive marginal zone 
(Figure 1.5) (Pahwa and Lyons, 2007).  
 
Figure 1.5 Substantia nigra of Parkinson’s disease brain. Arrow shows the Lewy body 
immunostained with AS antibody. Reprinted with permission from (Pahwa and Lyons, 2007). 
Copyright © 2008 Wolters Kluwer Health. All rights reserved.  
1.3.2.1 Genetic factors 
Although the detailed etiology of this condition is still unknown, several genetic and 
environmental risk factors have been identified. The second major risk factor after increasing age 
for developing PD is a family history of PD. Although familial PD is less common than the 
sporadic form of PD, having a family history of PD doubles the risk of PD development 
compared to the background population. Eleven monogenetic PARK loci have been identified in 
the development of PD. Some of these genes (PARK 1, 3, 4, 8 and 11) are autosomal dominant 
(AD) and others are autosomal recessive (AR). Mutations in these genes have been reported to 
be associated with PD (Bekris et al., 2010; Grosset et al., 2009; Pahwa and Lyons, 2007). 
Among the genes involving in PD pathology, just one of them (PARK6) is a mitochondrial 
gene but in the disease condition, the other genes are associated with mitochondrial function. The 
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PARK6 gene which encodes PINK1 is located on chromosome 1p35–p36. Mutations in this gene 
have been identified in early-onset familial cases of PD. PINK1 is synthesized as a 66 KD 
protein with 581 amino acids which contains a mitochondrial targeting sequence (MTS) at the N-
terminal and a  serine/threonine protein kinase domain at the C-terminal which faces the cytosol. 
The MTS is a transmembrane domain which spans the mitochondrial membranes (Moore et al., 
2005; Ottolini et al., 2013).   
PARK2 which encodes the parkin protein is located on chromosome 6q25.2–q27. Loss of 
activity mutations in this gene are common in recessively inherited PD. Parkin gene encodes a 
protein with 465 amino acids which contains three distinct domains including an ubiquitin-like 
(UBL) domain at the N terminus, a RING domain at the C-terminus which is composed of two 
RING finger motifs separated by an in-between RING (IBR) finger domain. As parkin is a RING 
finger–containing protein, it acts as an E3 ubiquitin protein ligase which is a part of the 
ubiquitin-proteasome system. Thus parkin function is to identify targeted proteins and label them 
with ubiquitin for degradation (Dauer and Przedborski, 2003; Moore et al., 2005). It has been 
shown that Synphilin-1 is the link between parkin and Lewy body formation in PD. This protein 
interacts with AS and coexpression of both of them in cultured cells causes the formation of 
intracellular inclusion bodies. Parkin is able to interact with ubiquitinated α-synuclein/synphilin-
1 inclusions and transfers them to be digested by the proteasomal complex. Thus, parkin activity 
has an important role in survival of neuronal cells against the toxicity of α-synuclein/synphilin-1 
Lewy body like inclusions (Moore et al., 2005). 
Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) or PARK5 is another gene which is 
involved in PD pathogenicity. Mutant forms of this protein have been identified in familial PD 
cases. UCK-L1 is one of the components of the ubiquitin-proteasome system and is responsible 
for recycling of poly-Ub chains by hydrolysis of Ub monomers after degradation of the targeted 
protein. One of the mutant forms of UCH-L1 which has been identified in familial PD (I93M) 
reduces the hydrolysis activity of UCH-L1 in vivo (Dauer and Przedborski, 2003; Moore et al., 
2005).  
DJ-1 which is encoded by PARK7 is located on chromosome 1p36 and the mutated forms of 
this gene have been identified in familial PD. DJ-1 is a 189 amino acid-protein with a DJ-1/PfpI 
domain that belongs to the DJ-1/PfpI superfamily of proteins. It has been reported that DJ-1 
might have protease activity and further studies found an active site involving Cys106 and 
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His126 which is similar to the active site of cysteine proteases (Moore et al., 2005). Another 
function for DJ-1 is its protective activity against oxidative stress (Dauer and Przedborski, 2003; 
Moore et al., 2005; Ottolini et al., 2013). This protective function is based on the findings that 
showed this protein acts as a peroxiredoxin-like peroxidase (Andres-Mateos et al., 2007).  
Another gene which has been identified in PD pathology is LRRK2. This gene possesses 51 
exons and encodes LRRK2 or dardarin protein with 2527 amino acids. Mutations in the LRRK2 
gene have been identified in autosomal-dominant and also in idiopathic PD (Smith et al., 2006). 
This protein has GTPase and kinase activities and is composed of several domains such as a 
leucine-rich repeat domain (LRR), a Ras of complex (ROC) domain which belongs to Ras-
like/small GTPase superfamily and a tyrosine kinase-like domain (Lin et al., 2011; Mata et al., 
2006). The most important functions of LRRK2 are its GTPase and kinase activities and 
mutations that impair these functions are associated with PD (Lin et al., 2011).  
1.3.2.1.1 Role of alpha-synuclein in Parkinson’s disease 
Loss of AS function has been proposed to be involved in the development of PD pathology. 
AS loss of function can be due to aggregation, reduced expression or overexpression (Kanaan 
and Manfredsson, 2012; Lashuel et al., 2013). Under normal conditions AS acts as a regulator of 
dopamine homeostasis and is involved in almost all of the dopamine metabolism pathways 
including dopamine biosynthesis, storage of dopamine in synaptic vesicles, dopamine release in 
the response to an action potential and re-uptake of released dopamine from the presynaptic 
space (Lotharius and Brundin, 2002a; Stefanis, 2012; Yu et al., 2005). The normal function of 
AS is important for clearance of dopamine from the cytoplasm of the presynaptic terminal and 
storage in synaptic vesicles. AS also regulates the re-uptake of released dopamine molecules 
from presynaptic space into the synaptic terminal. This homeostasis protects cells from 
deleterious effects of dopamine oxidation in the cytoplasm and also helps the replenishment of 
synaptic dopamine. Loss of normal AS function promotes the accumulation of dopamine in the 
cytoplasm of the presynaptic terminal which leads to oxidative stress (Lotharius and Brundin, 
2002a, b; Yu et al., 2005).  
There are three possibilities causing the AS loss of function. The first one is mutations in the 
AS gene associated with familial forms of PD. The main mutants of AS affecting its structure 
and function are A30P, A53T and E46K. Loss of function can also occur due to misfolding and 
aggregation (Yu et al., 2005) of AS which might be a result of SNCA multiplication, associated 
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with some familial forms of parkinsonism (Lashuel et al., 2013), or SNCA overexpression 
(Spinelli et al., 2014). Formation of AS oligomers or aggregates results in the reduction of 
available functional AS (Kanaan and Manfredsson, 2012). It has been shown that AS exists in 
three forms in presynaptic terminals. The first two forms of AS are the functional protein and 
exists as monomers which are unbound or bound to synaptic vesicles. The third form of AS is 
characterized by microaggregates of the protein.  Furthermore it has been demonstrated that in 
animal models with moderate overexpression of the SNCA gene, a condition which is similar to 
multiplication mutations linked to PD, the microaggregates are found in presynaptic terminals 
and ultimately lead to dysfunction of the presynaptic terminals (Spinelli et al., 2014). In the 
moderate overexpression condition, the pathology of AS microaggregates is similar to the AS 
aggregates in Lewy bodies including proteinase K-resistance, phosphorylation at serine-129 and 
oxidation damage (Spinelli et al., 2014).   
Dopamine is synthesized in the cytoplasm of presynaptic terminals but cannot be stored at the 
normal pH of the cytoplasm as it undergoes auto-oxidation or enzymatic oxidation by MAO and 
forms reactive oxygen species (ROS) which contribute to the pathogenesis of PD. The 
cytoplasmic dopamine which has been synthesized from L-DOPA or transported into the cell is 
isolated into monoaminergic vesicles by the vesicular monoamine transporter 2 (VMAT2) 
(Lotharius and Brundin, 2002a). Monoaminergic vesicles provide a low pH environment lacking 
MOA to protect cytosolic dopamine from oxidation. Efficient dopamine sequestration which 
requires formation of synaptic vesicles from early endosomes is a protective process against the 
toxic effects of dopamine oxidation. It has been shown that AS is involved in the formation of 
synaptic vesicles from early endosomes (Lotharius and Brundin, 2002a, b). As well, the normal 
structure of AS is required for its function in regulating oxidative stress and the pathology of AS 
mutants might be related to their reduced capability in the scavenging of reactive oxygen species 
(Kanda et al., 2000).  
The function of AS in dopamine presynaptic vesicle formation and release depends on its 
ability to bind with membrane phospholipid. Any change in AS structure which causes the loss 
of this ability disrupts synaptic plasticity and dopamine metabolism which finally leads to 
oxidative stress and cell death. It has been reported that the A30P and A53T mutants of AS 
which are associated with familial PD lose the phospholipid binding activity partially (A30P) or 
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completely (A53T). This shows another link between AS loss of function and PD pathology 
(Perrin et al., 2000).  
Besides AS loss of function, another hypothesis to explain the role of AS in PD is the 
cytotoxicity of AS oligomers (Wan and Chung, 2012; Winner et al., 2011). Aggregation of AS is 
a two stage process which starts from monomers. The first stage is the oligomerization of 
misfolded monomers follow by aggregation of oligomers to form fibrils. It has been shown that 
AS oligomers are more toxic than the fibrils and formation of fibrils is a protective mechanism to 
reduce the cytotoxicity of oligomers and increase cell survival (Colla et al., 2012b; Wan and 
Chung, 2012; Winner et al., 2011).  
Recent studies have shown that AS can transfer neuron to neuron and spread the hallmark of 
PD, i.e. Lewy pathology, throughout the brain in a prion-like manner as the disease progresses 
(Angot et al., 2012; Braak et al., 2003; Danzer et al., 2012; Desplats et al., 2009; Hansen et al., 
2011; Hansen and Li, 2012; Kordower et al., 2008; Kurowska et al., 2011; Li et al., 2008; Luk et 
al., 2012; Masuda-Suzukake et al., 2013; Steiner et al., 2011; Volpicelli-Daley et al., 2011). 
Support for the AS propagation hypothesis comes from reports which showed the development 
of Lewy body pathology in grafted neurons which were transplanted to PD patients many years 
before (Kordower et al., 2008; Kurowska et al., 2011; Li et al., 2008). These observations 
provide evidence for the prion like transmission of misfolded AS from the host cells to the 
normal grafted cells with spread of PD pathology (Hansen and Li, 2012; Kordower et al., 2008; 
Kurowska et al., 2011; Li et al., 2008; Volpicelli-Daley et al., 2011). In vitro experiments using 
pure WT AS preformed fibrils (PFFs) showed the entrance of the PFFs into primary neuronal 
cultures, prepared from E16-E18 C57BL/6 mouse brains, and conversion of normal and soluble 
endogenous AS into Lewy bodies (Volpicelli-Daley et al., 2011).  The uptake of AS by neuronal 
cells has been shown in vitro, i.e. in cell culture, (Desplats et al., 2009; Hansen et al., 2011) and 
in vivo, i.e. in mouse brain (Hansen et al., 2011; Luk et al., 2012; Masuda-Suzukake et al., 2013).  
1.3.2.2 Environmental factors 
Development of PD is not just due to mutation and impairment of genes, as environmental factors can 
also cause PD. Environmental factors such as heavy metals, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), pesticides, solvent and head injury increase the incidence of PD 
(Grosset et al., 2009; Pahwa and Lyons, 2007). MPTP which is an analog for narcotic 
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meperidine that inhibits the activity of complex I and leads to the reduction of oxidative 
phosphorylation in mitochondria. (Exner et al., 2012; Perier and Vila, 2012). 
6-hydroxydopamine (6-OHDA) has been widely used as a neurotoxin to create animal models 
for PD research. Because of its polarity, 6-OHDA does not cross the blood brain barrier (BBB) 
easily. The 6-OHDA structure is similar to dopamine and can bind to the dopamine transporter 
(DAT) to be transferred from the extracellular space to dopaminergic neurons (Bové et al., 
2005). Inside the cells 6-OHDA reacts with O2 and generates reactive oxygen species (ROS) 
such as hydrogen peroxide and semiquinone (Tirmenstein et al., 2005).  
Pesticides which are widely used to control different types of organisms have been identified 
as significant risk factors for PD. Several studies have reported that exposure to rotenone and 
paraquat increases the incidence of PD (Berry et al., 2010; Franco et al., 2010). Paraquat (1,1ʹ-
dimethyl-4,4ʹ-bipyridinium dichloride) is a quarternary nitrogen herbicide (Douna et al., 2012; 
Franco et al., 2010; Olanow and Tatton, 1999). It has been shown that paraquat enters into the 
dopaminergic cells by a Na-dependent transporter (Shimizu et al., 2001). Inside the neuronal 
cells paraquat induces oxidative stress and leads to the loss of dopaminergic neurons and also 
formation of AS containing inclusions (Franco et al., 2010). Another pesticide with potential risk 
for developing PD is rotenone. Rotenone is used as an insecticide and is a lipophilic compound 
which can easily cross the BBB. Several reports demonstrated that rotenone cytotoxicity is due 
to its ability to bind and inhibit mitochondrial complex I. It has been proposed that this inhibition 
could be due to the elevation of mitochondrial ROS level as ROS has an important role in 
apoptosis through inhibition of the respiratory chain (Li et al., 2003; Xiong et al., 2012).  
1.3.2.3 Current Treatments of Parkinson’s disease 
Despite significant progress in the understanding of the molecular mechanism of PD, there is 
no definitive treatment. The current strategy is based on the control of symptoms by restoring the 
loss of dopamine.  The most efficient treatment is L-3,4-dihydroxyphenylalanine (L-DOPA) 
which is a precursor of dopamine. To increase the lifetime of dopamine, levodopa is 
administrated with other drugs to slow the metabolism of dopamine. These adjunctive 
medications of levodopa include catechol O-methyltransferase (COMT) inhibitors, monoamine 
oxidase-B (MAO-B) inhibitors, and peripheral dopamine decarboxylase inhibitors (Grosset et al., 
2009; Olivares et al., 2009; Pahwa and Lyons, 2007). 
 25 
 L-DOPA is an aromatic amino acid and naturally is found in seedlings, pods, and broad 
beans. It crosses the blood–brain barrier (BBB) to maintain the level of dopamine (Grosset et al., 
2009; Olivares et al., 2009; Pahwa and Lyons, 2007). Metabolism of L-DOPA occurs 
peripherally (outside of the BBB) and centrally (inside of the BBB) (Figure 1.6). L-DOPA is co-
administrated with dopamine decarboxylase inhibitors such as carbidopa to prevent the 
peripheral conversion of levodopa to dopamine. These inhibitors lead to an increase of the half 
life of L-DOPA in peripheral cells and promote the transport across BBB. Dopamine 
decarboxylase inhibitors can not cross through the BBB and do not affect the conversion of L-
DOPA to dopamine in brain. L-DOPA in brain is converted to dopamine. L-DOPA is also 
converted to 3-O-methyldopa (3-OMD) by peripheral catechol-O-methyltransferase (COMT). To 
prevent the peripheral metabolism of levodopa to 3-OMD, peripheral catechol-O-
methyltransferase (COMT) inhibitor such as entacapone or tolcapone are added to increases the 
half-life. For example Stalevo® is a combination medication that contains carbidopa, levodopa, 
and entacapone for the treatment of Parkinson's disease. L-DOPA entering the BBB undergoes 
central metabolism. In the brain central dopamine decarboxylase converts levodopa to dopamine.  
Dopamine is the substrate of two enzymes in the brain (Di Giovanni et al., 2010; Grosset et 
al., 2009; Pahwa and Lyons, 2007). Monoamine oxidase-B (MAO-B) converts dopamine to 3,4-
dioxyphenylacetic acid (3,4-DPA) (Figure 1.6). MAO B inhibitors such as selegiline are 
administrated to maintain the level of dopamine in brain. Furthermore, central catechol-O-
methyltransferase (COMT) converts dopamine to 3-methoxytyramine (3-MT) which is a 
substrate of MAO-B. 3-MT is converted to homovanillic acid (HVA) but MAO-B inhibitors 
prevent this conversion (Di Giovanni et al., 2010; Grosset et al., 2009; Pahwa and Lyons, 2007).  
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Figure 1.6 Metabolism of L-DOPA and enzyme inhibitors. This pathway shows metabolism of 
L-DOPA to dopamine. Side products (green) and sites of enzyme inhibitors are shown as green 
and orange respectively. Abbreviations: 3-OMD, 3-O-methyldopa; 3,4-DPA, 3,4-
dioxyphenylacetic acid; HVA, homovanillic acid; 3-MT, 3-methoxytyramine. Reprinted with 
permission from (Grosset et al., 2009). Copyright © 2010 Oxford University Press. All rights 
reserved.   
1.4 Intrinsically disordered proteins 
Intrinsically disordered proteins (IDPs) are a group of proteins which share an unusual 
biophysical characteristic. The native form of these proteins lacks the secondary and tertiary 
structures observed in ordered proteins. Thus these proteins are also called natively unfolded 
proteins to be distinguished from folded or structured proteins with regular three dimensional 
structures (Theillet et al., 2013; Tompa, 2012; Uversky, 2011). Biophysical studies of these 
proteins revealed that their NMR spectrum is not as well resolved with some line-broadening and 
peak overlap which is typical for a random-coil conformation. Furthermore CD and FTIR 
spectroscopy experiments also show a random coil conformation of these proteins (Brucale et al., 
2014; Chiti and Dobson, 2006; Dyson and Wright, 2005; Uversky, 2013a, b; Uversky et al., 
2008). Natively unstructured proteins are very sensitive to their environment. Genetic mutations 
and environmental modification such as exposure to toxins or drugs folds these proteins into a 
non-functional state, a process which is called misfolding. The non-functional or misfolded 
conformations are prone to oligomerization and aggregation through β-sheet formation (Babu et 
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al., 2011; Oldfield and Dunker, 2014; Theillet et al., 2013; Tompa, 2012; Uversky, 2013a; 
Uversky et al., 2008). 
 A broad range of human diseases arise from the misfolding of IDPs which are referred to as 
protein conformational or protein misfolding diseases. Although the size of the protein and the 
primary location of the affected organs are variable, all protein misfolding diseases are 
characterized by the presence of fibrillar aggregates or amyloid plaques which are linked to cell 
toxicity and death (Chiti and Dobson, 2006). For example, in Type 2 diabetes amylin (37 
residues), also known as Islet Amyloid Polypeptide is the culprit whereas in Alzheimer’s Disease 
(AD) the peptide Aβ42 (40 or 42 residues) is clearly implicated (Jackson et al., 2013; Janson et 
al., 2004). AD is just one example of a neurodegenerative disease caused by protein misfolding; 
others include Amyotrophic Lateral Sclerosis (ALS) involving superoxide dismutase 1 (SOD1) 
(153 residues) (Valentine et al., 2005), and the prion protein (253 residues) which causes 
diseases such as Creutzfeldt - Jacob disease (CJD) and Fatal Familial Insomnia (FFI) (Prusiner, 
2001).  
1.4.1 Alpha-Synuclein 
 AS has 140 amino acids and lacks cysteine and tryptophan residues. The molecular weight 
and isoelectric point (pI) of this protein are 14460 D and 4.67, respectively.  The total numbers 
of negatively charged and positively charged residues are 24 and 15, respectively, so that the net 
charge of the protein is -9 (Fink, 2006; McClendon et al., 2009; Vigneswara et al., 2013). The 
structure of AS can be divided into three regions including N-terminal, non amyloid-β 
component (NAC) and C-terminal (Figure 1.7). AS is a natively unfolded protein which in 
aqueous environments does not achieve any secondary structure. Binding of the protein with 
lipid molecules or phospholipid membranes induces the formation of an α-helix in the N-
terminal region. Three missense mutations in this region are associated with familial PD (Figure 
1.7). The NAC region of the protein is able to undergo conformational changes from random coil 
to β-sheet. The acidic C-terminal is always unfolded, probably because of its highly acidic 
nature.(Ulmer et al., 2005a; Uversky, 2007; Uversky and Eliezer, 2009). 
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Figure 1.7 Schematic of the structure of AS, showing the N-terminal segment, the NAC segment, 
and the C-terminal segment. The positions of missense mutations in the N-terminus are also 
indicated.  
1.4.1.1 Physiology and biological function of alpha-Synuclein 
Whereas the biological function of AS is not fully characterized, it has been demonstrated that 
this protein is involved in the homeostasis of dopamine metabolism including dopamine 
biosynthesis,  vesicle recycling, dopamine storage, and release,  vesicle transportation, dopamine 
transporter activity and dopamine uptake (Yu et al., 2005). The major function of AS is synaptic 
vesicle recycling, dopamine storage, and release. It has been reported that AS is involved in 
dopamine storage by promoting the formation of synaptic vesicles from early endosomes (Figure 
1.8) (Lotharius and Brundin, 2002b). It is also involved in synaptic vesicle fusion with the 
presynaptic plasma membrane which leads to release of dopamine in the presynaptic space and 
also participates in vesicle recycling from the presynaptic plasma membrane (Lashuel et al., 
2013).  
AS involvement in synaptic vesicle recycling is important for dopamine homeostasis in the 
dopaminergic nigrostriatal terminal. As illustrated in Figure 1.8, despite dopamine being 
synthesized in the cytoplasm of the presynaptic terminal it cannot be stored in the normal pH of 
the cytoplasm as it undergoes auto-oxidation or enzymatic oxidation by MAO and forms reactive 
oxygen species (ROS) which contribute to the pathogenesis of PD (Lashuel et al., 2013; 
Lotharius and Brundin, 2002a, b). The cytoplasmic dopamine which has been synthesized from 
L-DOPA or transported into the cell is isolated into monoaminergic vesicles by the vesicular 
monoamine transporter 2 (VMAT2) (Lotharius and Brundin, 2002a). Monoaminergic vesicles 
provide a low pH environment lacking MOA to protect cytosolic dopamine from oxidation 
processes. Efficient dopamine sequestration which requires formation of synaptic vesicles from 
early endosomes is a protective process against the toxic effects of dopamine oxidation. It has 
been shown that AS is involved in the formation of synaptic vesicles through interactions with 
phospholipase D2 (PLD2) (Figure 1.8) (Lotharius and Brundin, 2002a, b).  
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Figure 1.8 The role of AS in the formation of synaptic vesicles. Phosphorylation of AS by G-
protein receptor kinases stops its inhibitory effect on phospholipase D2 activity and triggers the 
vesicle formation from the early endosome. Reprinted with permission from (Lotharius and 
Brundin, 2002b). Copyright © 2002 Nature Publishing Group. All rights reserved.   
There are two isoforms of PLD enzymes; PLD1 and PLD2. The membrane-bound enzymes 
catalyse the formation of phosphatidic acid (PA) from phosphatidylcholine (PC) in response to 
chemical signals such as neurotransmitters and hormones. They are involved in regulation of 
synaptic vesicle recycling and neurotransmitter release. The catalytic product of PLD, PA, acts 
as an intracellular messenger to activate coatomer or clathrin coat proteins and finally facilitates 
budding of vesicles from the plasma membrane, early endosomes and Golgi network. It has been 
shown that in the absence of stimuli, the activity of PLD enzymes is masked by AS. It has been 
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demonstrated that the N-terminal of AS interacts with PLDs and inhibits their function. The 
activation pathway occurs after a high-frequency stimulation which increases the intracellular 
concentration of Ca2+ and activates calcium-sensor proteins follow by the activation of G-protein 
receptor kinases. Finally phosphorylation of AS by the activated G-protein receptor kinases, 
stops the inhibitory effect of AS on PLD activity and leads to budding of vesicles from the early 
endosomes (Lotharius and Brundin, 2002a). Binding of AS through its N-terminus with 
membrane phospholipids is the critical stage in the formation of synaptic vesicles and dopamine 
storage as a protection against cytosolic oxidation of dopamine. Two mutations in the N-
terminal, i.e. A30P and A53T, which are associated with a familial form of PD have lower 
phospholipid binding ability. Thus these mutations impair the storage of dopamine in synaptic 
vesicles and increase the cytosolic concentrations of dopamine which can then undergo oxidation 
(Lotharius and Brundin, 2002a, b).  
AS also has a role in the fusion of synaptic vesicles with the presynaptic plasma membrane 
for releasing dopamine into the presynaptic space and then recycling of the fused vesicle from 
the presynaptic plasma membrane. For these functions, AS along with cysteine-string protein α 
(CSPα) act as a chaperone and changes the conformation of SNARE (Soluble NSF (N-
ethylmaleimide-sensitive factor) attachment protein (SNAP) receptor) proteins which are 
involved in synaptic vesicle fusion and recycling (Bonini and Giasson, 2005; Sharma et al., 
2011). In normal cells CSPα acts as a chaperone to stabilize the functional conformation of the 
SNAP-25 protein which is required for SNARE complex formation and membrane fusion. AS 
acts as an auxiliary molecular chaperone and assists CSPα to complete this step. Membrane 
fusion and neurotransmitter release occurs in response to an action potential which stimulates 
opening of Ca2+ channels and increases the intracellular concentration of Ca2+ and finally leads 
to SNARE complex formation and fusion of synaptic vesicles with the plasma membrane. The 
cooperation of CSPα and AS facilitates the priming stage in membrane fusion which is the 
interaction of vesicle-associated SNARE (v‑SNARE) and target membrane-associated SNARE 
(t‑SNARE). Upon membrane fusion and neurotransmitter release the SNARE complex 
dissociates and the synaptic vesicle is recycled (Bonini and Giasson, 2005; Chandra et al., 2005; 
Sudhof, 2013).  
Regulation of dopamine homeostasis by AS is not limited to dopamine storage and release. 
AS also is involved in regulation of dopamine transporter activity, dopamine reuptake and 
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dopamine biosynthesis (Yu et al., 2005). The effect of AS on dopamine biosynthesis occurs by 
regulating the expression and activity of a tyrosine hydroxylase enzyme which is the key enzyme 
in dopamine biosynthesis (Kanaan and Manfredsson, 2012; Yu et al., 2005). It also has been 
reported that AS has ferrireductase activity and provides Fe (II) required for tyrosine 
hydroxylase function (Brown, 2013; Davies et al., 2011). Baptista et al. have reported that 
overexpression of the wild type AS gene in human neuroblastoma cell lines causes 
downregulation of tyrosine hydroxylase (TH) (Baptista et al., 2003).  
After release of dopamine into the presynaptic space in response to an action potential, the 
released dopamine must be re-uptaken into the presynaptic terminal in order to terminate 
dopamine signaling and also replenish the synaptic dopamine. The dopamine transporter (DAT) 
is responsible for dopamine reuptake, a process which is regulated by AS. Uptake of positively 
charged dopamine molecules by DAT depends on co-transportation of Na+ and Cl- ions (Butler 
et al., 2012). Lee et al. have demonstrated a direct interaction between AS and DAT using a 
yeast model, neuronal cell culture and also a co-immunoprecipitation assay (Lee et al., 2001). 
This association involves interaction of the AS-NAC region with the C-terminal tail of DAT 
consisting of its last 22 amino acids (Glu598-Val620) (Butler et al., 2012; Lee et al., 2001). 
Overall AS binds to DAT and alters its activity in the uptake of dopamine from the presynaptic 
space (Butler et al., 2012).  
1.4.1.2 Structure of alpha-Synuclein 
In this thesis structural biology methods were used to characterize the structure and 
conformation of AS. In this section the structure of this protein will be reviewed. The AS protein 
is divided into three regions: the N-terminal region covering amino acids 1-60, the middle region 
residues 61-95 which is the NAC region; and the C-terminal residues 96-140 (Alderson and 
Markley, 2013; Uversky, 2007). The secondary structure content of AS has been previously 
measured with CD spectroscopy and Fourier-transform infrared spectroscopy (FTIR) (Weinreb 
et al., 1996). The CD spectra of AS is characteristic of a random coil or denatured protein and 
shows a maximum ellipticity at 200 nm and lacks the α-helical and β-sheet characteristic bands 
in the 210–230 nm region (Figure 1.9) (Serpell et al., 2000; Uversky et al., 2001b; Weinreb et al., 
1996; Zheng et al., 2013).  
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Figure 1.9 CD spectrum of AS which is typical for a random coil conformation and shows an 
ellipticity at around 200 nm. Reprinted with permission from (Zheng et al., 2013). Copyright © 
2013 Nature Publishing Group. All rights reserved.   
The random coil conformation of AS is independent of AS concentration (up to 600 μM), 
buffer properties such as pH (~5.5 to ~9) and the ionic strength. The conformation of AS does 
not change with increasing concentration which indicates that this protein normally exists as a 
monomer rather than oligomers or aggregates. At lower pH (pH<5), the negative intensity 
around 222 nm increases as a function of pH reduction. This shows that a very acidic 
environment leads to the formation of secondary structures in AS (Uversky et al., 2001b). The 
plot of ellipticity at 222 nm ([θ]222) versus pH changes is sigmoidal and has an isosbestic point at 
pH 5 which represents the transition point from natively unfolded state (pH>5) to partially folded 
intermediate (pH<5) (Uversky et al., 2001b).  Furthermore it has been shown that the 
conformational changes of AS induced by reduction in pH are reversible and also independent of 
AS concentration which indicates that this conformational change is due to folding of monomers, 
not intermolecular interaction or aggregation (Uversky et al., 2001b). There is also no 
conformational change in the presence of 2 mM NaCl, 2 mM MgCl2, 10 mM CaCl2 and 0.1 mM 
ATP. Thus ionic interactions are not involved in stabilizing the AS native conformation 
(Weinreb et al., 1996). The conformational change of AS at different temperatures was also 
studied using CD spectroscopy, which demonstrated that by increasing the temperature from 3°C 
to 50°C, the magnitude of [θ]222 increased. Therefore, at low temperatures AS has a random coil 
conformation which is typical for unstructured proteins, while high temperature causes 
secondary structure formation and induces the transition from unfolded conformation to a 
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partially folded intermediate similar to the conformation induced by low pH (Uversky et al., 
2001b).  
FTIR spectroscopy which is more sensitive for β-sheet detection also showed that AS has a 
natively unfolded structure (Meng et al., 2010b; Sandal et al., 2008; Silva et al., 2013; Uversky et 
al., 2001b; Weinreb et al., 1996). The attenuated total reflectance FTIR spectrum of AS at pH 7.5 
shows a broad amide I absorption band centered at 1642 cm-1 which is typical for the random 
coil conformation of unstructured proteins (Weinreb et al., 1996) but at pH 3 a new band 
appeared at around 1626 cm-1 which is characteristic for the β-sheet conformer. This result 
indicates that acidic pH causes a transition from natively unfolded AS to a partially folded 
intermediate with β-sheet structure (Uversky et al., 2001b). The natively unfolded structure of 
AS has also been characterized by 1H-15N-HSQC NMR (Chandra et al., 2003; Wu et al., 2008). 
The 1H-15N spectrum of AS is characteristic of unfolded proteins because it is not as well 
resolved with some line-broadening and peak overlap (Chandra et al., 2003; Wu et al., 2008).  
One of the biological roles of AS is the regulation of vesicular fusion and there are many 
reports which demonstrated the co-localization of AS with synaptic vesicles. These facts reveal 
that AS is a lipid binding protein and further studies showed that interaction of AS with lipids 
and membrane change the secondary structure content of protein. The 1-87 region of AS consists 
of seven imperfect repeats of an 11-amino acid sequence which is classified as an amphipathic α-
helical domain. The domains contain a six-amino acid core with the consensus KTKEGV and 
have homology with A2-type amphipathic α-helices in apolipoproteins and other lipid-binding 
proteins (Auluck et al., 2010; Dikiy and Eliezer, 2012; Jo et al., 2000). AS binds to membranes 
through the amphipathic α-helical domains. This binding causes the formation of either two α-
helices connected by a flexible linker or a single extended α-helix in the region of AS covering 
the seven repeats (Burré et al., 2012).  
To characterize the binding specificity of AS, small unilamellar vesicles (SUVs) were 
prepared from 1:1 (w/w) ratios of synthetic phospholipids. The results showed that AS does not 
bind to the SUVs containing phosphatidylcholine (PC) only, or a mixture of PC and 
phosphatidylethanolamine (PE) at a 1:1 ratio. However, AS binds with mixed SUVs containing 
acidic phospholipids such as phosphatidylinositol (PI), phosphatidylserine (PS) and phosphatidic 
acid (PA) (Davidson et al., 1998). Furthermore, CD spectroscopy has been used to investigate 
the secondary structure of AS in the presence of negatively charged phospholipids and revealed 
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that the AS conformation undergoes a transition from random coil to α-helical conformation 
upon binding to phospholipids (Davidson et al., 1998; Jo et al., 2000). It also has been shown 
with CD spectroscopy that acidic detergents such as lysosphatidylserine, lysophosphatidic acid 
and SDS change the CD spectra of natively unfolded AS in the same way as the acidic SUVs.  
The conformational change of AS in the presence of PS-SUVs and SDS was further 
investigated by NMR spectroscopy. The 1H-15N HSQC spectrum of AS (0.1 mM) was typical of 
an unfolded protein with a dense cluster of cross-peaks over a narrow range but in the presence 
of saturating concentrations of PS-SUVs and SDS most of the cross-peaks disappeared and their 
intensity reduced significantly. The residues which disappeared are involved in the folding of AS 
due to binding with large size SUVs which leads to broadening of the resonances of the 
corresponding amide groups of AS and are consistent with the formation of α-helical structure 
upon micelle binding. The position and intensity of some other cross-peaks remained unchanged 
and demonstrated that these residues do not bind to lipid and stay unfolded even in the presence 
of SUVs (Chandra et al., 2003). Diagnosis of the secondary structure properties of the AS:SDS 
complex was performed by analysis of short range Nuclear Overhauser Effect (NOE). The 
results showed that the first 100 residues of AS adopted a α-helical structure with a break at 
residues 43 and 44. In 2005 the detailed structure and dynamic of SDS-micelles:AS complex was 
characterized with NMR spectroscopy (Ulmer et al., 2005a). This study also showed a broken 
helix in the N-terminal of AS in the presence of SDS. Residues Val3-Val37 forms the first helix 
and residues from Lys45 to Thr92, are involved in the second helix. An extended linker which 
has an anti-parallel arrangement connected the two helixes. Subsequently there is a short 
extended sequence from Gly93 to Lys97 followed by the C-terminal flexible tail (Asp98-Ala140) 
(Ulmer et al., 2005a).  
The broken helix model for micelle-bound AS has been also demonstrated with site-directed 
spin labeling-electron paramagnetic resonance (SDSL-EPR) using 1-palmitoyl-2-oleoylsn-
glycero-3-[phospho-L-serine] PS-SUV or SDS micelles. The helix formation was also modeled 
by molecular dynamic simulations (Bortolus et al., 2008). Another proof of the broken helix 
model for AS structure in the presence of negatively charged detergents was demonstrated in 
2010 using a combination of NMR and EPR (Rao et al., 2010). In this study the partially folded 
intermediate conformation of AS in the presence of micelles of the detergent sodium lauroyl 
sarcosinate (SLAS) was characterized. It was found that SLAS-bound AS shows two antiparallel 
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α-helixes encompassing residues Asp2-Lys32 and Ser42-Thr92 which are connected by a linker 
(Rao et al., 2010). These results were consistent with SDS- and PS-SUV-bond AS and all of 
them showed the formation of a broken helix covering the first 100 residues of AS in the 
presence of negatively charged detergents (Bortolus et al., 2008; Rao et al., 2010; Ulmer et al., 
2005b). After these reports, another model was proposed for micelle-bond AS which implied that 
in the presence of micelles the AS conformation is not just a broken helix but another 
conformation, the elongated helix also exists (Georgieva et al., 2010; Lokappa and Ulmer, 2011). 
AS exists in both elongated and broken states and the population ratio of 7.6:1 has been reported 
(Lokappa and Ulmer, 2011). An ESR study of the structural changes of AS in the presence of 
SDS micelles revealed that inter-conversion between broken and extended helix conformations 
depends on the micelles shape, i.e. spheroidal or rod-like, which depends on the SDS and AS 
concentrations. Spheroidal micelles form at low concentrations of SDS (5-60 mM) but the 
critical concentration for rod-like micelles formation is 430 mM (Georgieva et al., 2010). A 
model has been proposed based on the AS physiological role in facilitating synaptic vesicle 
fusion with the plasma membrane by making a bridge between vesicle and the plasma membrane 
(Figure 1.10). In this model spheroidal and rod-like micelles represented the vesicular and 
plasma membranes. The natively unfolded AS binds to the synaptic vesicle and forms an 
extended helix which converted to membrane-spanning broken helix when the vesicle reaches 
the plasma membrane. The membrane-spanning broken helix facilitates the fusion of dopamine 
containing vesicles with the plasma membrane (Figure 1.10) (Georgieva et al., 2010). 
The natively unfolded conformation of AS monomer arises from expression of the AS gene in 
bacteria and purification of overexpressed protein using protocols requiring heating and 
denaturing of sample (Bartels et al., 2011). In 2011 a tetramer structure was reported for AS and 
defined as a four helix bundle (Bartels et al., 2011; Burre et al., 2013; Wang et al., 2011b). Wang 
et al. used a non-denaturing protocol to purify AS from E.coli. Size-exclusion chromatography 
demonstrated a peak with a molecular weight (MW) of 56 kDa which is almost 3.6 times an AS 
monomer. Subsequently, glutaraldehyde was added to the protein solution to cross-link AS 
monomers. Loading of the cross-linked AS on a 12% SDS-PAGE showed four bands which 
suggested that AS monomers are prone to form a tetramer structure (Wang et al., 2011b). Further 
analysis of the isolated cross-linked band also confirmed the existence of AS oligomers. The 
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oligomer structure has been detected on a Blue Native-PAGE (BN-PAGE) gel, a non-denaturing 
electrophoresis method, as a band with molecular weight of 48 kDa (Wang et al., 2011b).  
 
Figure 1.10 Proposed model for the role of AS in synaptic vesicle fusion with the plasma 
membrane. Binding of the natively unfolded AS to the synaptic vesicle (purple arrow) causes the 
transition from random coil to an extended helix. The extended helix converts to a broken helix 
(orange arrow) when vesicle reaches the plasma membrane. Reprinted with permission from 
(Georgieva et al., 2010). Copyright © 2010 American Society for Biochemistry and Molecular 
Biology. All rights reserved. 
In another study, Western blot analysis was performed on lysates of M17D cells (the 
dopaminergic human neuroblastoma line), HEK293, HeLa, COS-7, red blood cell (RBC) lysate 
and cells from the frontal cortex of mouse brain (mouse cort.). The AS from all of the lysates 
showed a 45–50 kDa band in BN-PAGE. The clear native–PAGE (CN–PAGE) gel system which 
lacks the coomassie-dye also has been used to clarify the native AS species from lysates. AS 
molecules from all lysates migrated as an apparent tetramer species with a MW of 55-60kDa on 
CN-PAGE (Bartels et al., 2011).  
The secondary structure of E. coli and RBS derived AS oligomers has been characterized 
using CD spectroscopy and showed a negative ellipticity at 222nm and 208nm with a positive 
ellipticity at 193nm which is typical for the α-helical conformation (Figure 1.11a) (Bartels et al., 
2011; Wang et al., 2011b). By comparison, the CD spectrum of recombinant AS monomer was 
typical for an unfolded protein with a mostly random coil conformation (Figure 1.11b). 
 37 
Furthermore no conformational change has been detected for tetrameric AS in the presence of 
negatively charged SUVs (Figure 1.11a) but the recombinant monomer AS undergoes an α-
helical transition upon binding to negatively charged SUVs (Figure 1.11b) (Bartels et al., 2011). 
Further structural characterization of tetramer AS was performed by in vivo 1H-15N HSQC NMR 
of labeled AS in E. coli cells and showed two α-helical regions encompassing residues Phe4-
Thr43 (α1) and His50-Asn103 (α2). The predicted structure for the C-terminal (104-140) was 
random coil (Wang et al., 2011b).  
 
Figure 1.11 CD spectra of monomeric and tetrameric AS in the presence and absence of lipids. 
(a) CD spectra of tetrameric AS in the absence and presence of negatively charged SUVs (PC/PS 
4:1; protein:lipid 1:500) (b) CD spectra of monomeric AS in the absence and presence of 
negatively charged SUVs (PC/PS 4:1; protein:lipid 1:500). Reprinted with permission from 
(Bartels et al., 2011). Copyright © 2011 Nature Publishing Group. All rights reserved.   
1.4.1.3 Misfolding and Aggregation 
As detailed above, the AS monomer is sufficiently stable to allow detailed structural studies. 
However, under some conditions it can rapidly aggregate. AS aggregation is a process which 
starts from the natively unfolded monomers which are finally converted to oligomers or fibrils of 
AS. The intermediate stage is the conformational change of monomers to form partially folded 
intermediates, a process which is called misfolding (Fink, 2006; Uversky et al., 2001a). 
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Mutations and environmental factors favor the conversion of the unfolded monomers into a 
partially folded conformation (Lee and Trojanowski, 2006). In these intermediates nonpolar side 
chains of residues form a hydrophobic surface which triggers the intra-molecular hydrophobic 
interaction and leads to the second stage which is the oligomerization and fibrillization of AS. 
The natively unfolded monomer lacks the hydrophobic surface. Thus factors shifting the 
equilibrium in favor of the partially folded intermediate can form soluble oligomers or insoluble 
fibrils depending on the conditions. (Figure 1.12) (Fink, 2006; Uversky and Eliezer, 2009; 
Uversky et al., 2001a; Uversky et al., 2001c).  
 
Figure 1.12 Schematic representation which shows the fibrillization process of natively unfolded 
monomers of AS (Nu). It shows misfolding of AS into partially folded intermediate and their 
assembly to form oligomers and fibrils. Reprinted and adopted with permission from (Fink, 
2006). Copyright © 2006 American Chemical Society. All rights reserved.   
The native AS monomer has predominantly a random coil conformation (Serpell et al., 2000; 
Uversky et al., 2001b; Weinreb et al., 1996; Zheng et al., 2013) but the partially folded 
intermediates usually contain α-helical or β-sheet conformations which can be detected by CD 
and FTIR spectroscopies. For example acidic pH causes a transition from natively unfolded AS 
to a partially folded intermediate with β-sheet structure (Uversky et al., 2001b) whereas it 
converts from random coil to an α-helical conformation upon binding to trifluoroethanol (TFE) 
and negatively charged phospholipids (Anderson et al., 2010; Davidson et al., 1998; Jo et al., 
2000). The conformational change of AS at low pH is due to a reduction in intramolecular 
charge-charge repulsion that favours intramolecular hydrophobic interactions (Uversky, 2008). 
Binding of TFE with AS induces a helical partially folded intermediate which has been detected 
in the UV CD spectrum absorbance at 208 and 222 nm. Furthermore, the TFE-induced AS 
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aggregates have been characterized by atomic force microscopy (AFM) and the thioflavin-T 
assay (Anderson et al., 2010). The conformational changes induced by some factors such as 
small molecules cannot be differentiated from the natively unfolded monomers by CD 
spectroscopy because the induced partially folded intermediate contains predominantly random 
coil conformers. For example, the CD spectra of the mutants of AS (Li et al., 2001) and AS in 
the presence of dopamine (Cappai et al., 2005; Outeiro et al., 2009), chlorazole black E (Rao et 
al., 2008), a copper complex of phthalocyanine tetrasulfonate (PcTS-Cu2+) (Rao et al., 2008), 
polycations (polylysine, polyarginine, and polyethyleneimine) (Goers et al., 2003), putrescine, 
spermine (Antony et al., 2003), congo red (Lendel et al., 2009; Rao et al., 2008), trehalose (Yu et 
al., 2012) and lacmoid (Lendel et al., 2009; Rao et al., 2008) were typical of a random coil 
conformation, demonstrating that mutation and complex formation with small molecules do not 
necessarily cause significant changes in the secondary structure of AS.  
Understanding the initiation stage of AS aggregation, i.e. formation of partially folded 
intermediates, will help in the design of inhibitors as new therapeutics to prevent this pathogenic 
process (Trexler and Rhoades, 2010a). NMR spectroscopy (Lendel et al., 2009; Rao et al., 2008) 
and single molecule biophysics techniques have been used to characterize the partially folded 
intermediate or misfolded conformation of AS. Sandal et al. have used single molecule force 
spectroscopy (SMFS) to characterize the conformation of AS under three very different 
conditions known to accelerate aggregation of AS including Cu2+ (1μM), the A30P mutant and 
high ionic strength (500 mM Tris/HCl). The results showed an increase in β-like structure in the 
conformation of AS and demonstrated that the partially folded intermediate for AS aggregation 
under these conditions predominantly contains β-like conformers (Sandal et al., 2008). This 
single molecule technique also has been used to characterize the conformation of pathological 
AS mutants A30P, A53T, and E46K and have found that the mutants gain more compact 
conformations as compared with native wild type AS. It already has been reported that the 
aggregation rate of AS mutants is significantly higher than wild type AS under the same 
conditions (Li et al., 2001; Pandey et al., 2006). So these compact conformations with high 
amount of β-like structure contents demonstrating the partially folded intermediates of AS 
(Brucale et al., 2009). Furthermore Trexler et al. have used single molecule Forster resonance 
energy transfer (smFRET) to characterize the conformation of AS at low pH or after addition of 
spermine and heparin. The results demonstrated that low pH (=3) induces the folding of the AS 
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C-terminus. Binding of spermine and heparin also causes folding of AS (Trexler and Rhoades, 
2010a). Another example of AS conformational characterization using smFRET is the effect of 
trimethylamine-N-oxide (TMAO), a protecting osmolyte, and urea, a denaturing osmolyte, on 
AS structure. This technique revealed that TMAO and urea change the average dimensions of the 
AS normal conformation into more compact and expanded conformations respectively (Ferreon 
et al., 2012). Folded intermediate conformations of AS induced by binding of congo red, PcTS-
Cu2+, chlorazole black E and lacmoid has been characterized using 1H-15N HSQC NMR (Lendel 
et al., 2009; Rao et al., 2008). The spectra of AS in the presence of these ligands showed a 
decrease in intensity of most peaks and the NMR resonances of AS residues involved in the 
interaction were severely broadened which is due to exchange on a slow to intermediate time 
scale (Lendel et al., 2009; Rao et al., 2008).  
AS fibril formation is a nucleation-dependent polymerization. This process involves assembly 
of the partially folded intermediates to form a transient soluble oligomeric species which serves 
as a nucleus for further polymerization to form the fibrils. Monitoring of fibrillization kinetics 
using the thioflavin T assay is based on a fluorescence enhancement of the bound dye to the 
amyloid fibrils. A sigmoidal curve results which is characterized by three phases: an initial lag 
phase, a consequent exponential growth phase, and a final equilibrium phase (Figure 1.13). The 
lag phase involves the misfolding of AS monomers to form partially folded intermediates which 
are aggregation prone and assembly of these intermediates to form the soluble oligomeric nuclei. 
Further association of misfolded monomers to the oligomeric nuclei in the exponential growth 
phase leads to the formation of proto-filaments with a diameter of 3.8±0.5 nm and the assembly 
of the proto-filaments forms the proto-fibrils with a diameter of 6.5±0.6 nm. Association of 
proto-fibrils in the exponential phase causes the formation of the mature insoluble fibrils with a 
diameter of 9.8±1.1 nm which represents the saturated aggregation form of AS and leads to the 
equilibrium phase (Conway et al., 2000; Fink, 2006; Khurana et al., 2003; Uversky et al., 2001c). 
In vitro fibrillization of AS depends on the concentration of AS, temperature and the duration 
and agitation of the sample. For example, agitation accelerates the fibrillization of 70μM AS 
from months to 3 days at 37°C (Fink, 2006; Uversky et al., 2001c). It has been shown that 
increasing the AS concentration causes the reduction of the lag time and an increase in the rate of 
fibrillization (Fink, 2006; Uversky et al., 2001c). Formation of transient soluble oligomeric 
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species has been characterized for A30P and A53T mutants of AS (Conway et al., 2000; Kaylor 
et al., 2005; Lashuel et al., 2002; Volles and Lansbury, 2002; Volles et al., 2001).  
 
Figure 1.13 Monitoring of the aggregation process using the thioflavin T assay which shows the 
lag, growth and equilibrium phases. Reprinted and adopted with permission from (Brorsson et 
al., 2010). Copyright © 2010 Frontiers in Bioscience. All rights reserved. 
It has been shown that fibrillization of AS wild type and the mutants under the same 
conditions occur with different lag times.The lag times for 200μM of A53T, A30P and wild type 
are 35–42 days, 45–49 days and 52–63 days, respectively. Addition of AS preformed fibrils to 
the incubation samples causes a significant reduction in the lag phase and accelerates fibril 
formation. Thus, formation of oligomeric nuclei in the lag phase is the rate-limiting step in the 
aggregation process and preformed fibrils serve as the nuclei which can induce significant 
fibrillization within 15–30 days. The fibrillization of the A53T mutant is faster than A30P and 
wild type (Conway et al., 2000). Furthermore, monitoring of AS aggregation by collecting CD 
spectra at several time points showed the transition from random coil conformation to the β-sheet 
structure for all AS types but the transition time for A53T was faster (Conway et al., 2000). The 
β-sheet structure of the transient soluble oligomeric species also has been characterized by 
Raman microscopy. The results showed the progressive increase in the Raman amide I band to 
1667 cm-1 which represents an increase in β-sheet structure occurring with the formation of more 
ordered aggregates (Apetri et al., 2006). The transient soluble oligomeric species of AS have 
been isolated after sedimentation of fibrils from incubated samples. Then gel-filtration 
chromatography of supernatant was used to separate oligomers as ≥600 kDa species. AFM 
analysis of the concentrated eluate showed spherical species as the transient soluble oligomeric 
nuclei of the AS fibrillization process (Conway et al., 2000). Monitoring of the aggregation 
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process of AS WT and mutants using electron microscopy revealed pore-like oligomer species. It 
has been shown that A30P and WT form annular and pore-like oligomers and A53T forms 
annular and tubular oligomers (Lashuel et al., 2002). The annular oligomers, not the monomeric 
and the fibrillar forms, are able to permeabilize and destroy vesicles via a detergent-like 
mechanism (Lashuel et al., 2002; Volles and Lansbury, 2002; Volles et al., 2001). This ability of 
AS oligomers is associated with their cellular toxicity. It has been shown that AS oligomers are 
more toxic than the fibrils and formation of fibrils is a protective mechanism to reduce the 
cytotoxicity of oligomers and increase cell survival (Colla et al., 2012b; Wan and Chung, 2012; 
Winner et al., 2011). AS fibrillization is a sensitive process which depends on environmental 
factors. Fibrillization-promoting factors include agitation (Fink, 2006; Uversky et al., 2001c), 
low pH (Trexler and Rhoades, 2010a; Uversky et al., 2001b), metals (like copper, lead, iron, 
mercury, zinc, and aluminum) (Bisaglia et al., 2009; Uversky et al., 2001c), pesticides (Silva et 
al., 2013; Uversky et al., 2002; Uversky et al., 2001d) and temperatures above 40 °C (Uversky et 
al., 2001b). There are some chemicals which prevent the fibrillization of AS such as nicotine 
(Hong et al., 2009; Ono et al., 2007b), selegiline (Braga et al., 2011; Ono et al., 2007a), 
entacapone, tolcapone (Di Giovanni et al., 2010), dopamine and its analogs (Leong et al., 2009; 
Li et al., 2005).  
1.4.1.4 Metals and drugs that influence alpha-synuclein misfolding and aggregation 
1.4.1.4.1 Metals 
Comparison of Parkinsonian and age-matched control brain tissue shows an elevation in total 
Fe (Dexter et al., 1989; Gorell et al., 1995; Griffiths et al., 1999; Mann et al., 1994; Minati et al., 
2007; Riederer et al., 1989) and a reduction in the Cu (II) contents in the substantia nigra (SN) 
(Davies et al., 2014; Dexter et al., 1989; Riederer et al., 1989). The zinc content of PD brain 
didn’t show any change as compared with normal brain (Davies et al., 2014). It also has been 
shown that there was a 50% reduction of copper transporter 1 (Ctr1) in PD brains in comparison 
with controls. Moreover the level of superoxide dismutase 1 (SOD1) was increased in the SN of 
PD brains (Davies et al., 2014). Furthermore the copper concentrations in cerebral spinal fluid 
(CSF) samples of PD patients (18.8 ng/ml) are higher than in control samples (10.2 ng/ml) (Boll 
et al., 2008; Hozumi et al., 2011; Pall et al., 1987). Under normal conditions, the blood–CSF 
barrier (BCB) is responsible for homeostasis of copper in the CSF a process with is regulated by 
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ctr1 and a divalent metal transporter-1 (DMT1) (Skjørringe et al., 2012; Zheng et al., 2012). 
Leaking of copper from brain tissues into CSF is due to the impairment of copper transportation 
(Dexter et al., 1989; Loeffler et al., 1996; Skjørringe et al., 2012; Zheng et al., 2012) and also 
damage of brain tissues in PD pathology (Dexter et al., 1989; Loeffler et al., 1996; Zheng et al., 
2012). It has been shown that there is an association between low concentrations of copper in PD 
tissues and impairment of copper binding proteins such as AS and copper- and zinc-containing 
superoxide dismutase (Cu/Zn-SOD). Cu/Zn-SOD protects cells against ROS by catalysing the 
conversion of superoxide to hydrogen peroxide using copper as a cofactor. So reduction of 
copper concentrations and elevation of SOD levels in SN of PD patients increases free radical 
production and cell death (Davies et al., 2014; Montes et al., 2014). It has been shown that 
chelation of copper in SH-SY5Y neuroblastoma cell cultures resulted in a decrease in SOD 
activity and also elevation of ROS (Lombardo et al., 2003). Another copper binding protein is 
AS which has ferrireductase activity. It binds to copper (II) and NADH in order to reduce Fe (III) 
to Fe (II) required for tyrosine hydroxylase function (Brown, 2013; Davies et al., 2011). 
Reduction of copper in PD reduces dopamine biosynthesis and might be involved in the 
pathology of PD (Montes et al., 2014).         
In vitro studies showed that di- and trivalent metal ions such as Al(III), Cd(II), Cu(II), Fe(III), 
Co(III), and Mn(II) interact with AS and cause conformational changes and form partially folded 
intermediates which have a high tendency for aggregation (Bisaglia et al., 2009; Uversky et al., 
2001c). Among the divalent metals which can induce conformational changes in AS structure, 
Cu(II) appears to have the highest affinity. AS has two binding sites with different affinities for 
Cu(II). The high affinity site (Kd~0.1) is located at 1MDVFMKGLS9 and 48VAHGV52. The 
anchoring residue for the binding site at the N-terminal is His50 (Figure 1.14). NMR studies 
show that Cu(II) binds to His50 and N-terminal residues (1-9) and forms a loop. The complex of 
Cu(II) and AS serves as a nucleation point for β-strand formation (Binolfi et al., 2012; Rose et 
al., 2011). Cu (II) at micromolar range (<100μM) binds to this site. There is a common, low 
affinity (Kd~1mM) binding site at the C-terminal located at 119DPDNEA124 for some divalent 
metals including: Zn(II), Fe(II), Mn(II), Co(II) and Ni(II) (Binolfi et al., 2012; Binolfi et al., 
2006; Rasia et al., 2005) (Figure 1.14). These metals and also Cu (II) at high concentrations bind 
to this site (Binolfi et al., 2012; Davies et al., 2014; Rasia et al., 2005).  
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Figure 1.14 Schematic representation showing Cu(II) binding sites in the N-terminus and a 
general metal binding site at the C-terminus of  AS. Reprinted with permission from (Binolfi et 
al., 2012). Copyright © 2012 Elsevier All rights reserved. 
1.4.1.4.2 Methamphetamine 
     Methamphetamine has a chiral center, and two optical isomers: (+)-methamphetamine (d-
methamphetamine) (Figure 1.15a) and (-)-methamphetamine (l-methamphetamine) (Figure 
1.15b) (Anglin et al., 2000; Mendelson et al., 2006).  
 
Figure 1.15 Structure of (+)-methamphetamine (d-methamphetamine) (a) and (-)-
methamphetamine (l-methamphetamine) (b).  
 The drugs may be abused as single isomers or a mixture, depending on the drug product or 
source. The d-isomer is most of the “illicit methamphetamine” in the United States (Mendelson 
et al., 2006). The pharmacological properties of (+)-methamphetamine are known and it is 
revealed that this drug promotes release of dopamine from the nerve endings into the synapse 
and increases the extracellular levels of the monoamine neurotransmitters. It has been shown that 
the striatum of the brain is the target area of d-methamphetamine.  At the molecular level d-
methamphetamine stimulates the reverse transportation of dopamine from synaptic vesicles to 
the cytoplasm of nerve endings by the vesicular monoamine transporter 2 (VMAT2) and then 
release of dopamine into the synapse by dopamine transporters (Granado et al., 2013; Kish, 
2008). The increase of synaptic levels of dopamine causes desired effects for abusers such as 
wellbeing, ecstasy, wakefulness, alertness, increased physical activity and energy. It also has 
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many adverse effects such as increased blood pressure and heart rate, damage of brain vessels, 
suppression of appetite and cerebrovascular accident (Granado et al., 2013; Kish, 2008; 
Mendelson et al., 2006).  
The effects of racemic and l-methamphetamine in humans are relatively unknown. The l- 
isomer of methamphetamine is present in the Vicks Vapor Inhaler (containing 50 mg l-
methamphetamine but called levmetamfetamine by the manufacturer). The dextrorotatory isomer 
of methamphetamine is marketed as Desoxyn for the treatment of attention deficit disorder and 
narcolepsy. In general, the d-isomer is more effective than the l-isomer in producing central 
nervous system (CNS) stimulation. Furthermore, human studies showed that d-
methamphetamine produces more cardiovascular effects than equivalent doses of l-
methamphetamine. L-methamphetamine intoxication is similar to that of the d-isomer at high 
doses, but the psychodynamic effects are shorter-lived and less desired by abusers (Mendelson et 
al., 2006).  
 As methamphetamine induces dopamine deficiency in animals, there was a concern that use 
of methamphetamine might damage dopamine neurons in humans and thereby increase the risk 
of developing PD (Callaghan et al., 2010; Granado et al., 2013). Positron emission tomography 
of d-methamphetamine abusers showed a significant loss of DA transporters in the striatum 
(Callaghan et al., 2010; Thrash et al., 2009; Volkow et al., 2001a; Volkow et al., 2001b). Drug 
abusers also have a low level of brain dopamine which might be due to brain damage (Granado 
et al., 2013; Kish, 2008). Recently it has been reported that methamphetamine addicts have a 
higher incidence of PD (Callaghan et al., 2010; Callaghan et al., 2012; Granado et al., 2013; 
Moszczynska et al., 2004). In this study competing risks analysis was used to determine whether 
the methamphetamine users group had elevated risk of developing PD in comparison to a 
matched population-proxy appendicitis group and a matched cocaine drug control group. The 
results demonstrated that the methamphetamine user group showed an increased risk of PD 
compared to the other groups (Callaghan et al., 2012). Further investigation showed the 
association between d-methamphetamine neurotoxicity and AS expression (Ajjimaporn et al., 
2007; Chen et al., 2013; Fornai et al., 2005; Mauceli et al., 2006). Fornai et al. showed that 
treatment of mice at a dose of 5mg/kg×3 with 2 hours intervals results in a significant decrease in 
dopamine levels of the striatum. Furthermore immunostaining of AS in the substantia nigra 
showed the enhancement of AS immunofluorescence in the treated mice and also demonstrated 
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that AS was assembled in compact spots within dopaminergic neurons. These findings suggested 
that d-methamphetamine causes the overexpression of AS which finally accumulates and 
aggregates in the brain (Fornai et al., 2005). Overexpression of AS after treatment with d-
methamphetamine has been demonstrated in human SK-N-SH neuroblastoma cells used as a 
model for dopaminergic cells. The results showed that treatment of cells with different 
concentrations of methamphetamine increased the AS levels up to about 50% in comparison with 
control cells and also reduces the cell viability (Ajjimaporn et al., 2007). Moreover it has been 
demonstrated that silencing of AS expression in methamphetamine treated SH-SY5Ycells, 
increases the viability of these cells (Chen et al., 2013). These results together showed the 
involvement of AS in methamphetamine induced pathology and suggested that the high 
incidence of PD pathology among methamphetamine abuser is due to the overexpression and 
aggregation of AS (Ajjimaporn et al., 2007; Chen et al., 2013; Fornai et al., 2005; Mauceli et al., 
2006). 
1.4.1.4.3 Nicotine 
Epidemiological studies reveal that tobacco smoking significantly decreases the risk of PD 
(Checkoway et al., 2002; Hernán et al., 2002; Kessler and Diamond, 1971; Ono et al., 2007b; 
Quik, 2004; Ross and Petrovitch, 2001). More than a thousand compounds have been identified 
in cigarette smoke and some of them may have therapeutic effects which may provide protection. 
It has been shown that the nicotine of tobacco smoke has a neuroprotective effect against PD 
symptoms (Alves et al., 2004; Hernán et al., 2002; Hong et al., 2009; Quik, 2004). The nicotine 
brain concentration after consumption of one cigarette has been calculated to be 50 ng/ml (Rose 
et al., 1999) based on the reported nicotine blood concentrations in smokers (Benowitz et al., 
1982; Brody et al., 2006; Gritz et al., 1981; Rose et al., 1999; Rose et al., 2010; Russell et al., 
1980). The average number of cigarettes consumed by smokers in a day is 30 to 36 (Benowitz et 
al., 1982; Russell et al., 1980) which would result in a maximum concentration 1500 to 1800 
ng/ml if the breakdown is slow.  
Tobacco is prepared from a plant which belongs to the Solanaceae family. Examples of edible 
products derive from the Solanaceae family are peppers, tomatoes, potatoes, and eggplants. The 
results of a study on 490 idiopathic PD patients and 644 normal controls revealed that a diet 
including Solanaceae family products such as peppers, tomatoes, tomato juice, and potatoes 
(baked or mashed) reduced the risk of PD (Nielsen et al., 2013).  Nicotine is an optically active 
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compound (Moore et al., 2003; Welter et al., 2005) and the naturally occurring form of nicotine 
is (-)-nicotine or l-nicotine (Figure 1.16a). The dextrorotatory form, (+)-nicotine or d-nicotine 
(Figure 1.16b) is physiologically less active than (-)-nicotine (Moore et al., 2003; Rapier et al., 
1988) and (-)-nicotine is more toxic than (+)-nicotine (Moore et al., 2003).  
 
Figure 1.16 Structure of (-)-nicotine or l-nicotine (a) and (+)-nicotine or d-nicotine (b).  
The neuroprotective effect of nicotine in PD is through stimulation of the nicotinic 
acetylcholine receptors (nAChRs). It has been shown that nicotine evoked the release of 
dopamine from striatal synaptosome in rats with an EC50 of 3.8 μM. This ability was 
stereospecific and it has been shown that the action of (-)-nicotine was 100 times stronger than 
(+)-nicotine (Fujita et al., 2006; Rapier et al., 1988). It also has been shown that chronic nicotine 
exposure changes the expression of genes in the substantia nigra pars compacta (SNc). In this 
study mice received 2 mg/kg/h (-)-nicotine for 14 days. Twenty dopaminergic neurons were 
isolated from mice brains and were subjected to single cell transcriptomics using Illumina 
Sequencing. The results revealed that the expression of 129 genes were changed after nicotine 
exposure (67 upregulated, 62 downregulated) including genes involve in the ubiquitin–
proteasome pathway which has an important role in the pathogenicity of PD (Henley et al., 
2013).  In vivo studies in a monkey model of PD, caused by chronic exposure to MPTP, has 
demonstrated the synergistic effect of levodopa and SIB-l508Y, a nAChR agonist, in relieving 
motor symptoms (Schneider et al., 1998). In another study using the monkey model of PD, both 
levodopa and nicotine therapies were administrated simultaneously. These monkeys received 20 
mg/kg daily doses of nicotine and levdopa for up to 6 months. The results showed a reduction in 
the levodopa-induced dyskinesias in animals treated with both nicotine and levodopa in 
comparison with those receiving just levodopa (Quik et al., 2013). Furthermore, (-)-nicotine 
administered orally by gum or transdermally by the patch has been shown to improve symptoms 
of PD (Hong et al., 2009; Quik, 2004; Quik et al., 2009). A clinical trial in six males suffering 
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from idiopathic PD received increasing doses of nicotine, 5–105 mg/day, within 14 weeks using 
nicotine patches. The results showed an improvement of motor symptoms in all subjects and also 
patients were less dependent on levodopa treatment (Villafane et al., 2007).  
Another mechanism proposed for the neuroprotective effects of (-)-nicotine in PD is anti-
fibrillogenic and fibril-destabilizing activity (Hong et al., 2009; Ono et al., 2007b). In one study 
the effect of (-)-nicotine and related compounds on AS fibrillization was investigated. 
Hydroquinone was used as a control in this study because it has a different structure from the 
other smoke compounds and also is a known inhibitor of AS fibrillization. Thioflavin T (ThT) 
assays, SDS-PAGE, Size-Exclusion HPLC (SEC-HPLC) and atomic force microscopy (AFM) 
were used to investigate the inhibitory effects. The results reveal that (-)-nicotine and 
hydroquinone inhibit AS fibril formation in a concentration-dependent manner. Hong et al. used 
the ThT fluorescence assay to study the inhibitory effect of different ratios of AS to (-)-nicotine 
([1:1.5], [1:3] and [1:6]).  They showed that as the (-)-nicotine concentration increases, the ThT 
fluorescence signal decreases, suggesting the effective inhibition of AS fibrillization. 
Furthermore, the AFM studies showed that at a ratio of AS to (-)-nicotine of 1:6, AS 
fibrillization is inhibited almost completely (Hong et al., 2009).  
In another study a fragmentation approach was used to examine the effects of (-)-nicotine and 
two components of (-)-nicotine (pyridine and N-methylpyrrolidine) on the formation and 
destabilization of AS fibrils from wild-type AS and the A53T mutant. Fluorescence spectroscopy 
with thioflavin S (ThS), electron microscopy (EM) and atomic force microscopy (AFM) were the 
techniques used. The results show that (-)-nicotine inhibited the formation of AS fibrils and 
destabilized the fibrils from both wild-type AS and the A53T mutant. The inhibitory effect of (-)-
nicotine was concentration-dependent. Furthermore, the N-methylpyrrolidine moiety of (-)-
nicotine was identified as the functional fragment for the anti-fibrillogenic and fibril-
destabilizing activity of (-)-nicotine (Ono et al., 2007b).  
1.4.1.4.4 Dopamine 
Dopamine is a member of the catecholamine family of compounds which acts as a 
neurotransmitter. Dopamine consists of an amine group (NH2) linked to a catechol structure 
(Figure 1.17). There are five known types of dopamine receptors; D1, D2, D3, D4, and D5 in the 
brain. Dopamine is produced in several areas of the brain, including the substantia nigra and the 
ventral tegmental area (Seth and Seth, 2009; Waller et al., 2001). Anden et al. have reported that  
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the dopamine concentration within striatal nerve terminals is as high as 50 mM (Andén et al., 
1966; Spencer et al., 1996). This concentration is an estimation of dopamine contents of the 
whole neuron and doesn’t reflect the cytoplasmic concentration of dopamine. The cytoplasmic 
dopamine which has been synthesized from L-DOPA or transported into the cell is isolated into 
monoaminergic vesicles to protect them from auto-oxidation processes promoted by the 
cytoplasmic high pH environment (Lotharius and Brundin, 2002a). The cytoplasmic 
concentration of dopamine has been measured in the μM range (0.5-2.2) in pheochromocytoma 
cells and a single neuron of the pond snail (Olefirowicz and Ewing, 1990; Perlman and Sheard, 
1982). This reveals the importance of efficient dopamine sequestration into monoaminergic 
vesicles (Lotharius and Brundin, 2002a, b). AS has an important role in the formation of synaptic 
vesicles and dopamine storage as a protection against cytosolic oxidation of dopamine (Lotharius 
and Brundin, 2002a; Sudhof, 2013).  
 
Figure 1.17  Structure of dopamine.  
Degeneration of the basal ganglia in the brains of PD patients primarily affects dopaminergic 
neurons in the substantia nigra which results in dopamine deficiency. Exogenous L-dopa can 
replace the endogenous deficient neurotransmitter. L-DOPA is taken up by the remaining 
dopaminergic neurons where it undergoes decarboxylation in the presynaptic terminal to form 
dopamine (Grosset et al., 2009; Pahwa and Lyons, 2007).  
There have been conflicting reports concerning the effect of dopamine on the 
aggregation/fibrillization of AS (Cappai et al., 2005; Conway et al., 2001; Follmer et al., 2006; 
Jethva et al., 2011; Lee et al., 2011; Leong et al., 2009; Li et al., 2005; Li et al., 2004; Norris et 
al., 2005; Ono et al., 2007a). It would appear that dopamine stabilizes the formation of 
oligomeric AS by inducing AS monomer oligomerization or destabilization of preformed AS 
fibrils. Figure 1.18 demonstrated the multiple effects of dopamine in the AS fibrillization 
process. Route 1 shows the AS fibril formation from AS monomers. In this process monomers 
are aggregated to form transient oligomers and assembly of these oligomers leads to the 
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formation of fibrils (Figure 1.18). It has been reported that dopamine destabilized preformed AS 
fibrils and dissolved them into soluble oligomers (Route 2) (Leong et al., 2009; Li et al., 2004; 
Ono et al., 2007a). It has been demonstrated that incubation of dopamine with monomeric AS 
causes the formation of stabilized oligomers which are SDS resistant and no significant 
fibrillization occurs from assembly of these oligomers (Route 3a) (Figure 1.18) (Cappai et al., 
2005; Fink, 2006; Lee et al., 2011; Leong et al., 2009; Norris et al., 2005). Further investigations 
revealed that these stabilized oligomers resulted from adduct formation between oxidized 
dopamine and AS monomers (Conway et al., 2001; Li et al., 2005; Li et al., 2004). Dopamine 
and AS were incubated with or without shaking at 37°C for a long time (1-30 days) (Cappai et 
al., 2005; Conway et al., 2001; Norris et al., 2005). This condition promoted the oxidative 
ligation of dopamine to AS, since addition of antioxidants eliminated adduct formation (Conway 
et al., 2001). The stabilized oligomers can be converted to fibrils slowly after prolonged 
incubation and with a very low rate (Route 3b) (Figure 1.18) (Follmer et al., 2006; Leong et al., 
2009).  
 
Figure 1.18 Schematic representation of the effect of dopamine in AS misfolding and 
aggregation. (Route 1) fibrillization of AS from monomers (Route 2) destabilization of AS fibrils 
by dopamine (Route 3a) Formation of stabilized oligomers of AS due to adduct formation 
between oxidized dopamine and AS monomers (Route 3b) conversion of stabilized oligomers to 
fibrils is a very slow process. Reprinted with permission from  (Leong et al., 2009). Copyright © 
2009 Springer. All rights reserved. 
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1.4.1.4.5 Other small molecules 
Epidemiologic studies demonstrated an inverse association between caffeine use and PD 
(Altman et al., 2011; Ascherio and Chen, 2003; Postuma et al., 2012; Rivera-Oliver and Díaz-
Ríos, 2014; Ross et al., 2000; Schapira et al., 2006). Caffeine (Figure 1.19a) is a nonselective 
adenosine antagonist which possesses neuroprotective properties (Chen et al., 2001; Schapira et 
al., 2006). In vivo studies using rat models of PD have demonstrated the neuro-protective effects 
of caffeine to prevent the degeneration of dopaminergic neurons (Chen et al., 2001; Machado-
Filho et al., 2014; Mpofana et al., 2014; Schwarzschild et al., 2003). Chen et al. have shown that 
treatment of the MPTP rat model of PD with caffeine (10 mg/kg) before intraperitoneal 
injections of MPTP (20 mg/kg ˟4) reduced the MPTP induced biochemical lesions of the 
dopaminergic nigrostriatal system including recovery of dopamine depletion and a significant 
increase in brain levels of the dopamine transporter, dopamine and its metabolite 
dihydroxyphenylacetic acid (DOPAC) (Chen et al., 2001). The neuro-protective effect of 
caffeine also has been demonstrated in a 6-hydroxydopamine (6-OHDA) rat model of PD. It has 
been shown that treatment of rats with 20 mg/kg caffeine results in improvement of locomotor 
activity, increased dopamine and tyrosine hydroxylase activity in the striatum and the attenuation 
of the 6-OHDA induced brain lesions (Machado-Filho et al., 2014; Mpofana et al., 2014).      
Curcumin (Figure 1.19b) is another natural compound with neuroprotective properties for PD 
(Ahmad and Lapidus, 2012; Darvesh et al., 2012; Jiang et al., 2013; Liu et al., 2011; Mythri and 
Bharath, 2012; Pandey et al., 2008; Qualls et al., 2014; Siddique et al., 2014; Singh et al., 2012; 
Wang et al., 2010b; Yang et al., 2014). Curcumin (diferuloylmethane) is a polyphenolic 
compound found in turmeric which has blood brain barrier crossing ability. This natural 
compound has a potential therapeutic role in neurological disorders including Alzheimer’s, 
Parkinson’s, and Huntington’s disease (Mythri and Bharath, 2012; Singh et al., 2012). In vivo 
and in vitro studies have shown the neuroprotective effects of curcumin against PD pathogenicity 
(Qualls et al., 2014; Siddique et al., 2014; Yang et al., 2014). Yang et al. have shown that 
curcumin improved the behavioral and pathological symptoms in a 6-OHDA-induced PD rat in a 
concentration dependent manner. Treatment of rat models of PD with 5-20 mg/kg/day of 
curcumin resulted in significant elevation in body weight and improvement in neurobehavior. 
Furthermore curcumin increased the level of monoamine neurotransmitters in hippocampus and 
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also prevented 6-OHDA-induced cell lesions and stimulated regeneration of neurons in the 
hippocampus (Yang et al., 2014). In another study it was demonstrated that pre-treatment of SH-
SY5Y cells with curcumin protects them against the neurotoxicity effect of rotenone and also 
increased the cell viability (Qualls et al., 2014). Curcumin also attenuated PD symptoms in a fly 
model of PD in a dose dependent manner. Treatment of transgenic Drosophila expressing human 
AS with 25-100 μM curcumin resulted in postponed loss of activity patterns, reduction in the 
oxidative stress and apoptosis, and an increase in the survival rate (Siddique et al., 2014). Other 
studies revealed a link between the neuroprotective effect of cucumin and AS pathogenicity in 
PD (Ahmad and Lapidus, 2012; Jiang et al., 2013; Liu et al., 2011; Pandey et al., 2008; Wang et 
al., 2010b). It has been shown that curcumin attenuates the cytotoxicity induced by 
overexpression of wild type and A53T mutant of AS by reducing apoptosis and ROS production 
in SH-SY5Y and PC12 cells (Jiang et al., 2013; Liu et al., 2011; Wang et al., 2010b). Curcumin 
also interacts with AS directly and inhibits its aggregation in vitro (Ahmad and Lapidus, 2012; 
Pandey et al., 2008). Pandey et al. showed that that curcumin (0.01-100 μM) modulated the 
fibrillization of 5μM AS in the presence of 1mM FeCl3, as an aggregation promoting agent, and 
increased the SDS-soluble AS monomers (14 kDa) in a dose-dependent manner. The fibril 
destabilizing effect of curcumin against AS aggregates also has been demonstrated in SH-SY5Y 
and dopaminergic MN9D cells transfected with the A53T mutant AS (Pandey et al., 2008). 
Ahmad et al. have shown that curcumin binds to the monomers of AS and the dissociation 
constant for this interaction has been measured as 10-5 M. Mutants of AS, Y39W/A69C and 
A69C/F94W, have been used to study the binding of curcumin by measuring Trp fluorescence. 
Furthermore monitoring fibrillization and oligomerization of AS in the presence of curcumine by 
ThT fluorescence and far-UV CD at 217 nm revealed the inhibitory effect of curcumin against 
AS fibril and oligomer formation. The results showed no increase in ThT fluorescence and β-
sheet structured (Ahmad and Lapidus, 2012).      
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Figure 1.19 Structure of caffeine (a) and curcumin (b).  
1.5 HSQC-NMR 
1.5.1 Principles 
Many serious human diseases have been linked to protein misfolding and aggregation. NMR 
has appeared as an important tool for studying the protein folding and misfolding process 
because of the unique structural insights it can provide into the events of the protein folding 
process (Dyson and Wright, 2004). The major aim of many studies on protein interactions with 
large or small molecules is delineation of the site of binding. The most frequently used NMR 
method for studying protein-ligand interactions is Heteronuclear Single Quantum Correlation 
(HSQC) spectroscopy which is based on chemical shift changes resulting from complex 
formation. HSQC-based experiments allow the detection of ligand interaction over a wide range 
of dissociation constant values. Binding is detected by comparing 2D 1H-15N HSQC spectra of 
15N-labeled protein in the absence and presence of ligand to reveal ligand-induced changes in 
chemical shift and peak intensity. Each residue of the protein (except proline) has an amide 
proton attached to nitrogen in the peptide bond. The HSQC provides the correlation between the 
nitrogen and amide proton and each amide yields a peak in the HSQC spectra. The spectrum 
provides an excellent high-resolution fingerprint of a protein as there is a signal for each 
covalently bonded 1H-15N group of each peptide bond in HSQC-NMR. In general, each residue 
should produce an observable peak in the spectrum (Barbar, 1999; Chatterjee et al., 2005; Dyson 
and Wright, 2004; Hartmann et al., 2008; Konrat, 2014; Kosol et al., 2013; Kwan et al., 2011). 
Some of the residual side chains also have a proton attached to nitrogen such as tryptophan and 
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asparagine. These 1H-15N groups also appear in the HSQC-NMR spectrum (Hartmann et al., 
2008; Kwan et al., 2011). The nuclei of 1H and 15N possess nuclear spin which generates a 
magnetic dipole. The NMR spectrometer applies a magnetic field to the solution containing 
protein samples labeled with 15N. This magnetic field forces the magnetic dipoles to be aligned 
with the applied field in two different ways; the same orientation (parallel) or the opposite 
orientation (antiparallel). The energy of antiparallel orientation is higher than the parallel 
orientation. By applying pulses of electromagnetic energy at the resonance frequencies, some 
energy is absorbed and permits the nuclei to switch into the high-energy state. The frequency of 
the absorbed energy depends on the nuclei and chemical environment and nuclei in different 
environments or different positions of a specific protein resonate at different frequencies. HSQC-
NMR is a 2D plot of 15N resonance frequency against 1H resonance frequency and the width of 
each signal represents the intensity of the absorbed electromagnetic energy. The resonance 
frequencies are described as chemical shifts in units of p.p.m. (Dyson and Wright, 2004; 
Hartmann et al., 2008; Kosol et al., 2013; Kwan et al., 2011). 15N labeled samples are 
recombinant proteins which are produced in bacteria with a medium containing nutrients with 
15N labeled isotope such as 15NH4Cl (Kwan et al., 2011).  
HSQC-NMR gives information about the structure and dynamics of proteins (Barbar, 1999; 
Chatterjee et al., 2005; Dyson and Wright, 2004; Hartmann et al., 2008; Konrat, 2014; Kosol et 
al., 2013; Kwan et al., 2011). The HSQC spectra for random coil and α-helix-rich proteins are 
less well dispersed than proteins with high β-sheet contents. The spectra for unfolded proteins 
show that all amide protons are exposed to solvent and exist in the same chemical environment. 
Structured proteins and natively unfolded ones have high quality spectra with sharp lines but the 
spectra for partially folded intermediates have a poorer quality with broader lines. This line 
broadening is a result of structural flexibility of molten globule intermediates which allows them 
to shift between different possible ensembles on the μs-ms timescale. Thus there is signal decay 
for nuclei of partially folded intermediates which results in line broadening (Chatterjee et al., 
2005; Dyson and Wright, 2004; Hartmann et al., 2008; Kosol et al., 2013; Kwan et al., 2011). 
This technique also can be used to characterize the stability of a protein over time if the sample 
undergoes aggregation or dimerization (Barbar, 1999; Dyson and Wright, 2004; Hartmann et al., 
2008; Kosol et al., 2013; Kwan et al., 2011).   
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1.5.2 Application in alpha-synuclein structure and function determination 
The natively unfolded structure of AS has been characterized by 1H-15N-HSQC NMR 
(Chandra et al., 2003; Sung and Eliezer, 2007; Wu et al., 2008). NMR spectroscopy has been 
used to characterize the partially folded intermediate or misfolded conformation of AS resulting 
from its interaction with small molecules and lipids (Lendel et al., 2009; Rao et al., 2008). The 
folded intermediate conformations of AS induced by binding of vitamin K (da Silva et al., 2013),  
congo red (Lendel et al., 2009; Maltsev et al., 2011; Rao et al., 2008), PcTS-Cu2+ (Rao et al., 
2008), exifone (Yamaguchi et al., 2010), chlorazole black E (Rao et al., 2008) and lacmoid 
(Lendel et al., 2009; Rao et al., 2008) have been characterized using 1H-15N HSQC NMR 
(FM19,20,NMR8 ). The spectra of AS in the presence of these ligands showed a decrease in 
intensity of most peaks and NMR resonances of AS residues involved in the interaction were 
severely broadened which is due to a slow to intermediate time scale as the main reason for the 
reduced residual peak intensity. In some cases a few peaks also shifted (Lendel et al., 2009; 
Maltsev et al., 2011; Rao et al., 2008).  
The conformational change of AS in the presence of phosphatidylserine-small unilamellar 
vesicles (PS-SUVs) and SDS was further investigated by NMR spectroscopy. The 1H-15N HSQC 
spectrum of AS (0.1 mM) was typical of an unfolded protein with a dense cluster of cross-peaks 
over a narrow range but in the presence of saturating concentrations of PS-SUVs and SDS most 
of the cross-peaks disappeared and their intensity reduced significantly. The disappeared residues 
are involved in the folding of AS due to binding with large size SUVs which leads to broadening 
of the resonances of the corresponding amide groups of AS and are consistent with the formation 
of α-helical structure upon micelle binding revealed by CD spectroscopy. The position and 
intensity of some other cross-peaks remained unchanged and demonstrated that these residues do 
not bind to lipid and stay unfolded even in the presence of SUVs (Chandra et al., 2003). 
Furthermore it has been demonstrated that in the presence of negatively charged lipids the first 
100 residues of AS interact with the surface of SUVs or detergents and adopt α-helical 
conformation. This conformational change causes them to broaden and therefore they did not 
show up in the HSQC spectra (Chandra et al., 2003; Davidson et al., 1998; Georgieva et al., 
2008; Jao et al., 2008; Ulmer et al., 2005a).  
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1.6 Objectives 
The purpose of this thesis is to characterize the conformational changes of AS in the presence 
of Cu(II) as a fibrillization agent, caffeine as an anti-parkinsonian small molecule, 
methamphetamine as a Parkinson’s developing toxin and anti-fibrillization agents such as 
dopamine, nicotine and curcumin. Nanopore analysis will be used as the main technique for 
studying conformational changes induced by the binding of copper and small molecules to AS. 
Further details of the interaction have been elucidated by CD spectroscopy, ITC and NMR 
spectroscopy.   
The Objectives of the project are as follow: 
1- Characterize the conformational changes of AS peptides in the presence of ligands using 
nanopore analysis, CD spectroscopy and NMR spectroscopy. 
2- Characterize the binding site(s) of the ligands by NMR spectroscopy and mapping of the 
binding site(s) using nanopore analysis of AS peptide fragments.  
3- Measure the dissociation constants of interactions using isothermal titration calorimetry.  
 
1.7 Hypothesis 
The central hypothesis of this thesis is that nanopore analysis is a useful technique to detect 
and differentiate conformational changes of AS in the presence of different ligands.  
 
  
 
 
 
 
 
 57 
2 MATERIALS AND METHODS 
2.1 Reagents, supplies, and equipment  
The reagents, supplies, and equipment used in this thesis are listed in Table 2.1.  Table 2.2 
lists the names and addresses of supplier companies.  
Table 2.1 List of chemical reagents and equipments with their suppliers. 
Item Supplier 
  
Chemical and biological reagents 
  
1,2-diphytanoyl-sn-glycero-3-phosphocholine in chloroform  Avanti Polar Lipids 
15N-Alpha-Synuclein (Uniform Label) rPeptide 
2,2-dimethyl-2-silapentane-5-sulfonic acid Sigma-Aldrich 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)   BDH 
Acetic acid, glacial (C2H4O2) BDH 
Alpha-hemolysin  Sigma-Aldrich 
Alpha-Synuclein rPeptide 
Alpha-Synuclein, 1-60 rPeptide 
Alpha-Synuclein, 61-140 rPeptide 
Alpha-Synuclein, 96-140 rPeptide 
Alpha-Synuclein, A30P mutant rPeptide 
Alpha-Synuclein, A53T mutant rPeptide 
Alpha-Synuclein, E46K mutant rPeptide 
Alpha-Synuclein, Delta NAC rPeptide 
Anabasine Sigma-Aldrich 
Caffeine solution (analytical standard) Sigma-Aldrich 
Copper sulfate (Cu2SO4∙5H2O)  Sigma-Aldrich 
Curcumin Sigma-Aldrich 
Decane (anhydrous)  Sigma-Aldrich 
Deuterium oxide (D2O) Sigma-Aldrich 
Disodium ethylenediaminetetraacetate dehydrate (EDTA-Na2)  Sigma-Aldrich 
Dopamine hydrochloride Sigma-Aldrich 
Ethanol  EMD 
Glycerol Thermo Fisher Scientific 
Hydrochloric acid (HCl)  BDH 
Magnesium chloride (MgCl2)  BDH 
(-)-Methamphetamine TRC 
(+)-Methamphetamine hydrochloride solution Sigma-Aldrich 
(+)-Nicotine TRC 
(-)-Nicotine solution (analytical standard) Sigma-Aldrich 
Nitrogen (gaseous)  Praxair 
Nuclease-free Water Life Technologies 
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Octyl β-D-glucopyranoside Sigma-Aldrich 
palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] Avanti Polar Lipids 
Phosphate buffered saline Sigma-Aldrich 
Potassium chloride (KCl)  EMD 
Pur-A-Lyzer™ Mini Dialysis Kit Sigma-Aldrich 
Sodium Acetate (CH3COONa) Sigma-Aldrich 
Sodium bicarbonate ( NaHCO3) Sigma-Aldrich 
Sodium carbonate, Na2CO3 Sigma-Aldrich 
Sodium hydroxide (NaOH), pellets  EMD 
Sodium phosphate dibasic (Na2HPO4)  Thermo Fisher Scientific 
Sodium phosphate monobasic (NaH2PO4)  Thermo Fisher Scientific 
Sulfuric acid (H2SO4)  EMD 
  
  
Equipment and supplies 
  
Amplifier, Axopatch 200B Axon Instruments  
Bruker Avance NMR spectrometer (600 MHz) Bruker 
CHIRASCAN PLUS CD spectrophotometer AppliedPhotophysics 
Digitzer, DigiData 1440A Axon Instruments  
Faraday cage  Warner Instruments  
Glass vials with caps Kimble Chase & VWR 
Headstage, CV203BU  Axon Instruments 
Microcentrifuge, Hettich Mikro 20 Hettich Zentrifugen 
Microcentrifuge tubes, non-stick Life Technologies 
Molecular Operating Environment (MOE) software package  Chemical Computing Group  
NanoAnalyze software TA Instruments 
Nano-ITC  TA Instruments 
Nano ITC Run Software TA Instruments 
NMRPipe  Dr. Bax Group, NIH 
NMRViewJ One Moon Scientific 
Origin 7 graphing software OriginLab 
Paintbrushes, size 000 Island Blue  
Parafilm  VWR 
Pasteur pipettes VWR 
pClamp 9.0 and 10.1 software suite Axon Instruments 
PCR microcetrifuge tubes VWR 
Perfusion bilayer chamber and cup  Warner Instruments 
pH meter  Thermo Fisher Scientific 
Pipettes  Eppendorf  
Power supply, ONEAC PC750A Oneac 
Pro-Data™ Software Suite  AppliedPhotophysics 
Silver wire Alfa Aesar  
Syringe filters, 0.2 μm Thermo Fisher Scientific 
Syringe needles Becton Dickinson  
Syringes, microliter Hamilton 
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Syringes, milliliter  Becton Dickinson  
 
Table 2.2 List of companies with addresses. 
Company Address 
Alfa Aesar  Alfa Aesar, Ward Hill, MA, USA 
AppliedPhotophysics Surrey, United Kingdom 
Avanti Polar Lipids Avanti Polar Lipids, Alabaster, AL, USA 
Axon Instruments  Molecular Devices,Sunnyvale, CA, USA 
BDH VWR International, Edmonton, AB, Canada 
Becton Dickinson  Becton Dickinson Canada, Mississauga, ON, Canada 
Bruker Milton, Ontario, Canada 
Chemical Computing Group Montreal, Quebec, Canada 
EMD EMD Millipore, Gibbstown, NJ, USA 
Eppendorf  Eppendorf Canada, Mississauga, Ontario, Canada 
Hamilton Hamilton Company, Reno, NV, USA 
Island Blue  Island Blue Print, Victoria, BC, Canada  
Life Technologies Life Technologies, Burlington, ON, Canada 
OriginLab OriginLab, Northampton, MA, USA 
Praxair Praxair, Saskatoon, SK, Canada 
rPeptide Bogart, GA, USA 
Sigma-Aldrich Sigma-Aldrich Canada, Oakville, ON, Canada 
TA Instruments New Castle, PA, USA 
Thermo Fisher Scientific Fisher Scientific Company, Ottawa, ON, Canada 
TRC Toronto Research Chemicals, Toronto, Ontario, Canada                
VWR VWR International, Edmonton, AB, Canada 
Warner Instruments  Warner Instruments, Hamden, CT, USA 
  
2.2 Nanopore sensing and patch-clamp experimental setup                                             
The nanopore experiments with 0.35 mg of 1,2-diphytanoyl-sn-glycero-3-phosphocholine 
(DPhPC) micelles and wild type AS were performed by David Boyle. The nanopore experiments 
with caffeine and curcumin were performed by Joe Kakish.  
In general the nanopore analysis was performed in a buffer containing 1 M KCl, 10 mM 
HEPES-KOH, pH 7.8 and EDTA was added to the cis chamber to a final concentration of 1 mM. 
Figure 2.1 shows a schematic representation of the nanopore experimental set up using the αHL 
pore. With a small brush a lipid bilayer of 1,2-diphytanoyl-sn-glycero-3-phosphocholine 
(DPhPC), was painted onto a 150 μm  opening in a Teflon ® perfusion cup (Figure 2.2b,c) which 
separated two buffer compartments, the cis and trans chambers, of 1.5 mL volume each. 
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Experiments were set up in a Faraday cage. Chambers were filled with the buffer and Ag/AgCl 
electrodes were placed into each chamber. The cathode was put into the cis chamber to allow the 
negatively charged AS proteins and peptides to move towards the trans chamber. Electrodes 
were connected to a current amplifier and a digitizer (Figure 2.1, Figure 2.2a). The experiments 
were carried out at 22 ± 1°C with an applied potential of -100 mV at a band width of 10 KHz 
using an Axopatch 200B amplifier (Axon Instruments) under voltage clamp conditions. To study 
the effect of voltage in the event time, a series of experiments were performed at three voltages 
usually -75 mV, -100 mV and -125 mV.    
 
Figure 2.1 Schematic representation of a nanopore experiment showing the αHL inserted in a 
lipid bilayer, chambers with AgCl electrodes and their connection with amplifier and digitizer. 
Idea adapted from (Merstorf et al., 2012). Copyright © 2012 Springer. All rights reserved.   
2.2.1 The patch-clamp hardware 
Nanopore experiments were performed using patch-clamp hardware which consists of three 
major components including the Faraday cage, patch clamp amplifier (Axopatch 200B, 
Molecular Devices) and digitizer (Digidata 1332A) (Figure 2.2a). Experiments were set up in the 
Faraday cage as shown in Figure 2.2b. All nanopore experiments were carried out in the 
perfusion unit (Figure 2.2b,c) consisting of two pieces; the black part which is the holder of the 
white part or cup (Figure 2.2c). The cup has a 150 µM aperture which is the place of lipid bilayer 
formation (Figure 2.2c). After painting the lipid bilayer onto the opening of the cup, it was 
installed into the holder to form cis and trans chambers (Figure 2.2b). Then the chambers were 
filled with buffer and the anode and cathode electrodes were placed into the trans and cis 
chambers (Figure 2.2b). To control the thickness of the membrane a syringe was connected to 
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the cis chamber through a hole on the holder. The thickness of the membrane was reduced using 
a painting brush.    
In some cases after formation of the lipid bilayer the capacitive spike disappeared which is 
due to the temporary removal of the painted lipid from the aperture. In this case pulling and 
pushing of some buffer from the cis side using the connected syringe mediate the reforming of 
the lipid bilayer on the aperture and a capacitive spike reappeared on the system.   
 
Figure 2.2 The patch-clamp hardware and a typical experimental setup. (a) The patch-clamp 
hardware compartments including Faraday cage, amplifier and digitizer. (b) The experimental 
setup inside the Faraday cage using the perfusion unit and the electrodes in the cis and trans 
chambers (c) The compartments of the perfusion unit including the cup and holder. 
2.2.2 Lipid bilayer formation and pore insertion 
 After the set up of the experiment, a voltage of -100 mV was applied. Formation of the lipid 
bilayer is detected as a membrane resistance (Figure 2.3a). The membrane thickness was 
measured by the patch-clamp hardware Clampex software as the capacitance of the formed 
membrane. The thickness was monitored until it reached about 10 pF.  The α-HL solution was 
made by diluting stock solution (1 mg/ml) in a buffer to a final concentration of 1 μg/mL. Then 5 
μL of this solution was added to one side of the membrane and the current was monitored until 
stable pore insertion was achieved. A successful pore insertion is determined by the sudden 
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appearance of a current (Figure 2.3b). For example in an experiment with 1 M KCl and an 
applied potential of -100 mV, formation of a single pore causes a current of 100±5 pA. Insertion 
of α-hemolysin into the membrane to make a pore is a spontaneous event and can take anything 
from a few seconds to several minutes to occur. A pore produces a current in the pA range due to 
ionic conductance (Figure 2.3b). Then an aliquot of the peptide to be studied was added to the 
chamber. The final concentration of protein on the cis-side was 1 μM.  
2.2.3 Data recording and processing 
Interaction of a molecule with the pore blocks the ionic flow and causes a blockade current, I, 
for a blockade time, T. Values of I and T depend on the biophysical properties of molecules such 
as net charge, molecular weight, charge distribution and structure. As shown in Figure 2.3c 
negatively charged unfolded peptides are able to translocate through the pore and cause a large 
drop in current. Peptides with compact conformation interact with the outside of the pore and 
block the ionic flow for a short time. This results in a smaller drop in the current as compared 
with the translocation events (Figure 2.3d). In some cases intercalation events can be recorded. 
An intercalation event occurs when a part of a peptide, for example a loop or a domain, enters 
the vestibule of the pore but the whole molecule cannot pass through the pore and is stuck there 
before diffusing away. Intercalation and translocation events can be distinguished by doing a 
voltage study experiment and monitoring the event time by increasing the applied voltage. For 
translocation events, the blockade time decreases with increasing applied voltage. The events 
were monitored real-time and captured on a PC connected to the patch-clamp hardware (Figure 
2.3e) using the “fixed-length events” mode of Clampex 9 software. Figure 2.3e shows an 
example of the snapshot of the events profile. The blockade current events were characterized 
and analyzed using Clampfit software to remove noise and then the blockade current populations 
were obtained by fitting the blockade current distribution with the Gaussian function using 
Origin software (Figure 2.3f). 
The recorded raw data were imported to Clampfit software for choosing well-defined events 
and removing the multiple or overranging events. At first the data was converted to concatenated 
traces, then a single-channel search was applied to detect and characterize the events. This 
involved specifying a region of data using cursors and then adjusting the thresholds to be 
screened by the software for detected events. Then the detected events on the event viewer were 
corrected by rejecting the events which were mostly out of the range of applied voltage or have 
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very small current values. The properties of the selected events including blockade time and 
current have been were output as an “.rlt” file and were imported to Origin7 for further 
processing and fitting. The detected events underwent further screening based on the blockade 
time and current. Blockade current correction involved removal of events with blockade current 
less than 10 pA and more than 100 pA. Blockade time correction involved removal of events 
with blockade times less than 0.05 ms and more than 50 ms. The blockade current profile was 
plotted versus the number of events and the peaks were fitted with the Gaussian function. The 
corresponding time values for each peak were extracted from the data and the blockade time 
profile was plotted versus the number of events. The blockade time distribution was fitted using 
an exponential (ExpDecay1) function.  
 
Figure 2.3 Schematic of data recording and processing in nanopore experiment. (a,b,c,d) The 
schematic representation of lipid bilayer formation, pore insertion, translocation and bumping 
events when a voltage of -100mV was applied. The drop in current for translocation and 
bumping events is also shown as I1 and I2 (e) A snapshot of the events profile (f) The blockade 
current histogram with bumping and translocation peaks. The idea behind the design of parts 
"a","b","c" and "d" were adopted from Oxford Nanopore Technologies Ltd. webpage. Image 
URL:https://www.nanoporetech.com/uploads/Technology_New/Nanopore_Sensing/filemanager-
1.jpg?mw=720.    
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2.3 HSQC-NMR 
All NMR experiments were performed in collaboration with Dr.Sergiy Nokhrin and Dr. Oleg 
Dmitriev. NMR spectra were collected at 15 °C using a 600 MHz Bruker Avance spectrometer 
equipped with 5 mm TXI Inverse Triple (1H,{15N,13C}) Resonance Cold Probe, located at the 
Saskatchewan Structural Science Centre, University of Saskatchewan. I prepared the 15N-AS and 
ligands samples. NMR sample preparation, experiments and data processing performed by 
Dr.Sergiy Nokhrin. I participated in NMR peak labeling.   
2.3.1 Sample preparation and experimental set up 
 The 15N-AS sample was prepared in 0.5×PBS (69 mM NaCl, 1.35 mM KCl, 5 mM Na2HPO4, 
and 1 mM KH2PO4) at a concentration of 50µM and dialyzed overnight in 250 ml of 0.5x PBS 
with 5% glycerol. Initially, the dialysis buffer also contained 0.05% of the detergent β-octyl 
glucoside (BOG). In the presence of this detergent, spectra were well resolved and there were no 
significant changes upon addition of ligand (dopamine). Thus, BOG interferes with binding of 
ligands and all dialysis was then performed in a buffer without BOG to get a typical spectrum for 
an unfolded protein which were not as well resolved with some line-broadening and peak 
overlap. The NMR sample was prepared with 5% D2O (v/v) and 2 mM DSS (2,2-dimethyl-2-
silapentane-5-sulfonic acid) as a proton reference standard. Ligands were added directly in the 
NMR tube at different ratios. All 1H,15N- HSQC spectra were collected with 50 μM  AS. For the 
dopamine titration, ligand was added directly in the NMR tube to final concentrations of 250 
µM, 500 µM and 1250 μM. For (-)- and (+)-nicotine titration, the ligand was added directly to 
the NMR tube to final concentrations of 100 µM, 250 µM and 500 μM. NMR spectra were also 
recorded in the presence of 0.02% of the lysolipid  palmitoyl-2-hydroxy-sn-glycero-3-[phospho-
rac-(1-glycerol)] (LPPG), which was above its critical micellar concentration (CMC) and 
dopamine was added in the NMR tube to a final concentration of 500 µM.  
 
2.3.2 Data recording and processing 
The 15N – HSQC spectra were collected using 64 x 1024 complex incremental data points in 
the F1 (15N) and the F2 (1H) dimensions, with 8 or 16 scans per increment and a 1 s relaxation 
delay. Spectral widths of 40 ppm (centred at 115.7 ppm) and 16 ppm (centred at 4.7 ppm) were 
used for the 15N and the 1H dimension, respectively.  
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NMR spectra were processed using NMRPipe (Delaglio et al., 1995) and analyzed using 
NMRPipe and NMRViewJ (Johnson and Blevins, 1994). The peak positions were labeled using 
the previously reported sequential chemical shift assignments (Maltsev et al., 2012). The first 
stage in data processing was the conversion of Bruker formatted files as input data to the 
NMRpipe formatted file using NMRpipe. Then the NMRpipe formatted output file underwent 
zero-filling, fourier transformation and phase correction. After processing, data were output as 
matrix in NMRPipe format and also these matrices were converted into NMRView format for 
visualization with NMRViewJ.  
For chemical shift assignments a script has been used for “pick picking” which picks all real 
peaks and discriminate them from the noise peaks. After mapping a clean 2D peak list, resonance 
signals were compared with their counterparts in the previously reported sequential chemical 
shift (Maltsev et al., 2012). In this process the resultant proton and 15N shifts were compared 
with the reference to find the matched residue for each detected peak. Then the chemical shifts 
and relative peak intensities, I/I0 (Ibound/Ifree), of the HSQC cross peaks in the AS/ligand complex 
and free AS were plotted versus the amino acid sequence of AS.      
2.4 Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) analysis was performed on a Nano-ITC (TA 
Instruments, New Castle, PA, USA), located at the Protein Characterization and Crystallization 
Facility (PCCF) of the College of Medicine, University of Saskatchewan. The experiment 
conditions were set up on the PC connected to the machine using the Nano ITC Run Software 
(TA Instruments).  
2.4.1 Sample preparation and experimental set up 
Peptide and ligand samples were dissolved in the buffer used for nanopore experiments, 
containing 1 M KCl and 10 mM HEPES-KOH, pH 7.8. For dopamine the experiments were also 
performed in the NMR buffer (0.5×PBS). Samples were degassed in a vacuum at 22 °C for 30 
minutes. Reference cell and sample cell were filled with 250 µl of degassed buffer solution and 
the peptide solution, respectively, using a long-needle syringe. The calorimeter syringe was filled 
with ligand solution. The ligand solution was injected into a sample cell containing 250 μl of 5 
μM AS at 22 °C. Other experimental settings were as follow: stirring rate (250 RPM), start delay 
(250 s) and injection intervals (200 s). The concentrations of ligands in the syringe, the number 
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of injections and the injection volume for the studied ligands were as follow: (-)-Nicotine (100 
μM- 10 injections- 5µl), (+)-Nicotine (150 μM- 10 injections- 5µl), (-)-Methamphetamine (150 
μM- 10 injections- 5µl), (+)-Methamphetamine (90 μM- 10 injections- 5µl) and dopamine (1 
mM- 8 injections- 6.25µl). The ITC set up for dopamine in the NMR buffer involved 14 
injections (3.5 μL each) of 2 mM dopamine. Blank experiments were performed by titrating 
ligands into the sample cell containing 250 µl of the buffer. 
2.4.2 Data recording and processing 
The background titration signal for the buffer was subtracted from that of the sample spectra. 
NanoAnalyze (TA Instruments) was used to fit the raw data. To find the binding model the data 
were fitted with different reaction models such as independent, multiple sites, competitive and 
cooperative to find the best model that fits with the data points. Then the best reaction model was 
used to fit the titration data. The fitting process involves a series of attempts to optimize the 
output fit. Each model is an equation with thermodynamic variables which correlates entropy 
(∆S) as a function of enthalpy (∆H), number of binding sites (n) and association constant (Ka). 
So the theoretical models used to explain stages of binding process and give rise to valuable 
thermodynamic information of the experimental data curve. All the ITC experiments performed 
in this thesis were fitted with the independent model with one binding site because this equation 
followed the resulted data points most closely. Finally the values of dissociation constant (Kd) 
have been reported to compare the affinity of ligands with AS. 
2.5 CD Spectroscopy 
Experiments were performed on an AppliedPhotophysics CHIRASCAN PLUS CD 
spectrophotometer equipped with a Quantum Northwest TC125 temperature controller, located 
at the Protein Characterization and Crystallization Facility (PCCF) of the College of Medicine, 
University of Saskatchewan. The experiment conditions were set up on the PC connected to the 
machine using the Pro-Data™ Software Suite (AppliedPhotophysics).  
2.5.1 Sample preparation and experimental set up 
The spectrophotometer was started up by purging the instrument with nitrogen for 15 minutes 
before switching on the light source. It took about 30 minutes for the light source to achieve 
stability. Experiments were performed at 22°C using a cell with a 0.05 cm path length. Samples 
consisted of 5 μM of AS in 10 mM sodium phosphate buffer (pH 7.4) with or without ligands. 
 67 
Circular dichroism (CD) spectra were recorded over the range 185-360 nm in millidegrees. For 
each sample three scans were recorded. For each protein sample the background spectra were 
recorded as the spectrum of the solvent. 
For dopamine experiments, samples consisted of 5 μM of wild type-AS or the A30P mutant 
AS with or without 50 μM and 125 μM of dopamine.  Methamphetamine experiments were 
performed with samples of 5 μM of wild type-AS with or without 25 μM, 50 μM and 100 μM 
(+)- or (-)-methamphetamine. For the nicotine experiments samples were composed of 5 μM of 
wild type-AS with or without 10 μM, 25 μM and 50 μM (+)- or (-)-nicotine.  
2.5.2 Data recording and processing 
Pro-Data™ Software Suite was used to process the raw data. The average of three scans was 
calculated by the software. The spectra of the samples were corrected by subtracting the 
spectrum of the corresponding solvent. The resulting spectra were smoothed 10 times and the 
units were converted from millidegrees to MRE (mean residue ellipticity) in deg х cm2 х dmol-1.  
2.6 Docking simulation of methamphetamine and alpha-synuclein interaction 
The 3D structure of AS(PDB ID: 1XQ8) together with the protonated form of the 3D 
conformer of (+)-methamphetamine (PubChem CID: 10836) were used for the docking 
simulation. The C-terminal of AS, residues 61 to 140, was removed from the structure to obtain 
the target binding peptide, i.e. residues 1 to 60. 
2.6.1 Software and docking set up 
The docking simulation was performed using the molecular operating environment (MOE) 
from the Chemical Computing Group, Inc. as described previously (Abe et al., 2007). Briefly, 
the target peptide, AS(1–60), was subjected to an MMFF94 energy minimization protocol until 
the root mean square of the conjugate gradient reached <0.05 kcal mol−1 Å−1. The MOE-Dock 
default parameters were used for the docking simulation. The MMFF94s was selected as the 
force field (Abe et al., 2007). Refinement and Rescoring 2 were set up to the Forcefield and 
Alpha HB, respectively. A global docking was performed with the target peptide. The docking 
was carried out for 30 iterations and the docking interaction with the lowest energy (−50 
kcal/mol) was reported.  
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3 RESULTS  
3.1 Nanopore analysis of AS in the presence of 1,2-diphytanoyl-sn-glycero-3-
phosphocholine and EDTA  
Nanopore experiments were used as the primary method to study AS/small molecule 
interactions. Two important controls are described first. To ensure that there was no metal 
contamination, a control experiment was performed with the standard HEPES buffer in the 
presence of 1 mM EDTA which chelates any unwanted divalent metals (Krasniqi and Lee, 
2012). The event profile of AS in the presence (Figure 3.1b) and absence (Figure 3.1a) of EDTA 
showed a translocation peak (see later) at -85 pA and a small bumping peak (see later) at -25 pA. 
This shows that the small bumping peak centered at -25 pA is not due to metal contamination 
and represents a very small proportion of the AS conformation (Figure 3.1). Furthermore it has 
been demonstrated previously that AS does not bind to phosphatidylcholine (PC) but has the 
ability to bind acidic phospholipids such as phosphatidylinositol (PI), phosphatidylserine (PS) 
and phosphatidic acid (PA) (Davidson et al., 1998; Jo et al., 2000).  To ensure that AS does not 
bind to the 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC) the following control was 
performed. AS was incubated with 0.35 mg of DPhPC micelles and the sample was added to the 
cis side of the cup. The event profile of AS (Figure 3.1b) in the presence of 0.35 mg of DPhPC 
was unchanged (Figure 3.1c).  
 
Figure 3.1 Blockade current histogram of AS in different buffers. Blockade current profile of AS 
in standard HEPES buffer (a) AS in standard HEPES buffer-1 mM EDTA (b) and AS in standard 
HEPES buffer-1mM EDTA and in the presence of 0.35 mg of DPhPC micelles (c) [Part “c” 
performed by David Boyle] 
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3.2 Nanopore analysis of wild type and mutants of AS                                              
The wild type and three major mutants of AS were analyzed using the patch clamp technique 
and a buffer of 1 M KCl, 10 mM HEPES–KOH (pH 7.8) containing 1 mM EDTA on the cis side. 
Figure 3.2 shows current blockade histograms of the wild type (a) and pathological AS mutants: 
A30P (b), E46K (c) and A53T (d). These results clearly demonstrate the conformational 
heterogeneity among the wild type and mutants. For the wild-type, (Figure 3.2a) the major peak 
was centered at -86 pA and represents the natively unfolded structure. There was also a very 
small bumping peak at -25 pA. The blockade current histogram for the E46K mutant (Figure 
3.2c) was similar to wild type and there were two peaks which are centered at -85 pA and -24 
pA. The difference between these two AS types is the proportion of bumping and translocation 
peaks.  The proportion of translocation events for E46K (Figure 3.2c) is about 67% which is less 
than for the wild type (Figure 3.2a). For the mutants A30P (Figure 3.2b) and A53T, there are 
three peaks including a bumping peak with lower blockade current, a translocation peak with 
high blockade current and a peak with intermediate blockade current. For the A30P mutant these 
peaks are centered at -85 pA, -41 pA and -25 pA. The Mutant A53T (Figure 3.2d) has three 
peaks at -86 pA, -42 pA and -23 pA. Mutants A30P and A53T show similar conformational 
properties but for mutant A53T the bumping peak is larger than the mutant A30P. Furthermore, 
the peak centered at around -85 pA which represents the translocation events shows that the 
mutant A30P has more translocation events than A53T. The event parameters including blockade 
current (I) and time (T) for the bumping (Ib and Tb) and translocation (It and Tt) peaks are 
summarized in Table 3.1. As the net charge of the mutant E46K is -7 it has the longest 
translocation time at 100mV. The other two mutants (A53T, A30P) and the wild type have a 
larger overall negative charge (-9) and their average translocation time is less than E46K. 
 To show that the peak which is placed at around -85 pA is due to translocation events a 
voltage study was done at 75 mV and 100 mV. The calculated event parameters are summarized 
in Table 3.2. The results show that by increasing the voltage the average time decreases which 
means that the protein is being electrophoretically driven through the pore. Figure 3.3 shows 
blockade time graphs for the translocation peaks of the wild type (a) and pathological AS 
mutants: A30P (b), E46K (c) and A53T (d) at 100 mV.  
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Table 3.1 Event parameters for the translocation and bumping peaks of AS and mutants at 100 
mV.  
 
AS Ib (pA) It (pA) Tb (ms) Tt (ms) 
Wild type -25 -85 0.12 0.49 
A30P -25 -87 0.02 0.34 
E46K -24 -86 0.03 0.71 
A53T -23 -87 0.23 0.28 
I and T represent the intensity and duration of the current blockade.  The subscripts  
b and t refer to  bumping and  translocation event populations.  
(The error is estimated to be ±1 pA for I and ±10% for T)  
 
 
Figure 3.2 Blockade current histograms for AS. (A) wild type, (B) mutant A30P, (C) mutant 
E46K and (D) mutant A53T. The applied voltage was 100 mV. 
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Table 3.2 Event parameters for the translocation peak of the AS peptides at two different 
voltages  
 I75 (pA) I100 (pA) T75 (ms) T100 (ms) 
AS  -63 -85 0.61 0.49 
A30P -62 -87 0.82 0.34 
E46K -63 -86 1.17 0.71 
A53T -66 -87 0.75 0.28 
I and T represent the intensity and duration of the current blockade.  The subscripts 75 and 100 
refer to translocation peak when 75 mV and 100 mV of voltage are applied respectively. (The 
error is estimated to be <±1 pA for I and <±10% for T) 
 
 
Figure 3.3 Blockade time profiles for AS. (A) wild type, (B) mutant A30P, (C) mutant E46K and 
(D) mutant A53T. The applied voltage was 100 mV. 
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3.3 Alpha-synuclein and methamphetamine isomers interaction 
3.3.1 Introduction 
It has been shown previously that the incidence of PD is increased among methamphetamine 
users (Callaghan et al., 2010; Callaghan et al., 2012). Therefore the interaction of 
methamphetamine isomers with AS was studied using nanopore analysis, CD spectroscopy and 
ITC. In order to delineate the binding site of (+)- and (-)-methamphetamine, three segments of 
AS were analyzed. 
3.3.2 Nanopore discrimination of the interaction of methamphetamine isomers with 
alpha-synuclein 
 
Figure 3.4a,f show snapshots of the typical current trace for (a) AS and (f) AS in the presence 
of 20µM (+)-methamphetamine. For AS the majority of events have large current blockades at 
around -85pA (Figure 3.4a) while in the presence of (+)-methamphetamine most of the events 
have a short current blockade at around -25pA (Figure 3.4f).  
Figure 3.4b,c,d,f shows the current blockade histogram for AS and AS in the presence of 
increasing concentrations of (+)-methamphetamine, i.e. 5µM, 10µM and 20µM. As described 
above, for AS there are two peaks centered at -85pA and -25pA which are due to translocation 
and bumping. The majority of the events (81%) are translocation and only a small proportion of 
events (9%) are bumping (Figure 3.4b). Upon addition of increasing concentrations of (+)-
methamphetamine to AS the proportion of bumping events increased in a concentration 
dependent manner with a simultaneous decrease in the proportion of translocation events (Figure 
3.4c,d,f). The percentage of bumping events in the presence of 5 µM, 10 µM and 20 µM (+)-
methamphetamine was increased from 9% to 34% (Figure 3.4c), 43% (Figure 3.4d) and 50% 
(Figure 3.4e). This proportional change caused a decrease in the percentage of the translocation 
peak centered at -85pA as follow: 40% (Figure 3.4c), 35% (Figure 3.4d) and 31% (Figure 3.4e) 
in the presence of 5µM, 10µM and 20µM drug respectively.  There are also a large number of 
events with intermediate current blockades between -40pA to -75pA which are difficult to 
characterize because they do not yield a clear Gaussian distribution. The other isomer, (-)-
methamphetamine, was also studied. Figure 3.5 shows the blockade current histogram of AS 
alone (a) AS to (-)-methamphetamine ratio 1:5 (b), 1:10 (c) and 1:20 (d). Considering the 
blockade current histograms for (+)-methamphetamine (Figure 3.4c,d,e), the results together 
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show that both (+)- and (-)-methamphetamine change the conformation of AS by changing the 
proportion of translocation and bumping peaks towards an increase in bumping events. 
 
Figure 3.4 Nanopore analysis of the interaction of (+)-methamphetamine with full length AS. (a, 
f) Typical current traces for AS and AS with 20 μM methamphetamine. (b–e) Blockade current 
histograms for AS with 0, 5, 10, 20 μM methamphetamine, respectively.  
They change the AS conformation in a different manner and at the same concentrations of 
drugs the changes in the proportion of translocation and bumping peaks are different. For 
example the proportion of translocation (35%) and bumping (43%) peaks in the presence of 20 
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μM of (-)-methamphetamine (Figure 3.5d) is similar to the blockade current profile of AS in the 
presence of 10 μM (+)-methamphetamine (Figure 3.4d).  
 
Figure 3.5 Blockade current profiles showing the interaction of (-)-methamphetamine with AS.  
AS (a), AS to (-)- methamphetamine ratio: (b) 1:5, (c) 1:10 and (d) 1:20. 
 
 
3.3.2.1 Mapping of the (+)-Methamphetamine binding site using nanopore analysis and 
a docking simulation 
Three segments of the AS protein have been used to map the (+)-methamphetamine binding. 
These segments include AS(1-60), AS(61-140) and ∆NAC which lacks the middle segment of 
AS (61-95). Figure 3.6 shows the current blockade histograms for AS(1-60) (a) and in the 
presence of 5 µM (b), 10 µM (c) and 20 µM (d) (+)-methamphetamine. The AS(1-60) peptide 
 75 
itself shows a single bumping peak centered at -25pA due to its positive net-charge (+4).  The 
interaction of this positively charged peptide with the pore is diffusion controlled rather than 
electrophoretically driven and gives rise to a major bumping peak with a proportion of 73% 
(Figure 3.6a). Addition of increasing concentrations of the drug to this peptide causes a 
concentration dependent decrease of the proportion of bumping events from 73% to 51% (Figure 
3.6b), 30% (Figure 3.6c) and 23% (Figure 3.6d) at the concentrations of 5 µM, 10 µM and 20 
µM respectively. These results suggest an N-terminal binding site for (+)-methamphetamine.  
As expected (+)-methamphetamine (10 µM) didn’t change the current blockade current 
profile for AS(61-140) (Figure 3.7c,d), and the N-terminal binding site for this drug was 
confirmed by investigating AS(ΔNAC) (Figure 3.7a,b). In the absence of drug the current 
blockade histogram for AS(ΔNAC) shows a major translocation peak at -88 pA with a 
proportion of 61% and a bumping peak centered at -25 pA (Figure 3.7a). Upon addition of 10 
µM of drug, the proportion of translocation events underwent an almost 50% decrease and the 
bumping events were increased from 28% to 44% (Figure 3.7b).   
Docking simulations of interactions between (+)-methamphetamine and AS(1-60) were 
performed using molecular operating environment (MOE) from the Chemical Computing Group, 
Inc.. A possible binding site encompassing residues 35–44 (Figure 3.8) was identified. The 
interaction was stabilized in part by polar interactions between Glu35, Gly36, Tyr39 and Thr44, 
and the amine of the drug as well van der Waals interactions between Leu38, Val40 and Lys43 
and the benzene ring of the drug. This interaction causes folding of the peptide around the drug 
to form a loop which is locked by ionic interaction between Glu35 and Lys43 (Figure 3.8). 
 
Figure 3.6  Blockade current histograms for N-terminal AS(1–60) in the presence of (+)-
methamphetamine. (a-d) Blockade current histograms for N-terminal AS(1–60), with 0, 5, 10, 
20 μM (+)-methamphetamine, respectively. 
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Figure 3.7 Blockade current histograms for AS(ΔNAC) and AS(ΔNAC) in the presence and 
absence of (+)-methamphetamine. (a, b) Blockade current histograms for AS(ΔNAC) with 0 μM 
and 10 μM (+)-methamphetamine. (c, d) Blockade current histograms for AS(61–140) with 0 μM 
and 10 μM (+)-methamphetamine. 
 
Figure 3.8 Results from docking simulations showing the proposed binding site for (+)-
methamphetamine in the N-terminal region of AS. 
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3.3.2.2 Mapping of the (-)-Methamphetamine binding site using nanopore analysis 
The interaction of the (-)-isomer with the same peptides was also studied. Figure 3.9 shows 
the nanopore analysis of (-)-methamphetamine and AS (61-140) (b), AS (1-60) (d) and AS 
(∆NAC) (f). The results showed a conformational change of the C-terminus (Figure 3.9b) and 
∆NAC (Figure 3.9f) in the presence of 10 μM of the ligand and suggests a C-terminal binding 
site for (-)-methamphetamine. The current blockade profile of AS(1-60) in the absence (Figure 
3.9c) and presence of (-)-methamphetamine (Figure 3.9d) was the same.  
 
Figure 3.9 Blockade current profiles showing the interaction of (-)-methamphetamine with AS 
peptides (96-140, 1-60 and ΔNAC). AS (61-140) (a), AS (61-140) to (-)-methamphetamine ratio: 
(b) 1:10, AS (1-60) (c), AS (1-60) to (-)-methamphetamine ratio: (d) 1:10, AS (ΔNAC) (e), AS 
(ΔNAC) to (-)-methamphetamine ratio: (f) 1:10. 
3.3.3 CD spectroscopy of the AS-methamphetamine interaction  
The CD spectrum of AS is typical of an intrinsically disordered protein and is mostly random 
coil (Serpell et al., 2000; Uversky et al., 2001b; Weinreb et al., 1996; Zheng et al., 2013) (Figure 
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3.10, black line). Figure 3.10 also shows the CD spectra for AS in the presence of different 
concentrations of (+)- and (-)-methamphetamine. The addition of increasing amounts of (-)-
methamphetamine (25 µM, 50 µM and 100 µM) causes a change in mean residue ellipticity 
(MRE) at 196 and 220 nm. In contrast (+)-methamphetamine causes no significant change in the 
magnitude of MRE. Addition of (+)- and (-)-methamphetamine did not cause a significant 
change in the secondary structure content of AS which implies that the drug is not inducing an α-
helical or β-sheet conformation. This might be due to formation of a simple loop or binding 
pocket which would not be expected to alter the CD spectrum.   
 
Figure 3.10 CD spectra for full length AS in the presence of (+)- and (-)-methamphetamine. CD 
spectra for full length AS (black) and in the presence of 25 μM (red-dotted line), 50 μM (blue-
dotted line), 100 μM (yellow-dotted line) of (+)-methamphetamine and 25 μM (purple-solid 
line), 50 μM (brown-solid line), 100 μM (green-solid line) of (-)-methamphetamine.   
3.3.4 Isothermal Titration Calorimetry of AS-methamphetamine interaction 
ITC experiments have been done to measure the Kd of methamphetamine isomers with AS. 
Figure 3.11 shows the calorimetric characterization of the interactions between AS and (+)-
methamphetamine (a,b) and (-)-methamphetamine (c,d). Titrations of 90 μM (+)-
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Methamphetamine (Figure 3.11a,b) and 150 μM (-)-Methamphetamine (Figure 3.11c,d) into 5 
μΜ AS solution indicated a one-site interaction mechanism with Kds of (5.00 ± 0.02) × 10-7 M 
and (1.95 ± 0.03) × 10-6 M (averages of two experiments) respectively. This is in agreement with 
the nanopore results which showed that (+)-methamphetamine binds tighter than (-)-
methamphetamine.  
 
 
Figure 3.11 Calorimetric characterization of the interactions between AS and (+)-
methamphetamine (a), (b) and (-)-methamphetamine (c), (d) in a buffer containing 1 M KCl and 
10 mM HEPES-KOH, pH 7.8. Data is fitted with the one-site model which corresponds to “n=1” 
& “Kd= 0.5 μM” (a) and “Kd= 2 μM”. 
 
3.4 Alpha-synuclein and nicotine isomers interaction 
3.4.1 Introduction 
Nicotine is another commonly used drug. In contrast to methamphetamine, smokers have a 
lower incidence of PD (Checkoway et al., 2002; Hernán et al., 2002; Kessler and Diamond, 
1971; Ono et al., 2007b; Quik, 2004; Ross and Petrovitch, 2001). Therefore the interaction of 
nicotine isomers with AS was studied using nanopore analysis, CD spectroscopy, ITC and NMR 
spectroscopy. In order to delineate the binding site of (+)- and (-)-methamphetamine, three 
segments of AS were analyzed.  
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3.4.2 Nanopore discrimination of the interaction of nicotine isomers with alpha-
synuclein 
Nanopore experiments were performed in the presence of 2 µM, 5 µM and 10µM of both (-)- 
and (+)-nicotine (Figure 3.12). Anabasine was used as the control, because anabasine is another 
component of cigarette smoke and has the same molecular weight as nicotine. Current 
histograms for AS alone and anabasine are shown in Figure 3.12a,e. Figure 3.12b-d shows 
current blockade histograms of AS in the presence of 2 μM (Figure 3.12b), 5 μM (Figure 3.12c) 
and 10 μM (Figure 3.12d) of (-)-nicotine. In contrast, the corresponding current profiles for the 
(+)-nicotine are shown in Figure 3.12f-h. In the absence of ligand, (Figure 3.12a) AS blockade 
current profile shows a sharp translocation peak at -86 pA. The control experiment in the 
presence of 10 μM anabasine (Figure 3.12e) shows little change in the blockade current profile. 
After adding 2 μM of (-)-nicotine to the cup, the translocation peak shifted to -81 and also an 
intermediate peak developed at -40 pA (Figure 3.12b). In contrast, for (+)-nicotine there was just 
the shift of the translocation peak to -80 pA and an increase in the bumping peak intensity 
(Figure 3.12f). In the presence of 5 μM of (-)-nicotine the proportion of the  intermediate peak 
increased to 40% and some events with intermediate current blockade appeared between -40 pA 
to -80 pA (Figure 3.12c). For (+)-nicotine at 5 μM the intensity of the intermediate peak at -40 
pA is 70%  because the events between -40 pA to -80 pA are not present in the histogram and the 
profile is much simpler than the (-)-nicotine profile (Figure 3.12g). By increasing the 
concentration of ligands to 10 μM the intermediate peak became the most significant 
conformation. At this concentration both ligands show an intermediate peak but at different 
blockade currents (Figure 3.12d,h); at -62 pA and -42 pA for (-)- and (+)-nicotine respectively. 
Furthermore, a bumping peak exists at -25 pA. The (-)-nicotine bumping peak is larger than that 
of the (+)-nicotine. These results show that (-)- and (+)-nicotine change the conformation of AS 
in two different ways. This might explain why at the concentration of 5 μM (+)-nicotine the 
profile is much simpler than (-)-nicotine and also why different intermediate peaks are found at 
the concentration of 10 μM. 
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Figure 3.12 Blockade current profiles showing the interaction of anabasine, (+)- and (-)-nicotine 
with AS (1 µM). AS  (a), AS to (-)-nicotine ratio: (b) 1:2, (c) 1:5, (d) 1:10, AS + 10 μM 
anabasine (e), AS to (+)-nicotine ratio (f) 1:2, (g) 1:5, (h) 1:10. [Anabasine experiment 
performed by Joe Kakish] 
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3.4.2.1 Mapping of (-)- and (+)-nicotine binding sites using nanopore analysis 
In order to delineate the binding site of (+)- and (-)-nicotine, several AS fragments were 
studied. Figure 3.13a,b,c show the blockade current histograms for the C-terminal peptide 
AS(96-140). In the absence of ligand (Figure 3.13a) there are two peaks; one with a blockade 
current more than -40 pA (91%) and a bumping peak at -25 pA (9%). AS(96-140) underwent a 
conformational change in the presence of 10 μM (-)-nicotine (Figure 3.13b). Addition of (-)-
nicotine to this peptide causes a reduction in the intensity of the translocation peak to 77% and 
an increase in the bumping peak simultaneously. An intermediate peak was also found at -40 pA 
(Figure 3.13b). In contrast, the current profile of this peptide  showed only a minor change after 
adding the same concentration of (+)-nicotine with the proportion of the translocation peak 
decreasing to 86% (Figure 3.13c). Figure 3.13d,e,f shows the blockade current histograms for the 
N-terminal peptide AS(1-60). In the absence of drug (Figure 3.13d) there was no clear 
translocation peak and about 52% of the events are bumping. Upon addition of 10μM of (-)- and 
(+)-nicotine the proportion of bumping events decreases to 25% and 21% respectively (Figure 
3.13e,f). Furthermore, there is an intermediate peak at -41 pA in the presence of (-)-nicotine 
(Figure 3.13e). Figure 3.13g,h,i shows the current profile for ∆NAC in the absence and presence 
of 10uM (-) and (+)-nicotine respectively. The current profile of this peptide underwent 
conformational changes in the presence of both isomers of nicotine. For (-)-nicotine an 
intermediate peak is found at -41 pA and in the presence of (+)-nicotine the translocation peak 
shifted from -90 pA to -80 pA and the proportion of the bumping peak increased. These 
nanopore results demonstrate that (-)-nicotine has a binding site consisting of both N- and C-
terminal residues of AS but (+)-nicotine has a binding site which mostly involves residues from 
the N-terminus. 
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Figure 3.13 Blockade current profiles showing the interaction of nicotine isomers with AS 
peptides (96-140, 1-60 and ΔNAC). AS (96-140) (a), AS (96-140) to (-)-nicotine ratio: (b) 1:10, 
AS (96-140) to (+)-nicotine ratio: (c) 1:10, AS (1-60) (d), AS (1-60) to (-)-nicotine ratio: (e) 
1:10, AS (1-60) to (+)-nicotine ratio: (f) 1:10, AS (ΔNAC) (g), AS (ΔNAC) to (-)-nicotine ratio: 
(h) 1:10 and AS (ΔNAC) to (+)-nicotine ratio: (i) 1:10. 
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3.4.3 Circular dichroism spectroscopy of the alpha-synuclein-nicotine interaction 
The interaction of AS with (-)- and (+)-nicotine has been investigated with CD-spectroscopy. 
Figure 3.14 shows the CD spectra for AS itself and AS to ligand ratios 1:2, 1:5 and 1:10. As 
above, the spectrum for AS is typical of a random coil and is in agreement with a largely 
unstructured protein (Hoyer et al., 2004; Lendel et al., 2009; Rao et al., 2008; Uversky et al., 
2001b) The addition of increasing amounts of (+)- and (-)-nicotine results in mean residue 
ellipticity (MRE) changes at 196 and 220 nm but there is no significant increase in α-helix or β-
sheet content. By increasing the concentration of (+)- and (-)-nicotine there is an increase in the 
magnitude of  MRE in 196-200 nm region due to the binding of ligand to AS as reported 
previously for other small molecules such as congo red (Lendel et al., 2009; Rao et al., 2008). 
 
 
Figure 3.14 CD spectra for full length AS in the presence of (+)- and (-)-nicotine. (a) CD spectra 
for full length AS (black) and in the presence of 10 μM (red-dotted line), 25 μM (yellow-dotted 
line), 50 μM (green-dotted line) of (+)-nicotine and 10 μM (purple-solid line), 25 μM (brown-
solid line), 50 μM (blue-solid line) of (-)-nicotine.   
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3.4.4 ITC of the alpha-synuclein-nicotine interaction 
Titrations of 100 μM (-)-nicotine (Figure 3.15a,b) and 150 μM (+)-nicotine (Figure 3.15c,d) 
into a 5 μΜ AS solution indicated a one-site interaction mechanism with Kds of (7.40 ± 0.2) × 
10-7 M and (2.50 ± 0.2) × 10-6 M (averages of two experiments) )respectively. Thus (+)-nicotine 
has a lower affinity compared to (-)-nicotine.  
 
Figure 3.15 Calorimetric characterization of the interactions between AS and (-)-nicotine (a,b) 
and (+)-nicotine (c,d) in a buffer containing 1 M KCl and 10 mM HEPES-KOH, pH 7.8. Data is 
fitted with the one-site model which corresponds to “n=1” & “Kd= 0.74 μM” (b) and “Kd= 2.5 
μM” (d).   
3.4.5 HSQC-NMR 
To investigate the conformational changes of AS with time during the NMR spectroscopy, a 
control sample of AS was kept in an incubator at 15° C during the titration of the AS sample 
with nicotine (~5 hours) and the spectrum of the control sample was collected immediately after 
the titration experiments (Figure 3.16). The control experiment showed that AS is stable during 
the NMR experiment and any changes in conformation are induced by adding ligand to the AS 
sample. For (-)-nicotine and (+)-nicotine, 1H-15N- HSQC spectra were collected with 50 μM  AS 
, and ligands were added directly in the NMR tube to the ratios of 1:2, 1:5 and 1:10 (AS to 
ligands). Figure 3.16 shows the 1H-15N HSQC spectra for the ratios of (a) 1:10 AS to (-)-nicotine 
and (b)1:10 AS to (+)-nicotine. The changes in intensity at the ratio of 1:10 AS to nicotine are 
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summarized in Figure 3.16c ((-)-nicotine) and Figure 3.16d ((+)-nicotine). The 1H-15N HSQC 
spectra show that AS underwent a significant conformational change in the presence of (-)-
nicotine (Figure 3.17a) and the intensity of most of the peaks are decreased at this concentration 
of (-)-nicotine (Figure 3.17a). In contrast at the same ratio of (+)-nicotine, the 1H-15N HSQC 
spectra shows only a few changes in intensity (Figure 3.17b). The changes in the intensity ratio 
as a function of drug concentration are described in Figure 3.18 for well-resolved residues. In 
general (+)-nicotine effects few residues from the N-terminal and NAC residues (T33, T44, G67, 
G68, T81, S87 and G93) but (-)-nicotine causes an overall change in AS conformation involving 
residues from N-terminal (G7, G41 and K60), NAC (G67, T81 and T92) and C-terminal (E130).  
Furthermore, the relative signal intensities (Figure 3.18) show that titration of AS with increasing 
concentrations of (+)- or (-)-nicotine causes a gradual decrease of residue intensity. Therefore, 
conformational change of AS in the presence of nicotine isomers is concentration dependent and 
is in agreement with the nanopore analysis which shows different conformational changes 
induced by each isomer. 
 
Figure 3.16 1H-15N HSQC NMR spectrum of a control sample of AS.  1H-15N HSQC NMR 
spectrum of AS alone (black), control sample of AS which was kept in incubator for ~5 hours 
(purple) [Experiments performed by Dr. Sergiy Nokhrin]. 
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Figure 3.17 1H-15N HSQC NMR spectra and relative peak intensities graph of AS in the presence 
of nicotine isomers. 1H-15N HSQC NMR spectrum of AS alone (black) (a,c) and in presence of 
the ratio of 1:10 (AS to (-)-nicotine) (red) (b) and  the ratio of 1:10 (AS to (+)-nicotine) (c). Plot 
of the relative peak intensities of the HSQC cross peaks in the AS/(-)-nicotine (b) and AS/(-)-
nicotine (d) complexes and free AS versus the amino acid sequence of AS. The baseline intensity 
ratio is 0.8 due to dilution upon addition of dopamine [Experiments performed by Dr. Sergiy 
Nokhrin]. 
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Figure 3.18 Relative signal intensities at three concentrations of (-)- and (+)-nicotine for selected 
residues as a function of the AS:nicotine ratio. 
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3.5 Interaction of  copper and dopamine with alpha-synuclein 
3.5.1 Introduction 
Cu(II) and dopamine have an important role in PD. As a proof of concept, a comparison of 
Parkinsonian and age-matched control brain tissue showed a reduction in the Cu (II) content in 
the substantia nigra (SN) (Davies et al., 2014; Dexter et al., 1989; Riederer et al., 1989). AS has 
an important role in dopamine homeostasis and is involved in almost all of the dopamine 
metabolism pathways including dopamine biosynthesis, storage of dopamine in synaptic 
vesicles, dopamine release in the response to an action potential and re-uptake of released 
dopamine from the presynaptic space (Lotharius and Brundin, 2002a; Stefanis, 2012; Yu et al., 
2005). Furthermore, the main feature of PD is aggregation of AS which results in AS 
malfunction and dopamine depletion. Thus dopamine replacement therapy is the main treatment 
for PD (Grosset et al., 2009; Lotharius and Brundin, 2002a, b; Pahwa and Lyons, 2007; Yu et al., 
2005). Therefore the interaction of Cu(II) and dopamine with AS was studied using nanopore 
analysis, CD spectroscopy, ITC and NMR spectroscopy. In order to delineate the binding site of 
Cu(II) and dopamine, three segments of AS were analyzed. 
3.5.2 Nanopore sensing of copper binding to AS 
Figure 3.19 shows the current blockade histograms for wild type AS in the presence of 10 µM 
and 25 µM of Cu (II) and Mg (II) and also E46K in the presence of 10 µM and 25 µM of Cu (II). 
Mg(II) was used as the control, because AS has a specific binding site for Cu(II) at N-terminal 
and a general binding site at C-terminal which binds to Cu(II), Fe(II), Mn(II), Zn(II), Ni(II) and 
Co(II). Furthermore, no specific interaction between Mg (II) and AS has been reported  (Binolfi 
et al., 2012). Cu(II) alters the proportion of translocation and bumping events by increasing the 
percentage of the bumping peak in a concentration dependent manner (Figure 3.19b,c). At the 
concentration of 10 μM (Figure 3.19b) and 25 μM (Figure 3.19c) Cu(II) increases the bumping 
proportion to 45% and 65%, respectively. In contrast Mg(II) at the same concentrations (Figure 
3.19d,e) causes a much smaller change in the peak intensities. This shows that the interaction of 
Cu(II) is specific and causes folding and compaction of AS. The E46K mutant was selected to be 
investigated by nanopore analysis as this mutation is close to the His50 residue which acts as an 
anchoring residue in the interaction of Cu(II) with AS (Binolfi et al., 2012; Rose et al., 2011). 
Adding Cu(II) to E46K causes a significant change in the peak intensities and at the 
concentration of 10 µM and 25 µM the majority of events are bumping and few translocation 
 90 
events are observed (Figure 3.19g,h). This shows that the conformation of E46K is more 
sensitive to Cu(II) binding as compared to the AS wild type.   
 
Figure 3.19 Blockade current histogram showing the interaction of Cu(II) and Mg(II) with AS 
and E46K mutant. (a, b, c) Blockade current histograms for AS with 0 μM, 10 μM and 25 μM 
Cu(II). (d, e) Blockade current histograms for AS with 10 μM and 25 μM Mg(II) (f,g, h) 
Blockade current histograms for E46K with 0 μM, 10 μM and 25 μM Cu(II). 
3.5.2.1 Mapping of copper binding sites using nanopore analysis 
Three peptides, the N-terminal (1-60), C-terminal (96-140) and ∆NAC have been used to map 
the Cu(II) binding site. For each peptide, nanopore experiments were performed at 10 µM and 25 
µM Cu(II) (Figure 3.20). As shown in Figure 3.20a,b,c Cu(II) did not change the current 
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blockade profiles of AS(96-140) at 25 µM but it reduced the proportion of the bumping peak of 
the AS(1-60) peptide to 52% (Figure 3.20e) and 30% (Figure 3.20f) at 10 µM and 25 µM 
respectively. These results together show that AS(1-60) is the region of Cu(II) binding. Because 
the AS(1-95) lacks the C-terminal acidic tail of AS, was not electrophoretically driven through 
the pore and caused frequent blockage, the N-terminal binding site for Cu(II) was confirmed by 
doing nanopore experiments with ∆NAC. Cu(II) changes the intensity of the bumping and 
translocation peaks by increasing the proportion of bumping events in a concentration dependent 
manner (Figure 3.20h,i). There are also increases in the number of events with intermediate 
blockade currents which do not form a clear Gaussian peak but have been considered in the 
calculation of the peak magnitudes.     
 
Figure 3.20 Blockade current profiles showing the interaction of Cu(II) with AS peptides (96-
140, 1-60 and ΔNAC) (a, b, c) Blockade current histograms for AS (96-140) with 0 μM, 10 μM 
and 25 μM Cu(II). (d, e, f) Blockade current histograms for AS (1-60) with 0 μM, 10 μM and 25 
μM Cu(II) (g, h, i) Blockade current histograms for AS ΔNAC with 0 μM, 10 μM and 25 μM 
Cu(II). 
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3.5.3 Nanopore sensing of dopamine binding to alpha-synuclein 
In the presence of dopamine the translocation peak of AS which is centered at -85 pA (Figure 
3.21a) shifts to lower blockade current (-80 pA) and also there is an increase in the intensity of 
the bumping peak (Figure 3.21b). For the A30P mutant in the absence of drug the majority of 
events (72%) are bumping (Figure 3.21c) and upon addition of 25 µM dopamine a new peak 
forms at -80 pA which includes the majority of the events (Figure 3.21d). The peaks at -80 pA 
represent a new conformation of AS and A30P induced by dopamine. To investigate if these 
peaks are still due to translocation of peptides through the pore, a voltage study was performed 
and the event parameters are summarized in Table 3.3. For both AS and A30P, increasing the 
applied voltage from 75 mV to 100 mV caused the average time for the peak centered at -80 pA 
to decrease which shows that these peaks are due to translocation. Figure 3.22 shows the 
blockade time profiles for the peak centered at -80 pA of AS at 75 mV (a) and 100mV (b) with 
average event times of 1.25 ms and 0.56 ms respectively (Table 3.3). 
 
Figure 3.21 Blockade current profiles showing the interaction of dopamine with 1µM AS or 
A30P mutant. (a, b) Blockade current histograms for AS with 0 μM and 25 μM dopamine (c, d) 
Blockade current histograms for A30P with 0 μM and 25 μM dopamine. 
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Figure 3.22 Blockade time profiles for AS in the presence of 25 μM dopamine. Profiles show the 
blockade times for the events at -80 pA at 75 mV (a) and 100 mV (b) 
 
Table 3.3 Event parameters for the AS peptides (Wild type and A30P) 
 I75 (pA) I100 (pA) T75 (ms) T100 (ms) 
AS  -63 -85 0.61 0.49 
A30P -62 -87 0.82 0.34 
AS + Dopamine [1:25] -59 -80 1.25 0.56 
A30P + Dopamine [1:25] -59 -80 0.63 0.54 
I and T represent the intensity and duration of the current blockade.  The subscripts 75 and 100 
refer to translocation peak when 75 mV and 100 mV of voltage are applied respectively. (The 
error is estimated to be <±1 pA for I and <±10% for T) 
 
3.5.3.1 Mapping of dopamine binding sites using nanopore analysis 
Figure 3.23 shows the blockade current histograms of AS(96-140), AS(1-60) and AS(∆NAC) 
in the absence and presence of 10 µM and 25 µM dopamine. For AS(96-140) dopamine changes 
the event profiles by increasing the proportion of bumping events and a simultaneous decrease of 
the proportion of translocation events (Figure 3.23b,c). In the case of AS(1-60), dopamine 
reduces the intensity of bumping peak centered at -25 pA in a concentration dependent manner 
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(Figure 3.23e,f). At the concentration of 10 µM a sharp intermediate peak also occurs at -45 pA 
(Figure 3.23e). The conformational change of AS(∆NAC) in the presence of dopamine involves 
an increase in the proportion of bumping events. Events with intermediate current blockades 
were also found between -40 pA and -80 pA. These events did not show a Gaussian distribution 
and therefore were not fitted in the graphs (Figure 3.23h,i). 
 
 
Figure 3.23 Blockade current profiles showing the interaction of dopamine with AS peptides (96-
140, 1-60 and ΔNAC). (a, b, c) Blockade current histograms for AS (96-140) with 0 μM, 10 μM 
and 25 μM dopamine. (d, e, f) Blockade current histograms for AS (1-60) with 0 μM, 10 μM and 
25 μM dopamine. (g, h, i) Blockade current histograms for AS ΔNAC with 0 μM, 10 μM and 25 
μM dopamine. 
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3.5.4 Study of the interaction of Cu(II) and dopamine with AS  
Nanopore experiments were also performed in the presence of both ligands to investigate 
whether the binding sites for Cu(II) and dopamine are independent. Figure 3.24 shows the 
nanopore analysis of AS in the presence of different ratios of Cu(II) and dopamine. The current 
blockade histogram of AS in the presence of 10 µM Cu(II) and 25 µM dopamine (Figure 3.24e) 
shows three peaks centered at -25 pA, -47 pA and -80 pA. The peak at -47 pA was not observed 
in the presence of 10 µM Cu(II) (Figure 3.19b,3.24c) or 25 µM dopamine (Figure 3.21b,3.24b) 
and is a new peak of events with intermediate current blockade that suggests a new conformation 
of AS upon binding to both Cu(II) and dopamine. Upon adding 25 µM of Cu(II) and dopamine, 
two intermediate peak found between -35pA and -80 pA and the proportion of the bumping peak 
increased from 26% to 39% with a simultaneous reduction in the intensities of the intermediate 
and translocation peaks.    
 
Figure 3.24 Blockade current profiles showing the interaction of Cu(II) and dopamine with AS. 
Blockade current histogram for AS (a) and AS with; 25 μM dopamine (b), 10 μM Cu(II) (c), 25 
μM Cu(II) (d), 10 μM Cu(II) and 25 μM dopamine (e) and 25 μM Cu(II) and 25 μM dopamine. 
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3.5.5 Circular dichroism of the alpha-synuclein-dopamine interaction 
The binding of dopamine to AS wild type and A30P mutant was investigated by CD. As 
shown in Figure 3.25 the CD spectra of both wild type (Figure 3.25a-black line) and A30P 
mutant (Figure 3.25b-black line) is typical for random coil conformation with a maximum 
ellipticity at 200 nm and lacks the α-helical and β-sheet characteristic bands in the 210–230 nm 
region (Serpell et al., 2000; Uversky et al., 2001b; Weinreb et al., 1996; Zheng et al., 2013). 
Dopamine at the concentrations of 10 µM and 25 µM didn’t change the secondary structure 
content of AS and the resulted spectra (Figure 3.25a,b) are still mostly random coil 
conformation.  
 
Figure 3.25 CD spectra for AS and A30P mutant in the presence of dopamine. (a) CD spectra for 
full length AS (black) and in the presence of 50 μM (red) and 125 μM (blue) of dopamine.  (b) 
CD spectra for full length mutant A30P (black) and in the presence of 50 μM (red) and 125 μM 
(blue) of dopamine. 
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3.5.6 ITC of alpha-synuclein-dopamine interaction 
ITC has been used to measure the Kd of AS and dopamine interaction in both nanopore (1 M 
KCl, 10 mM HEPES-KOH, pH 7.8) and NMR (0.5x PBS) buffers. The best fit to the 
experimental points was obtained with a single binding site model (i.e. n=1) and a Kd of (2.85 
±0.01) × 10-4M was measured under ionic conditions used for performing both nanopore analysis 
(Figure 3.26a,b) and NMR spectroscopy (Figure 3.26c,d).  
 
 
Figure 3.26 (a,b) Calorimetric characterization of the interactions between dopamine and AS in a 
buffer containing 1 M KCl and 10 mM HEPES-KOH, pH 7.8. Data is fitted with the one-site 
model which corresponds to “n=1” and Kd = 2.85×10-4 M. (c,d) Calorimetric characterization of 
the interactions between dopamine and AS in 0.5xPBS. Data is fitted with the one-site model 
which corresponds to “n=1” and Kd = 2.85×10-4 M. 
 
3.5.7 HSQC-NMR of alpha-synuclein-dopamine interaction 
Primary NMR spectroscopy experiments were performed in a buffer containing 5% glycerol 
and 0.05% BOG. The resulting 1H,15N-HSQC NMR spectra were well dispersed but no 
significant change was observed upon addition of dopamine which showed that BOG interferes 
with the binding of dopamine. Therefore NMR experiments were performed without adding 
BOG to the buffer. As show in Figure 3.27a the 1H-15N HSQC NMR spectrum of AS alone 
(black) is characteristic of unfolded proteins because it is not as well resolved with some line-
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broadening and peak overlap. At a ratio of 1:25 (AS to dopamine) (red) most of the peaks such 
as L8, T22, T33, G41, V63, G67, G68,T92, G106, M116, D135 and E137 underwent a reduction 
in their intensities. The changes in residue intensities are summarized in Figure 3.27b which is a 
plot of the relative peak intensities, I/I0 (Ibound/Ifree), of the HSQC cross peaks in the AS/dopamine 
complex and free AS versus the amino acid sequence of AS. Furthermore a few peaks (L8, G106 
and E137) shifted in the presence of dopamine and their chemical shift perturbations are shown 
in Figure 3.27c,d,e. The changes in the intensity ratio as a function of drug concentration are 
described in Figure 3.28 for well-resolved residues (G41, G67, G68 and G106) and show that 
titration of AS with increasing concentrations of dopamine causes a gradually decrease of 
residue intensity. This shows that this interaction is concentration dependent.  
Previously it has been demonstrated that in the presence of negatively charged lipids, the first 
100 residues of AS interact with the surface of micelles and adopt an α-helical conformation. 
However because of the size of the micelles, these residues disappeared from the spectrum 
(Chandra et al., 2003; Davidson et al., 1998; Georgieva et al., 2008; Jao et al., 2008; Ulmer et 
al., 2005a). Figure 3.29a shows the 1H-15N HSQC NMR spectrum of AS alone (black) and in 
presence of 0.02% LPPG (green) (a). The peaks of the first 100 residues of AS became 
“invisible” by NMR and the visible peaks are from the last 40 residues of AS. Adding dopamine 
at the ratio of 1:10 (AS to dopamine) to the experiment (red) (Figure 3.29b) didn’t change the 
spectrum and shows that LPPG interferes with binding of dopamine to AS. The chemical shifts 
plot of the HSQC cross peaks in the AS/dopamine/LPPG complex and free AS is shown in 
Figure 3.29c. This graph shows that E110, E114, and E137 are significantly shifted compared to 
the AS alone.  
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Figure 3.27 1H-15N HSQC NMR spectrum and relative peak intensities graph of AS in the 
presence of dopamine. (a) 1H-15N HSQC NMR spectrum of AS alone (black) and in presence of 
the ratio of 1:25 (AS to dopamine) (red) (b) Plot of the relative peak intensities of the HSQC 
cross peaks in the AS/dopamine complex and free AS versus the amino acid sequence of AS. 
The baseline intensity ratio is 0.8 due to dilution upon addition of dopamine. (c, d, e) Expanded 
view of the chemical shifts for residues L8, G106 and E137 [Experiments performed by Dr. 
Sergiy Nokhrin]. 
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Figure 3.28 Relative signal intensities at three concentrations of dopamine for selected residues 
as a function of the AS:dopamine ratio. (a) G41 (b) G67 (c) G68 (d) G106. 
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Figure 3.29 1H-15N HSQC NMR spectrum and chemical shift graph of AS in the presence of 
LPPG and dopamine. (a) 1H-15N HSQC NMR spectrum of AS alone (black) and in presence of 
0.02%LPPG (green) (b) 1H-15N HSQC NMR spectrum of AS alone (black) and in presence of 
0.02%LPPG and at the ratio of 1:10 (AS to dopamine) (red)  (c) Plot of the chemical shifts of the 
HSQC cross peaks in the AS/dopamine/LPPG complex and free AS versus the amino acid 
sequence of AS [Experiments performed by Dr. Sergiy Nokhrin]. 
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3.6 Other drugs and natural small molecules 
The nanopore analysis, NMR spectroscopy and ITC showed that nicotine has high affinity for 
AS and caused a significant change in AS conformation. In order to find another effective 
chemical, the interactions of other natural products, caffeine and curcumin, with AS have been 
studied using nanopore analysis. Epidemiological studies suggested that both caffeine and 
nicotine intake is associated with lower incidence of PD (Altman et al., 2011; Ascherio and 
Chen, 2003; Darvesh et al., 2012; Mythri and Bharath, 2012; Postuma et al., 2012; Ross et al., 
2000). 
 
3.6.1 Caffeine and Curcumin 
Figure 3.30 shows the blockade current histograms of AS in the presence of 5 µM and 10 µM 
of caffeine and curcumin. Both caffeine and curcumin cause a shift in the AS translocation peak 
from -86 to lower blockade currents between -70 to -80 pA and also change the intensity of 
bumping and translocation peaks (Figure 3.30). In the presence of 5 µM caffeine there are two 
peaks centered at -78 pA and -35 pA with intensities of 44% and 38% respectively (Figure 
3.30b). By increasing the concentration of caffeine to 10 µM, 93% of events formed a peak at -
76 pA and a few events observed with lower current blockades (Figure 3.30d). Adding 5µM 
curcumin to AS results in two peaks centered at -70 pA and -29 pA with intensities of 38% and 
57% (Figure 3.30c). In the presence of 10µM of curcumin there are two peaks centered at -79 pA 
and -31 pA with intensities of 53% and 37% (Figure 3.30e).   
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Figure 3.30 Blockade current profiles showing the interaction of caffeine and curcumin with AS.  
AS (a) and AS to caffeine ratio: (b) 1:5, (c) 1:10 and AS to curcumin ratio: (d) 1:5, (e) 1:10. 
[Experiments performed by Joe Kakish] 
3.6.2 Binding of caffeine and (-)-nicotine simultaneously  
Our results showed that (-)-nicotine (Figure 3.31b) and caffeine (Figure 3.31c) at the 
concentration of 10 μM shifted the AS translocation peak (Figure 3.31.a) from -86 pA to -60 pA 
and -80 pA respectively. To investigate the effect of these small molecules on the AS 
conformation a nanopore experiment has been done in the presence of 5 μM of each molecule 
(Figure 3.31d). The blockade current histogram showed an increase in the intensity of the peak 
centered at -25 pA when both drugs are present (Figure 3.31d) in comparison with (-)-nicotine 
(Figure 3.31b) and caffeine experiments (Figure 3.31c) and also the intermediate peaks in the 
presence of nicotine and caffeine were disappeared (Figure 3.31b,c). 
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Figure 3.31 Blockade current profiles showing the interaction of (-)-nicotine, caffeine and their 
synergic effect with AS.  AS (a) and AS to (-)-nicotine ratio: (b) 1:10, AS to caffeine ratio: (c) 
1:10, synergic experiment with AS to (-)-nicotine to caffeine ratio: (d) 1:5:5. [Caffeine 
experiment (Part b) performed by Joe Kakish] 
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4 DISCUSSION  
4.1 Biophysical study of AS-ligand interaction 
4.1.1 Introduction 
Nanopore analysis was the primary technique used in this thesis to characterize the partially 
folded intermediate conformations of AS. The concentration of AS used to perform the nanopore 
experiments was 1 µM whereas classical techniques such as NMR spectroscopy require at least 
50 µM of AS (Maltsev et al., 2012). Working with low concentrations of AS reduces the chance 
of AS oligomerization and aggregation which occur at high concentrations of AS (Fink, 2006; 
Wood et al., 1999). Interestingly, the total concentration of AS in dopaminergic neurons has 
been measured to be 6 µM (Cremades et al., 2012; Iwai et al., 1995) which is the same order of 
magnitude as the concentrations used in nanopore experiments. Thus the nanopore analysis 
results have more relevance to the physiological conditions as compared with the classical 
methods. Nanopore analysis is a single molecule technique which has been successfully used to 
study the conformational changes of unfolded proteins such as prion peptides (Madampage et al., 
2010; Madampage et al., 2013a; Madampage et al., 2013b; Stefureac et al., 2010), β-amyloid 
(Asandei et al., 2013; Wang et al., 2011a) and AS (Wang et al., 2013). Other examples of single 
molecule techniques which have been successfully used in studying the conformation of 
unfolded proteins are single-molecule force spectroscopy (SMFS) and Single-Molecule Förster 
Resonance Energy Transfer (FRET) (Brucale et al., 2014; Hoffmann et al., 2013). As single 
molecule techniques overcome the limitations of classical methods, i.e. averaging of time and 
ensemble signals, they have been widely used to study unfolded proteins (Hoffmann et al., 
2013). The main advantage of these techniques is their ability to study single monomers in a 
real-time scale and avoid the averaging of ensembles (Brucale et al., 2014; Hoffmann et al., 
2013). The ability to individually recognize molecules within a population at the maximum 
possible temporal resolution makes them a useful tool to study the early stages of the aggregation 
process (Hoffmann et al., 2013). Although single molecule techniques have the ability of 
monitoring individual molecules one at a time, nanopore analysis has features which make it 
more feasible for studying protein misfolding (Hoffmann et al., 2013; Madampage et al., 2011). 
The main advantage of nanopore analysis is that this technique does not require any labeling or 
chemical modification of proteins whereas FRET and SMFS do require chemical modifications 
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(Brucale et al., 2009; Brucale et al., 2014; Ferreon et al., 2012; Hoffmann et al., 2013; Sandal et 
al., 2008; Trexler and Rhoades, 2010a). For example, FRET requires a donor–acceptor dye pair 
attached to the unfolded proteins and SMFS samples must have an atomic force microscopy 
(AFM) tip and surface or bead and surface attachments (Brucale et al., 2014; Hoffmann et al., 
2013). Thus the ability of nanopore analysis in detecting unmodified proteins makes this 
technique a faster and lower cost technique as compared to FRET and SMFS. Another benefit of 
nanopore analysis is the possibility of studying oligomers and aggregates by using artificial pores 
with different diameters (Hoffmann et al., 2013; Yusko et al., 2011).  
One challenge that has been discussed by Hoffmann et al. in a review is the possibility of 
undesired interaction between the protein sample and lipid surfaces (Hoffmann et al., 2013). To 
eliminate any noise arising from the undesired interaction between AS and the lipid used to set 
up the nanopore experiments, a control was set up with 0.35 mg of 1,2-diphytanoyl-sn-glycero-3-
phosphocholine (DPhPC) micelles and wild type AS (Figure 3.1c). Our control experiment was 
in agreement with previous work (Wang et al., 2013) and showed no interaction between DPhPC 
and AS. Further control experiments were performed by adding the drugs into the nanopore cup 
to investigate any noise arising from the interaction of the drugs with αHL pore. After making 
sure that the drug does not alter the event profile, AS was added to the cup. Also to eliminate any 
metal contaminations (Krasniqi and Lee, 2012), experiments were performed in the presence of 1 
mM EDTA which chelates any unwanted divalent metals (Figure 3.1b).  
Another challenge which has been discussed by Hoffmann et al. is that “it can be difficult to 
relate blockade currents to structures, especially when the possible structures are themselves 
unknown” (Hoffmann et al., 2013). First, it can be argued that this is also true for the other single 
molecule techniques. Second, structural information is available for nanopore analysis.  
Nanopore analysis signals or events arise from the interaction of the analyte with the αHL pore 
leading to a reduction of the baseline ionic current due to partial or complete occupation of the 
pore which is called the current blockade (Figure 2.3) (Brucale et al., 2014; Christensen et al., 
2011; Iqbal and Bashir, 2011; Ma and Cockroft, 2010; Meng et al., 2010a; Mulero et al., 2010; 
Sutherland et al., 2004; Wang et al., 2010a). Quantitative parameters of the blockade, such as its 
duration (T) and amplitude (I) depend on the structure of the analyte and are signatures for each 
analyte (Figure 2.3) (Brucale et al., 2014; Christensen et al., 2011; Meng et al., 2010a; Stefureac 
et al., 2008; Stefureac and Lee, 2008; Stefureac et al., 2010; Sutherland et al., 2004; Wang et al., 
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2010a). In the nanopore experiments performed for AS, the T and I values have been measured 
for translocation and bumping peaks to investigate the conformational changes of AS under 
different conditions. Furthermore, the changes of the intensity of bumping and translocation 
peaks have been measured to compare the conformational changes in different conditions. CD 
and NMR spectra of AS have shown the random coil or unstructured conformation for AS 
(Figure 3.10, 3.14, 3.17a,c, 3.25a, 3.27a and 3.28a) which were in agreement with previous work 
(Antony et al., 2003; Cappai et al., 2005; Chandra et al., 2003; Goers et al., 2003; Lendel et al., 
2009; Maltsev et al., 2011; Outeiro et al., 2009; Rao et al., 2008; Serpell et al., 2000; Sung and 
Eliezer, 2007; Uversky et al., 2001b; Weinreb et al., 1996; Wu et al., 2008; Yu et al., 2012; 
Zheng et al., 2013). As this protein has a random coil conformation, the blockade current 
histogram of AS wild type showed a significant peak at -85 pA (Figure 3.2a). Furthermore 
voltage studies were performed at two voltages and showed that this peak is due to translocation 
of the AS monomers through the αHL pore. Mutants of AS (A30P, E46K and A53T) also were 
studied (Figure 3.2) and the quantitative parameters of the peaks centered at -25 pA and -85 pA 
were measured (Table 3.1). For all peptides the T values for the peak centered at -25 pA were 
less than the T values for the peak at -85 pA. As the bumping events are due to the blockage of 
the ionic flow by compact conformations for a short time (Christensen et al., 2011; Meng et al., 
2010a; Stefureac and Lee, 2008; Stefureac et al., 2010), the peak centered at -25 pA represent the 
bumping peak. However, voltage studies of the peak at -85 pA showed that by increasing the 
voltage the average time decreases which means that the protein is being electrophoretically 
driven through the pore as has been shown for other proteins (Jetha et al., 2013; Krasniqi and 
Lee, 2014; Madampage et al., 2011; Wang et al., 2013). Thus, the peaks centered at -85 pA in 
the blockade histograms of the AS mutants are also due to the translocation of these peptides 
through the pore.  As the net charge of the mutant E46K is -7 it has the longest translocation time 
at 100mV. The other two mutants (A53T A30P) and the wild type have a strong overall negative 
charge (-9) and their average translocation time is less than E46K (Table 3.2). The blockade 
current histograms of AS wild type and mutants were different and clearly demonstrate the 
conformational heterogeneity among the wild type and mutants (Figure 3.2). Previous work with 
SMFS also showed that the wild type and mutants of AS have different conformations (Brucale 
et al., 2009; Sandal et al., 2008). They have found that the conformation of the AS mutants are 
more compact as compared to the AS-wild type. This is in agreement with our nanopore results 
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which showed that the blockade current histograms of AS mutants contain significantly more 
bumping events than the AS wild type. Moreover, mutants A30P and A53T show similar 
conformational properties with some differences in the proportion of bumping and translocation 
events (Figure 3.2). As a proof of concept, the SMFS results also showed that A30P and A53T 
have a similar conformation that is significantly different from that of wild type and the E46K 
(Brucale et al., 2009; Sandal et al., 2008). Thus Hoffmann et al. may be correct but detailed 
conformation information also cannot be extracted from other single molecule techniques. 
Wang et al. (2013) used the αHL pore to investigate AS fibrillization. Their experimental set 
up was the same as our nanopore experiments; a voltage of 100 mV was applied and both the 
αHL and the AS were added to the cis side (Wang et al., 2013). Although they recorded the 
typical translocation events with a magnitude of 85 pA, the way that they processed and 
interpreted the collected data was different from our methods. Normally the open pore current 
level is considered as the baseline (in our experiments at 100 pA) (Figure 2.3a,b,c,d) 
(Christensen et al., 2011; Krasniqi and Lee, 2012; Krasniqi and Lee, 2014; Krasniqi et al., 2012; 
Madampage et al., 2013a; Madampage et al., 2013b; Meng et al., 2010a; Stefureac et al., 2008; 
Stefureac et al., 2010) but in this paper a second baseline also was recognized at 20 pA. They 
believed that the interaction of AS with the pore is a two step process and causes two drops in 
the first baseline, i.e. the open pore current level. They showed that the first drop of current from 
the primary baseline (100 pA) to the secondary baseline (20 pA) is due to the capture of AS into 
the vestibule of the pore. The next drop occurs from the second baseline (20 pA) to 15 pA due to 
translocation of AS monomers from vestibule to the trans side (Wang et al., 2013). The overall 
interaction of AS wild type with αHL causes a total blockade with the magnitude of 85 pA due to 
translocation of AS which is in agreement with our experiments. In our data processing, we 
measured the total current blockade from the open pore current level to 15 pA which is 
consistent with their reports.    
Recently Gurnev et al. (2014) used nanopore analysis to study the AS conformation but 
indicated that they were not able to detect any blockages upon addition of the AS into the cis-
side, even at voltages up to 100 mV of both polarities (Gurnev et al., 2014). Wang et al. (2013) 
and our nanopore experiments showed that AS is electrophoretically driven through the αHL 
pore due to its negative net charge (-9). The main problem of this paper is that their αHL stock 
solution contained 8 M urea (Gurnev et al., 2014) which results in structural change to the αHL 
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(Pastoriza-Gallego et al., 2007). Thus αHL which was added to the cis side was already 
denatured and this might be the reason for the unsuccessful detection of an AS blockade from the 
cis side. The poor interaction of AS with the cis side of the pore might be due to contamination 
or low purity of the sample. They also suggest that AS binds to the membrane but our control 
shows that this is wrong. To ensure that AS does not bind to the 1,2-diphytanoyl-sn-glycero-3-
phosphocholine (DPhPC) the following control was performed (Figure 3.1c). AS was incubated 
with 0.35 mg of DPhPC micelles and the sample was added to the cis side of the cup. The event 
profile of AS (Figure 3.1b) in the presence of 0.35 mg of DPhPC was unchanged (Figure 3.1c). 
Furthermore it has been demonstrated previously that AS does not bind to phosphatidylcholine 
(PC) but has the ability to bind acidic phospholipids such as phosphatidylinositol (PI), 
phosphatidylserine (PS) and phosphatidic acid (PA) (Davidson et al., 1998; Jo et al., 2000).    
Natively unstructured proteins such as AS and β-amyliod (Aβ) are very sensitive to their 
environment. Environmental modification such as exposure to toxins or drugs folds these 
proteins into partially folded intermediates, a process which is called misfolding (Fink, 2006; 
Uversky et al., 2001a). These intermediates can oligomerize and eventually form aggregates 
which are associated with the pathology of neurodegenerative diseases such as PD and 
Alzheimer disease (Finder and Glockshuber, 2007; Fink, 2006; Nasica-Labouze and Mousseau, 
2012; Rijal Upadhaya et al., 2014; Uversky and Eliezer, 2009; Uversky et al., 2001a; Uversky et 
al., 2001c). Thus, characterization of these intermediates are important for the development of 
small molecules as misfolding inhibitors. Previous work has used nanopore analysis to study the 
interaction of unfolded proteins with different ligands and characterized the partially folded 
intermediates (Asandei et al., 2013; Baran et al., 2010; Stefureac et al., 2010; Wang et al., 2013; 
Wang et al., 2011a). For example, Baran et al. studied the interaction of the recombinant murine 
myelin basic protein (MBP) with Cu(II) and Zn(II) using nanopore analysis. Monitoring of the 
proportion of translocation and bumping events showed that both Cu(II) and Zn(II) cause a 
reduction in the number of translocation events. Binding of metals with MBP induces folding or 
compaction of this protein into one or more conformations that are too large to pass through the 
pore and results in an increase in the number of bumping events (Baran et al., 2010). Similar 
folding and compaction also occurred for AS in the presence of Cu(II) (see below). Another 
example of conformational change due to binding of metals with unfolded proteins is the 
interaction of human and rat amyloid fragments Aβ (1−16) with copper (II) (Asandei et al., 
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2013). Addition of various concentrations of Cu(II) causes a reduction in the number of events 
with long blockage and a simultaneous increase in the number of events with short blockage. The 
results showed that Cu(II) causes folding and compaction of this peptide (Asandei et al., 2013). 
Another example is the interaction of a zinc-finger molecule (Zif268) with Zn(II). The event 
profile of this motif was changed in the presence of Zn(II) and showed an increase in the 
intensity of the bumping peak and a simultaneous decrease in the proportion of the translocation 
peak (Stefureac and Lee, 2008). 
The partially folded intermediates induced by interaction of AS and small molecules such as 
dopamine, nicotine and methamphetamine, were characterized in this thesis (see below). 
Previous work showed that nanopore analysis can detect the opposite effects of β-cyclodextrin 
(β-CD) and Congo Red (CR) in aggregation transition of β-amyloid-42 (Aβ42). β-CD and CR 
are aggregation promoter and inhibitor agents, respectively, and their effects on Aβ42 misfolding 
and aggregation has been detected by monitoring the corresponding blockade current and time. 
The blockade current histogram for Aβ42 showed two peaks representing translocation events, 
and bumping events. In the presence of CR the bumping peak dramatically decreases and there is 
an increase in translocation events. This profile showed that CR reduces formation of the 
misfolded or compact conformation of Aβ42. In the presence of β-CD a significant peak at 23.25 
pA has been detected which was different from free Aβ42 and Aβ42-CR complex (Wang et al., 
2011a).  
Nanopore analysis was used in this thesis to characterize the conformational change of AS in 
the presence of anti-parkinsonian small molecules (dopamine, nicotine, curcumin and caffeine) 
and methamphetamine as a Parkinson’s inducing toxin. Other biophysical techniques such as 
NMR spectroscopy assisted to verify the nanopore analysis results and also to study other 
biophysical properties of the partially folded intermediates such as binding constant of the 
interaction and the secondary structure content. 
4.1.2 Interaction of methamphetamine isomers with alpha-synuclein                                              
Several studies showed that methamphetamine addicts have a higher incidence for developing 
PD (Callaghan et al., 2010; Callaghan et al., 2012; Granado et al., 2013; Moszczynska et al., 
2004). Thus, we studied the interaction of methamphetamine with AS to investigate a possible 
mechanism for the psychoactivity of methamphetamine as well as an increased incidence of 
Parkinson’s disease amongst users of the drug.  Addition of both optical isomers of 
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methamphetamine to AS changed the blockade current profile of AS by increasing the number of 
events with current blockades lower than -80pA (Figure 3.4, 3.5).     
For both (+)- and (-)-methamphetamine the current blockade histograms showed a 
concentration dependent increase in the intensity of bumping peak centered at -25 pA as 
compared with the current blockade profile of AS alone (Figure 3.4, 3.5). An increasing in the 
proportion of bumping events suggests that the protein folds and gets a more compact 
conformation which cannot translocate through the pore. The effect is similar to adding Zn(II) to 
the zinc-finger peptide causing folding into a compact conformation which cannot translocate 
(Stefureac and Lee, 2008). 
The CD spectra of AS alone and in the presence of increasing concentrations of (+)- and (-)-
methamphetamine showed a maximum ellipticity at 200 nm which is characteristic for random 
coil or denatured proteins. The CD spectrum showed no indication in the 210–230 nm region of 
an increase in either α-helix or β-sheet (Figure 3.10).  This implies that binding of these ligands 
to AS does not cause a significant change in the secondary structure content of this peptide. 
Based on the nanopore and CD spectroscopy results, we proposed a “loop formation” model for 
the interaction of both optical isomers of methamphetamine with AS (Figure 4.1). This model 
suggests that AS folds around the ligand and forms a loop or an induced binding pocket. As 
illustrated in Figure 4.1b for (+)-methamphetamine, this partially folded conformation can be 
detected by nanopore analysis because this induced conformation cannot translocate the pore and 
results in an increase in the proportion of bumping events. However, formation of a loop does 
not alter the secondary structure content of the peptide and cannot be detected with CD 
spectroscopy. Previous studies also showed that the conformational changes induced by small 
molecules cannot be differentiated from the natively unfolded monomers using CD spectroscopy. 
For example, CD spectra for the mutants of AS (Li et al., 2001) and the AS in the presence of 
dopamine (Cappai et al., 2005; Outeiro et al., 2009), chlorazole black E, copper complex of 
phthalocyanine tetrasulfonate (PcTS-Cu2+) (Rao et al., 2008), polycations (polylysine, 
polyarginine, and polyethyleneimine) (Goers et al., 2003), putrescine, spermine (Antony et al., 
2003), congo red (Lendel et al., 2009; Rao et al., 2008), trehalose (Yu et al., 2012) and lacmoid 
(Lendel et al., 2009; Rao et al., 2008) were typical for random coil conformation and 
demonstrated that mutation and complex formation with small molecules do not cause significant 
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change in the secondary structure of AS. On the other hand, nanopore analysis as a single 
molecule biophysics technique has the ability to detect subtle conformational changes.    
Further comparison of the blockade current histograms for (+)- and (-)-methamphetamine 
(Figure 3.4, 3.5) showed that they change the AS conformation in a different manner and at the 
same concentrations the proportion of bumping events induced by (+)-methamphetamine is more 
than that induced by the (-)-isomer. Thus, the interaction of AS with methamphetamine is 
stereospecific and further characterization of these interactions using AS deletion mutants 
confirmed these specific interactions and showed the N- and C-terminal binding sites for the (+)- 
and (-)-isomer respectively (Figure 3.6, 3.7, 3.9).  
The measured Kd for the interaction of (+)- and (-)-methamphetamine indicated one binding 
site for each ligand with different Kds. The affinity of interaction for (+)-methamphetamine 
(2x106 M-1) is greater than (-)-methamphetamine (5x105 M-1) (Figure 3.11). These isomers also 
have different physiological effects. In general, the (+)-isomer is more effective than the (-)-
isomer in producing central nervous system (CNS) stimulation. Furthermore, human studies 
showed that (+)-methamphetamine produces more cardiovascular effects than equivalent doses 
of (-)-methamphetamine. (-)-Methamphetamine intoxication is similar to that of the (+)-isomer at 
high doses, but the psychodynamic effects are shorter-lived and less desired by abusers 
(Mendelson et al., 2006).  
 
Figure 4.1 Proposed model for binding of (+)-methamphetamine to the N-terminal region of AS. 
Full length AS can readily translocate the α-hemolysin pore from the C-terminal end which 
carries a net negative charge. In the presence of methamphetamine, a loop is formed which 
causes bumping events to be more likely.  
4.1.3 Interaction of nicotine isomers with alpha-synuclein  
Epidemiological studies showed that PD is less prevalent in smokers (Checkoway et al., 2002; 
Hernán et al., 2002; Kessler and Diamond, 1971; Ono et al., 2007b; Quik, 2004; Ross and 
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Petrovitch, 2001). It has been shown that the nicotine of tobacco smoke has a neuroprotective 
effect against PD symptoms (Alves et al., 2004; Hernán et al., 2002; Hong et al., 2009; Quik, 
2004). Tobacco is prepared from a plant which belongs to the Solanaceae family. Examples of 
edible products derive from the Solanaceae family are peppers, tomatoes, potatoes, and 
eggplants. Furthermore the results of a study on 490 idiopathic PD patients and 644 normal 
controls revealed that a diet including Solanaceae family products such as peppers, tomatoes, 
tomato juice, and potatoes reduces the risk of PD (Nielsen et al., 2013). Nicotine is an optically 
active compound (Moore et al., 2003; Welter et al., 2005) and the naturally occurring form of 
nicotine is (-)-nicotine or l-nicotine (Figure 1.16a). The dextrorotatory form, (+)-nicotine or d-
nicotine (Figure 1.16b) is physiologically less active than (-)-nicotine (Moore et al., 2003; Rapier 
et al., 1988) and (-)-nicotine is more toxic than (+)-nicotine (Moore et al., 2003). The 
neuroprotective effect of nicotine in PD is through stimulation of the nicotinic acetylcholine 
receptors (nAChRs). It has been shown that nicotine evoked the release of dopamine from 
striatal synaptosomes in rats with an EC50 of 3.8 μM. This ability was stereospecific and it has 
been shown that the action of (-)-nicotine was 100 times stronger than (+)-nicotine (Fujita et al., 
2006; Rapier et al., 1988). Another possible mechanism for the neuroprotective effect of nicotine 
in PD is modulation of AS aggregation (Hong et al., 2009; Ono et al., 2007b) and the study of 
the interaction of nicotine with AS may be useful in designing new small molecules as 
antifibrillization agents. The nanopore studies showed that (-)- and (+)-nicotine change the 
conformation of AS in a concentration dependent manner and by increasing the ligand 
concentration, the protein conformation changed differently (Figure 3.12) (see below). 
Previously thioflavin S (ThS) assays have been used to study the effect of (-)-nicotine on AS 
fibrillation which requires high concentrations of AS (70 µM). The results showed that (-)-
nicotine inhibits the fibrillation of AS and the ThT fluorescence signal decreases as a function of 
nicotine concentration. In the absence of nicotine, AS monomers are misfolded and aggregated 
to form transient oligomers and assembly of these oligomers leads to the formation of fibrils but 
incubation of nicotine with monomeric AS causes the formation of stabilized oligomers which 
will not fibrillize anymore (Hong et al., 2009). Our nanopore results were performed at a very 
low concentration of AS (1 µM) to characterize the early stages of AS aggregation, the formation 
of partially folded intermediates, in the presence of nicotine. The conformations detected by 
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nanopore analysis (Figure 3.12) might represent the misfolded conformations of AS which are 
able to oligomerize and form the stabilized oligomers at high concentrations. 
 Furthermore the conformational changes induced by (-)- and (+)-nicotine at the same 
concentrations were different (Figure 3.12). Thus the interaction of AS with nicotine is 
stereospecific and at a concentration of 5 μM (+)-nicotine (Figure 3.12g) the profile is much 
simpler than (-)-nicotine (Figure 3.12c) and also different intermediate peaks are found at a 
concentration of 10 μM (Figure 3.12d,h). At this concentration for (-)- and (+)-isomers the 
intermediate peaks were centered at -62 pA (Figure 3.12d) and -42 pA (Figure 3.12h) 
respectively. The CD spectra of AS demonstrated no significant increase in ordered secondary 
structure content in the presence of nicotine even at the highest AS:nicotine ratio of 1:10, the 
spectra remain dominated by random coil (Figure 3.14). Upon addition of increasing 
concentrations of (+)- and (-)-nicotine the magnitude of  MRE, in the 196-200 nm region, 
increased in a concentration dependent manner similar to those reported for other small 
molecules such as such as chlorazole black E , copper complex of phthalocyanine tetrasulfonate 
(PcTS-Cu2+) (Rao et al., 2008), congo red (Lendel et al., 2009; Rao et al., 2008), trehalose (Yu 
et al., 2012) and lacmoid (Lendel et al., 2009; Rao et al., 2008).    
Nanopore analysis with AS fragments demonstrated that (-)-nicotine has a binding site 
consisting of both N- and C-terminal residues of AS but (+)-nicotine has a binding site which 
involves mostly residues from the N-terminus (Figure 3.13). This difference in the binding sites 
shows the interaction of AS with nicotine optical isomers is specific. Another proof of these 
specific interactions is the difference in Kas measured by ITC (Figure 3.15) which shows (+)-
nicotine has a lower affinity (4x105 M-1) compared to (-)-nicotine (1.35x106 M-1). Physiological 
activity measurments of nicotine have shown that (+)-nicotine is physiologically less active than 
(-)-nicotine (Moore et al., 2003; Rapier et al., 1988) and (-)-nicotine is more toxic than (+)-
nicotine (Moore et al., 2003).  
The interaction of AS with (-)- and (+)-nicotine was investigated by HSQC NMR 
spectroscopy (Figure 3.17). Titrations of the protein with increasing amounts of each isomer 
showed concentration dependent changes in the intensities of several peaks in the 1H-15N 
spectrum as compared with AS alone which represents a change in conformation. Furthermore 
the observed changes in intensities were more significant for (-)-nicotine (Figure 3.17a,b) than 
for (+)-nicotine (Figure 3.17a,b), in agreement with the higher Ka for the (-)-isomer (Figure 
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3.15). This is similar to the previous NMR spectroscopy spectra for the interaction of Congo Red 
and Lacmoid with AS which showed that the interaction of Congo Red with AS is stronger than 
Lacmoid and causes more changes in the intensity of the NMR signals (Lendel et al., 2009).   
The changes in peak intensity observed in the 1H-15N spectra which make them invisible in 
the spectra is due to broadening of the AS NMR signals as a result of  chemical exchange on the 
μs-ms time scale upon binding to the ligands. This has been previously observed for the 
interaction of Congo Red, Lacmoid (Lendel et al., 2009; Rao et al., 2008), chlorazole black E, 
PcTS-Cu2+ and rosmarinic acid (Rao et al., 2008).   
Moreover the NMR spectroscopy results (Figure 3.17b,d) are in agreement with the mapped 
binding sites detected by nanopore analysis (Figure 3.13) which demonstrated N- and C-termini 
binding site for (-)-nicotine and a N-terminal binding site for (+)-nicotine.  NMR spectroscopy 
demonstrated that (+)-nicotine effects few residues from the N-terminal and NAC residues 
(Figure 3.17c,d) but (-)-nicotine causes an overall change in AS conformation involving residues 
from the N-terminal, NAC and C-terminal (Figure 3.17a,b). Based on these results, models can 
be proposed for the binding of nicotine to AS (Figure 4.2b,c). (+)-Nicotine has an N-terminus 
binding site and its binding might induce a loop formation in the first 100 residues of AS (Figure 
4.2c). (-)-Nicotine has a binding site involving residues from both N- and C-terminal and its 
binding to AS might cause a large conformational change involving the folding and compaction 
of the whole sequence which leads to the broad change of intensities in the 1H-15N HSQC spectra 
(Figure 4.2b). 
 
Figure 4.2 Schematic of the structure of AS protein, showing (a) the N-terminal segment, the 
NAC segment, and the C-terminal segment. (b) The proposed model for interaction of (-)-
nicotine  and (c) (+)-nicotine  with AS. (-)-Nicotine mediates the interaction between the N- and 
C-termini of AS (b) whereas (+)-nicotine binds to the N-terminus of AS. 
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4.1.4 Interaction of dopamine and copper with alpha-synuclein  
Cu(II) has an important role in the development of PD. In support of this, comparison of 
Parkinsonian and age-matched control brain tissue showed a reduction in the Cu (II) contents in 
the substantia nigra (SN) (Davies et al., 2014; Dexter et al., 1989; Riederer et al., 1989). 
Previous work using NMR spectroscopy have shown that AS has two binding sites for Cu(II) 
with different affinities (see below). Thus we studied the interaction of Cu(II) and AS to 
characterize the AS folded conformation induced by Cu(II). The nanopore analysis of the 
interaction of Cu(II) with the AS wild type and E46K mutant (Figure 3.19) showed that adding 
increasing concentrations of Cu(II) leads to a concentration dependent increase in the intensity of 
the bumping peak and a simultaneous decrease in the proportion of the translocation peak and 
suggested a binding constant of ~105M-1, because there is an approximately 50% reduction in the 
translocation peak at 10 µM Cu(II) (Figure 3.19b). The bumping events represent the folded 
conformation of AS which is more compact as compared with the native conformation of AS and 
cannot pass through the pore. Previous work has shown that Zn(II) and Cu(II) increase the 
number of bumping events due to folding and compaction of zinc finger peptide (Stefureac and 
Lee, 2008), prion protein (Stefureac et al., 2010) and myelin basic protein (Baran et al., 2010).  
Cu(II) at micromolar range (<100μM) binds tightly to the N-terminal site with high affinity 
(Kd~0.1 µM) located at 1MDVFMKGLS9 and 48VAHGV52. M1, D2 and H50 are the residues 
which are directly involved in the interaction with Cu(II) and result in the formation of a loop in 
the structure. The complex of Cu(II) and AS serves as a nucleation point for β-strand formation 
(Figure 4.3) (Rose et al., 2011). The nanopore experiments were performed at concentrations of 
Cu(II) in the affinity range of the N-terminal binding site and even at the highest Cu(II) 
concentration (25 µM) (Figure 3.19c,i), Cu(II) binds to the N-terminal and induced loop 
formation (Rose et al., 2011). Nanopore experiments with the AS segments (Figure 3.20) 
showed that Cu(II) changes the blockade current profile of the N-terminal and ∆NAC but no 
conformational change were observed for the C-terminal.  
Residues encompassing 48VAHGV52 have an important role in the interaction of Cu(II) with 
AS and especially H50 acts as an anchoring residue for loop formation (Binolfi et al., 2012; 
Binolfi et al., 2006; Rasia et al., 2005). Nanopore analysis of the E46K mutant (Figure 3.19g,h,i) 
which is close to this region showed that the conformation of E46K is more sensitive to Cu(II) 
binding as compared to AS wild type.  
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Figure 4.3 Misfolding events in AS due to copper binding. a: Snapshot of the free AS showing 
the location of His-50 (upper). b: Snapshot of Cu-bound AS with dynamically stable β-sheet. 
Insets show close-ups at the β-sheet nucleation point (Rose et al., 2011). Copyright © 2011 
Rights Managed by Nature Publishing Group. All rights reserved. 
Previous work using Thio-T fluorescence assay showed that the aggregation rate of AS 
mutants (A30P, A53T and E46K) in the presence of Cu(II) is more than that of the wild type AS 
and among the mutants E46K had the largest rate of fibril formation (Bharathi and Rao, 2008).  
There is a low affinity (Kd~1 mM) binding site at the C-terminal of AS located at 
119DPDNEA124 which serves as a general binding site for divalent metals such as Cu(II), Fe(II), 
Mn(II), Co(II) and Ni(II) (Binolfi et al., 2012; Binolfi et al., 2006; Rasia et al., 2005). As the 
nanopore analysis was performed at concentrations below the Kd of the C-terminal binding site, 
Cu(II) did not bind to the C-terminal peptide and the blockade current profile of this peptide was 
the same in the absence and presence of Cu(II).  
AS has an important role in dopamine homeostasis and is involved in almost all of the 
dopamine metabolism pathways including dopamine biosynthesis, storage of dopamine in 
synaptic vesicles, dopamine release in response to an action potential and re-uptake of released 
dopamine from the presynaptic space (Lotharius and Brundin, 2002a; Stefanis, 2012; Yu et al., 
2005). Furthermore the main feature of PD is aggregation of AS which results in AS malfunction 
and dopamine depletion (Grosset et al., 2009; Lotharius and Brundin, 2002a; Pahwa and Lyons, 
2007; Yu et al., 2005). Previous work has shown that dopamine interacts with AS and decreases 
the fibrillization of AS by stabilizing the oligomers of AS (Cappai et al., 2005; Fink, 2006; Lee 
et al., 2011; Leong et al., 2009; Norris et al., 2005). Thus there is a possible link between 
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dopamine depletion, AS misfolding and PD development. Therefore different biophysical 
techniques were used to characterize the partially folded intermediates of the AS:dopamine 
complex. Dopamine at a concentration of 25 µM changed the blockade current profile of both 
Wild type AS (Figure 3.21b) and A30P (Figure 3.21d) to a significant peak centered at -80 pA 
which was shown to be a translocation peak. The peak at -80 pA might represent a partially 
folded conformation of AS induced by dopamine which is the precursor for stabilized oligomer 
formation. The CD spectra of AS showed that dopamine does not change the secondary structure 
content of AS (Figure 3.25) and was in agreement with previous work (Cappai et al., 2005; 
Outeiro et al., 2009; Pham and Cappai, 2013). Thus binding of dopamine to AS might cause a 
simple loop which cannot be detected by CD spectroscopy but is readily detected by nanopore 
analysis. ITC measurements showed a single binding site for dopamine with a dissociation 
constant (Kd) of 2.85×10-4 M (Figure 3.26). Moreover nanopore analysis of AS segments showed 
that the binding site included residues from both N- and C-terminal of AS (Figure 3.23). HSQC 
NMR was performed to characterize which residues were involved in the interaction with 
dopamine (Figure 3.27). The control experiment (incubation of AS at 15 ̊ C for 5 hours) showed 
that AS is stable during the NMR experiment and any changes in conformation are induced by 
adding ligand to the AS sample (Figure 3.16). Titrations of AS with increasing amounts of 
dopamine at three ratios of AS:dopamine (1:5, 1:10 and 1:25) showed concentration dependent 
changes in the intensities of 1H-15N HSQC signal along the length of the AS sequence which 
represents a new ensemble of AS structures due to the binding of dopamine (Figure 3.27, 3.28). 
The intensity changes mostly involve loss of peak intensity rather than chemical shift changes 
(Figure 3.27a). Such behavior could reflect exchange processes in an intermediate regime caused 
by drug binding, including conformational transitions and intra-protein interactions as have been 
observed for the interaction of other small molecules such as congo red, PcTS-Cu2+, chlorazole 
black E and lacmoid with AS (Lendel et al., 2009; Rao et al., 2008). Conformational changes of 
AS in the presence of negatively charged lipids was in agreement with previous NMR studies 
and showed that in the presence of negatively charged lipids (LPPG in our study) (Figure 3.29), 
the first 100 residues of AS bind to the micelles and become invisible in the NMR spectra 
(Chandra et al., 2003; Davidson et al., 1998; Georgieva et al., 2008; Jao et al., 2008; Ulmer et 
al., 2005a). This is another proof of the N- and C-terminal binding sites for dopamine as 
dopamine did not bind to the last 40 available residues of AS in the presence of LPPG micelles. 
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The NMR results showed that the dopamine binding site does not overlap with the N-terminal 
binding site for Cu(II). This is in agreement with the nanopore experiments of AS that showed 
that a new peak was found in the presence of both dopamine and Cu(II) (Figure 3.24). Residues 
M1 and D2 are not well resolved in our NMR experiments in the presence of dopamine but for 
residues F4, M5 and K6 the intensity ratio is at the baseline level. Similarly, H50 is not well 
resolved but there is little change in the intensity ratio for residues V49, G51 and V52 in the 
presence of dopamine.  
There are two possibilities to explain these results; folding of AS monomers to form a loop or 
head to tail oligomerization of AS monomers.  Since the loss of peak intensity of HSQC NMR 
peaks does not occur for all residues, our results are not consistent with dopamine-induced 
oligomerization.  Conformational exchange appears to be the explanation most consistent with 
the nanopore data, which suggests a change in the population distribution of AS conformations 
in the presence of dopamine. In other words, the peak at -80 pA which appears on addition of 
dopamine is not consistent with oligomerization. Also, there was no change in the event profile 
with time.  
Taking all the results together, a model is proposed to explain the conformational changes of 
AS in the presence of dopamine (Figure 4.4).  AS folds to form a loop which involves the 
interaction between the N- and C-termini as shown in Figure 4.4b. Nanopore experiments 
showed that the NAC region is not directly involved in the interaction with dopamine. As 
dopamine mediates the interaction between the N- and C-termini, the conformation of NAC is 
significantly changed due to loop formation which was detected by NMR spectroscopy. Another 
model would be head to tail dimerization of AS monomers but it seems unlikely that this would 
cause a significant translocation peak to be observed in the nanopore analysis. Previously a C-
terminal binding site was reported for dopamine using molecular dynamic simulations (Herrera 
et al., 2008) but the structural biology approach used in this thesis to pursue this interaction 
showed that this interaction is complex and involves residues from both N- and C-terminal 
regions of AS.   
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Figure 4.4 . Schematic representation showing the interaction of dopamine with AS. (A) 
Schematic of the structure of AS, showing the N-terminal segment, the NAC segment, and the C-
terminal segment. The positions of missense mutations in the N-terminus are also indicated. (B) 
The proposed model for interaction of dopamine with AS. Dopamine mediates the interaction 
between the N-terminus and C-terminus of AS. 
4.1.5 Physiological relevance of in vitro studies  
All of the small molecules and ligands studied in this thesis have been selected based on 
previous work performed in vitro and in vivo and the relevance to their effects on AS 
conformation or PD development (see below).  For example, previous work showed that AS has 
an important role in the control of cytoplasmic dopamine concentrations by promoting the 
formation of synaptic vesicles from early endosomes and storage of dopamine in these vesicles 
(Lotharius and Brundin, 2002a, b; Yu et al., 2005). In the cytoplasm of dopaminergic neurons 
there are two pools of AS molecules, the free AS molecules with unfolded structure and AS 
bound to the membranes which has a mostly α-helical conformation.  Binding of free AS through 
its N-terminal with membrane phospholipids is the critical stage in the formation of synaptic 
vesicles and dopamine storage to maintain the cytoplasmic concentration of dopamine in the 
range of 0.5 μM to 2.2 μM as a protective strategy against cytosolic oxidation of dopamine 
(Lotharius and Brundin, 2002a, b; Olefirowicz and Ewing, 1990; Perlman and Sheard, 1982). 
The nanopore experiments performed in this thesis showed that dopamine at the concentration of 
25 µM binds to both N- and C-terminal of AS and causes folding of AS molecules into a new 
ensemble. No conformational change has been observed at dopamine concentrations less than 5 
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µM  (data not shown). ITC results revealed that the affinity of dopamine for AS is 150 to 300 
times less than the affinity of methamphetamine and nicotine for AS. The in vivo function of AS 
can be explained using our in vitro results.  Inside the cells at the safe concentrations of 
dopamine (0.5-2.2 µM), dopamine cannot change the conformation of free cytoplasmic AS 
molecules. Upon increasing the cytoplasmic concentration of dopamine, it binds to AS and might 
serves as a signal to trigger the formation of monoamine vesicles by changing the conformation 
of unfolded AS into the partially folded intermediate. These intermediate conformations which 
have been characterized in this thesis might promote vesicle formation by binding to the 
membrane of early endosomes for storage of the excess of cytoplasmic dopamine into these 
vesicles. Furthermore, the NMR results demonstrated that dopamine binds to the free unfolded 
AS molecules and no interaction has been detected in the presence of lipid micelles. Thus it 
could be concluded that dopamine just binds to the free AS molecules with unfolded structure 
and causes the formation of partially folded intermediates. Based on the in vitro results of this 
thesis it could be proposed that the unfolded AS in the cytoplasm of dopaminergic neurons might 
act as a sensor to detect the increase of cytoplasmic dopamine.  
Previous work has shown that nicotine from cigarette smoke has protective effects against PD 
(Alves et al., 2004; Hernán et al., 2002; Hong et al., 2009; Quik, 2004). Furthermore the nicotine 
brain concentration after consumption of one cigarette has been calculated to be 50 ng/ml (Rose 
et al., 1999) based on the reported nicotine blood concentrations in smokers (Benowitz et al., 
1982; Brody et al., 2006; Gritz et al., 1981; Rose et al., 2010; Russell et al., 1980). Moreover the 
half life for nicotine elimination from the body has been determined to be 100 to 150 min (Gritz 
et al., 1981). The average number of cigarettes consumed by smokers in a day is 30 to 36 
(Benowitz et al., 1982; Gritz et al., 1981; Russell et al., 1980) which results in a maximum 
concentration of 1500 to 1800 ng/ml nicotine in the brain. The concentrations of nicotine used in 
this thesis were in the range of 300 to 1600 ng/ml which is in the same range as the nicotine 
concentration in the brain of smokers. Thus it is not unreasonable to propose that the protective 
effect of nicotine is due to binding to AS.  
Considering the density of brain (1.081 gr/cm3) (Barber et al., 1970) the maximum 
concentration of total Cu(II) in the SN is 11.5 μg/ml (Lutsenko et al., 2010; Rongzhu et al., 
2009).  Moreover it has been reported that the total copper content of the SN showed a maximum 
reduction of 45% in PD brain samples as compared with the normal brain (Dexter et al., 1989). 
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Thus the maximum concentration of total Cu(II) in SN of PD patients would be about 6.3 μg/ml. 
As the majority of Cu(II) in brain is bound to Cu(II)-binding molecules, the concentration of free 
Cu(II) would be less than the above values (Bohic et al., 2008; Davies et al., 2014). Based on 
previous work, Cu (II) at concentrations less than 6.35 μg/ml binds to the N-terminal and at 
higher concentrations binds to the C-terminal of AS (Binolfi et al., 2012; Binolfi et al., 2006; 
Rasia et al., 2005). For the nanopore experiments performed in this thesis, the Cu(II) 
concentrations were 2.5 μg/ml and 6 μg/ml which are consistent with the Cu(II) concentrations in 
the SN of PD brains. The differences in Cu(II) concentrations in normal and PD brains can be 
explained from the viewpoint of Cu(II) affinities for AS. In normal brain the concentration of 
Cu(II) is high and copper has the ability to bind with both binding sites at N- and C-terminals. 
However, reduction of copper concentration in PD tissues might favour the binding of Cu (II) to 
the high affinity N-terminal site. Thus the misfolded conformation of AS upon binding of Cu(II) 
to the N-terminal might be associated with the pathogenicity of PD.   
It has been reported that methamphetamine addicts have a higher risk of developing 
symptoms of PD (Callaghan et al., 2010; Callaghan et al., 2012; Granado et al., 2013; 
Moszczynska et al., 2004). Pharmacokinetics of methamphetamine in the human brain showed 
that this toxic drug reaches peak concentrations 9 min after consumption which lasts for more 
than 75 min. It also has been shown that 9.6% of the consumed dose will be distributed in this 
organ (Volkow et al., 2010). The total daily amount of drug consumed by addicts is in the range 
of 0.7 to 1 gram. Chronic abusers smoke this recreational drug every 30 minutes during the day 
and stop smoking the drug at night to sleep (Cho and Melega, 2002). Consumption of this 
amount at once results in a brain concentration of 244 µM to 349 µM but gradual consumption 
results in the concentration of at least 18 µM (Cho and Melega, 2002).  Our nanopore 
experiments suggested that 20 µM of methamphetamine is high enough to cause a significant 
folding of AS (Figure 3.4e). The high concentration of this recreational drug in the brain of the 
drug abusers causes a significant change in the normal function of brain cells which finally 
results in the appearance of PD symptoms (Callaghan et al., 2010; Callaghan et al., 2012; 
Granado et al., 2013; Thrash et al., 2009). Previous work has shown that methamphetamine 
alters the cellular levels of AS and dopamine (Ajjimaporn et al., 2007; Chen et al., 2013; Kish, 
2008; Mauceli et al., 2006; Volkow et al., 2001a; Volkow et al., 2001b; Volkow et al., 2010). 
Thus there would be a link between methamphetamine consumption and failure of AS function 
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in dopamine homeostasis. Treatment of SK-N-SH neuroblastoma cells with methamphetamine 
causes overexpression of AS (Ajjimaporn et al., 2007). Furthermore (+)-methamphetamine 
stimulates the reverse transport of dopamine from synaptic vesicles to the cytoplasm of nerve 
endings by vesicular monoamine transporter 2 (VMAT2) (Granado et al., 2013; Kish, 2008). 
Although overexpression of AS itself increases the aggregation rate of AS, binding of 
methamphetamine with AS might prevents its role in dopamine homeostasis. The normal 
function of AS is important for clearance of dopamine from the cytoplasm of the presynaptic 
terminal and storage in synaptic vesicles. AS also regulates the re-uptake of released dopamine 
molecules from presynaptic space into the synaptic terminal. This homeostasis protects cells 
from the deleterious effects of dopamine oxidation in the cytoplasm and also helps the 
replenishment of synaptic dopamine. Loss of normal AS function promotes the accumulation of 
dopamine in the cytoplasm of the presynaptic terminal which leads to oxidative stress (Lotharius 
and Brundin, 2002a, b; Yu et al., 2005). Thus methamphetamine causes overexpression and 
aggregation of AS and also results in an increase in the cytoplasmic dopamine levels which 
finally together are responsible for creating PD pathology in the drug abusers.  
4.1.6 Conclusions leading into future directions 
Nanopore analysis is an emerging technique for studying protein misfolding. The results of 
this thesis showed that nanopore analysis differentiates the conformational changes of AS 
partially folded intermediates in the presence of anti-parkinsonian and Parkinson developing 
small molecules. The anti-parkinsonian small molecules can be used as candidates for designing 
inhibitors as new therapeutics for treatment of PD using a fragmentation drug design approach 
(see below). An important impact of this thesis is that the interaction of AS with D- and L-
enantiomers of nicotine and methamphetamine is stereospecific. This shows the importance of 
chirality in drug design and development for treatment of PD.  
4.2 Future directions  
4.2.1 Lead compound selection 
One promising approach in order to develop therapeutics for treatment of PD is to inhibit AS 
fibrillization with anti-fibrillization agents identified using high-throughput screening (Acharya 
et al., 2014; Kritzer et al., 2009; May et al., 2006; Prabhudesai et al., 2012; Rochet, 2007; 
Shaltiel-Karyo et al., 2010; Toth et al., 2014).  Fibril formation is a multistage process which 
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starts from the monomers of AS. The first stage is misfolding of the protein by formation of 
partially folded intermediates which are pre-molten globule-like conformers of AS (Fink, 2006; 
Uversky et al., 2001a). The native AS monomer has predominantly a random coil conformation 
(R51,R52,R48,R50) but the partially folded intermediates usually contain α-helical or β-sheet 
conformations (Frid et al., 2007; Serpell et al., 2000; Uversky and Eliezer, 2009; Uversky et al., 
2001b; Weinreb et al., 1996; Zheng et al., 2013). Intermolecular interactions of partially folded 
intermediates lead to the formation of oligomers and the assembly of oligomers forms fibrils 
(Fink, 2006; Uversky and Eliezer, 2009). Anti-fibrillization agents can be divided into two 
groups based on their mechanism of action. Some of them stop the fibrillization at the early stage 
by stabilizing the unfolded conformation of AS (Acharya et al., 2014; Amer et al., 2006; Attar 
and Bitan, 2014; Attar et al., 2012; Ferreira et al., 2014; Fokkens et al., 2005; Kim et al., 2009; 
Prabhudesai et al., 2012; Sinha et al., 2012a; Sinha et al., 2011b; Soto, 2003) and others can 
prevent this pathogenic process at the second step by stabilizing the oligormers of AS (Cappai et 
al., 2005; Fink, 2006; Hong et al., 2009; Lee et al., 2011; Leong et al., 2009; Norris et al., 2005). 
The biochemical properties of anti-fibrillization agents determine their mechanism of action. For 
example molecular tweezers and β-sheet breakers peptides (see below) stabilize the unfolded 
conformation of AS and prevent the misfolding process but nicotine (Hong et al., 2009) and 
dopamine (Cappai et al., 2005; Fink, 2006; Lee et al., 2011; Leong et al., 2009; Norris et al., 
2005) result in the formation of stabilized oligomers which no longer convert to the fibrils. 
Although their biochemical mechanisms are different, all of the anti-fibrillization agents result in 
a reduction of fibril formation which is associated with the pathology of PD (Acharya et al., 
2014; Amer et al., 2006; Attar and Bitan, 2014; Fink, 2006; Leong et al., 2009; Sinha et al., 
2011a; Soto, 2003).  
An important group of chemicals which has been shown to prevent AS fibrillization are 
catecholamines. Two drug screening studies using different groups of chemicals have shown that 
catecholamines are the most efficient anti-fibrillization agents with the lowest IC50. In the first 
screening, a library of 79 compounds belonging to twelve chemical groups were screened to find 
compounds with inhibitory effects on AS fibril formation (Masuda et al., 2006). Three in vitro 
assays were used to assess the fibril formation. They included electron microscopy, thioflavin S 
(ThS) fluorescence, and the formation of sarkosyl-insoluble α-synuclein. The IC50 values of all 
79 compounds for inhibiting AS filament assembly were determined by quantifying the levels of 
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sarkosyl-insoluble AS. Strong inhibitors of AS filament assembly (IC50 values of <10 μM) 
belong to polyphenols. They include baicalein, delphinidin, dopamine chloride, epigallocatechin 
gallate, exifone, (-)-gallocatechin, (-)-gallocatechin gallate, gossypetin, hinokiflavone, hypericin, 
procyanidin B1, procyanidin B2, rosmarinic acid and theaflavine. The common structural feature 
among them is that they contain adjacent phenolic OH groups. It has been suggested that at least 
two adjacent phenolic OH groups may be required for the inhibition of AS filament formation 
via covalent modification. 23 out of the 27 inhibitory polyphenols identified in this study have 
two adjacent phenolic OH groups. The substitutions of hydroxyl groups on the aromatic benzene 
are very important to increase their solubility and their tendency for hydrogen bond interaction. 
For example, exifone (2,3,3',4,4',5'-Hexahydroxybenzophenone) which contains six hydroxyl 
substitution in both benzene rings has the lowest IC50 (2.5 μM) among polyphenols. The IC50 of 
2,3,4-trihydroxybenzophenone which has three hydroxyl group on just one of its benzene ring is 
increased to 18.6. In the absence of hydroxyl groups the hydrophobic structure binds to the NAC 
part of α-synuclein and triggers its misfolding (Masuda et al., 2006). 
In another study a library of 127 compounds was screened to identify AS fibrilization 
inhibitors. Fourteen compounds out of fifteen inhibitors were catecholamines, including 
dopamine (DA), L-DOPA, norepinephrine, and epinephrine. The common structural feature is 
that all of them have dopamine as their backbone and contain substituted groups on at least one 
of the following atoms: amine group, carbon alpha and carbon beta. The results showed that the 
adjacent phenolic hydroxyl groups of the catechol moiety are critical for the inhibitory function 
of the compound and modification of them leads to loss of function. Removal of one or both of 
the adjacent phenolic hydroxyl groups and exchanging one of them with methoxy or hydroxyl-
ethyl leads to loss of inhibitory function. Eight out of 15 inhibitors have a hydroxyl group on 
carbon beta. A hydroxyl group on the beta carbon (Figure 4.5, Figure 4.6) of catecholamines 
might increase the binding affinity of the ligand to the target molecule (Conway et al., 2001).  
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Figure 4.5 Structure of catecholamine which shows the amine group, adjacent phenolic hydroxyl 
groups, alpha and beta carbon 
Furthermore it has been demonstrated that micromolar concentrations of dopamine or L-dopa 
can significantly inhibit fibril formation or disaggregate existing fibrils of AS in vitro (Li et al., 
2004). The reason for choosing dopamine as an anti-fibrillization agent in this thesis was that it 
is an endogenous catecholamine which is synthesized from L-tyrosine and its pharmacokinetics 
are known. Epinephrine and norepinephrine  are other endogenous catecholamines which prevent 
the aggregation of AS by stabilizing oligomers of AS (Masuda et al., 2006). These 
catecholamines belong to the adrenergic drug family. As adrenergic drugs produce effects 
similar to those produced by the sympathetic nervous system, they are also called 
sympathomimetic drugs. Common functions of catecholamines are stimulation of the nervous 
system, constriction of the peripheral blood vessels, increase heart rate and dilation of the 
bronchi (Springhouse, 2008). The advantage of using endogenous chemicals such as dopamine 
as anti-fibrillization agents is that the molecular function and pharmacokinetics of these 
chemicals are already established. Because these chemicals have a primary physiological target, 
AS can be their secondary target. Thus these chemicals can act as dual function agents to 
maintain the peripheral autonomic system and the central nervous system and also to prevent the 
AS fibrillization. Their inhibitory effects on AS fibrillization and also their safety for animal 
studies make catecholamines an important group of chemicals to screen lead compounds for 
designing new and efficient anti-fibrillization agents.  
The results of this thesis showed that dopamine causes folding of AS monomers into a new 
conformation and previous work demonstrated that dopamine has the ability of preventing 
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fibrillization by stabilizing oligomers of AS. The limitation of using endogenous catecholamines 
such as dopamine as therapeutics is that they cannot be taken orally because digestive enzymes 
can destroy them. As all catecholamines contain hydroxyl and amine groups, they are polar 
molecules.  Thus, at physiological pH they are protonated and will not cross the blood brain 
barrier easily, so that in effect the catecholamine pools in the brain and in the periphery will not 
interfere with each other (Golan et al., 2007; Springhouse, 2008). It is possible to modify them 
chemically in order to overcome their limited absorbance and also increase their half-life in the 
brain (see below).  
Another group of compounds with anti-fibrillization activity are anti-Parkinson’s disease 
drugs such as L-DOPA, entacapone, tolcapone and selegiline (Braga et al., 2011; Di Giovanni et 
al., 2010). Entacapone and tolcapone block the fibril formation (Di Giovanni et al., 2010) and 
selegiline lengthens the nucleation phase of fibril formation (Braga et al., 2011). These drugs 
stabilize the oligomers of AS and lead to formation of nontoxic species (Braga et al., 2011; Di 
Giovanni et al., 2010). It has been demonstrated that micromolar concentration of L-DOPA can 
inhibit fibril formation of AS in vitro (Li et al., 2004). The advantage of using these drugs as 
anti-fibrillization agents is that all of them are FDA approved, have known pharmacokinetics and 
pharmacodynamics, and are administrated for PD patients to control the PD symptoms (Grosset 
et al., 2009; Seth and Seth, 2009). As dopamine is not able to cross the BBB, Levodopa which is 
its immediate precursor is admitted. Levodopa is transported across BBB by a large neutral 
amino acid transporter. In striatal tissue, L-dopa is decarboxylated to dopamine by L-aromatic 
amino acid decarboxylase. L-dopa is also a precursor of norepinephrine and epinephrine (Seth 
and Seth, 2009). The half-life of levodopa is short so to prevent its catabolism in peripheral 
tissues Monoamine oxidase-B (MAO-B) inhibitors such as selegiline and catechol O-methyl 
transferase (COMT) inhibitors such as tolcapone and entacapone are used as adjuncts to 
levodopa/carbidopa therapy (Pahwa and Lyons, 2007; Seth and Seth, 2009).   
4.2.2 Proposed strategies to prevent AS aggregation  
From the above several lead compounds are available. Overall a good lead compound 
candidate for designing more efficient anti-fibrillization agents is L-DOPA because it is the 
precursor of dopamine and is administrated to maintain the dopamine depletion in PD patients. 
Furthermore it does not have the dopamine administration limitations and can be absorbed 
rapidly and pass the BBB. PD patients take the anti-fibrillization agent such as L-DOPA, 
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entacapone, tolcapone and selegiline together as their regular treatment for PD. Co-
administration of L-DOPA with other drugs increases the half-life of this molecule in the brain. 
However, the experiments performed in this thesis showed that the Kd of dopamine and AS 
interaction (285 µM) (Figure 3.26) is higher than the normal cytoplasm dopamine concentration 
(0.5-2.2 µM) (Olefirowicz and Ewing, 1990; Perlman and Sheard, 1982). This shows that the 
affinity of dopamine for AS is low and a series of chemical modifications are required to 
increase this affinity. Thus the structure of dopamine can be considered as the pharmacophore 
because it contains the minimum functional groups (catechol and amine) which are required for 
binding to the target sites (Figure 4.6) (Herrera et al., 2008). In Figure 4.6, R1 and R2 groups 
represent the positions of substituent modifications to increase the affinity of dopamine for AS. 
As soon as the active inhibitor is designed its prodrug can be proposed by adding a carboxyl 
group on carbon alpha (Figure 4.6). As the proposed active inhibitor has a positive net charge at 
physiologic pH adding a carboxyl group makes it neutral and facilitates its absorption by the 
large neutral amino acid transporter from gut wall and the final transportation by a similar 
transporter across the BBB (Seth and Seth, 2009). The logP of the prodrug would be less than the 
active molecule which will facilitate its absorption (Patrick, 2009; Seth and Seth, 2009). In 
striatal tissue the prodrug undergoes decarboxylation and is converted to the active anti-
fibrillization molecule. 
 
Figure 4.6 The pharmacophore and the substituent groups (R1 and R2) which are considered to 
improve the binding affinity of the pharmacophore to the target motif. 
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 Another drug design strategy is to find an anti-fibrillization lead compound among the 
natural compounds found in plants. For example, it has been reported that nicotine, caffeine and 
curcumin reduce the incidence of PD (Altman et al., 2011; Ascherio and Chen, 2003; 
Checkoway et al., 2002; Darvesh et al., 2012; Hernán et al., 2002; Kessler and Diamond, 1971; 
Mythri and Bharath, 2012; Postuma et al., 2012; Quik, 2004; Ross et al., 2000; Ross and 
Petrovitch, 2001). It also has been reported that nicotine and curcumin inhibit AS fibril formation 
by stabilizing AS oligomers (Ahmad and Lapidus, 2012; Hong et al., 2009; Singh et al., 2012).  
As these natural chemicals are parts of the daily diet of most people, their structure can be used 
as lead compounds to design new anti-fibrillization agents. Our results showed that (-)-nicotine 
and caffeine at the concentration of 10 μM shifted the AS translocation peak from -86 pA to -60 
pA and -80 pA (Figure 3.31a,b). These small molecules can be used as candidates to design a 
new drug as an AS misfolding inhibitor using a fragmentation drug design approach (Hajduk and 
Greer, 2007; Joseph-McCarthy et al., 2014). The blockade current histogram showed an increase 
in the intensity of the peak centered at -25 pA when both drugs are present (Figure 3.31d) in 
comparison with (-)-nicotine (Figure 3.31b) and caffeine (Figure 3.31c) and also the intermediate 
peaks in the presence of nicotine and caffeine were disappeared (Figure 3.31b,c). This new peak 
might represent a new conformation of AS which cannot complete the aggregation process. 
Thus, these small molecules could be connected together using a linker like the linker of the 
curcumin molecule (Figure 1.19b). The new drug, caffetine, (Figure 4.7) would possess the 
features of both caffeine and nicotine and might be used as a new therapeutic to prevent AS 
misfolding and aggregation. The effect of the new synthesized drug on AS misfolding and 
aggregation must be evaluated using nanopore analysis, NMR spectroscopy and the ThT assay to 
characterize the biochemical mechanism. ITC can be used to measure the dissociation constant 
of the interaction. As the goal in fragment based drug design is to increase the efficacy of the 
interaction (Hajduk and Greer, 2007; Joseph-McCarthy et al., 2014), the results of in vitro 
experiments with the combined drug must be compared with the individual drugs.  Then cell 
culture assays and animal models can be used to measure the IC50 of this drug and also to 
evaluate its safety. 
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Figure 4.7 Structure of caffetine which results from connection of caffeine and (-)-nicotine using 
curcumin linker.  
Another group of anti-fibrillization agents are β-sheet breaker peptides (Amer et al., 2006; 
Soto, 2003). Since protein aggregation, which is the result of protein–protein interactions is very 
specific, preventing these interactions is a feasible strategy to cure and treat PD (Kim et al., 
2009). One of the approaches that could attack AS misfolding and aggregation is destabilization 
of the pathological β-sheet conformation of misfolded proteins, for example by using β-sheet 
breaker peptides to inhibit and reverse the protein misfolding process (Figure 4.8) (Amer et al., 
2006; Soto, 2003). Beta-sheet breakers are modified synthetic peptides based on the native 
sequences of amyloid peptides or proteins that are able to bind to the native proteins. These short 
peptides are designed to arrest the folding of the polypeptide chain in a β-sheet structure and to 
prevent the conversion of native protein or peptide sequences into the β-sheet-rich aggregate (El-
Agnaf et al., 2004; Soto, 2003).  
 
 
Figure 4.8 Schematic representation of inhibition and reversal of protein misfolding by β-sheet 
breaker peptides which are shown in brown (Soto, 2003). Copyright © 2003 Nature Publishing 
Group. All rights reserved. 
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A part of the hydrophobic region or NAC (amino acids 68–78: “GAVVTGVTAVA”) has 
been determined as the critical binding site for AS. The identified binding region has been used 
for the design of homologous short peptides which would interact with the same region in the 
full-length AS molecule, and prevent its misfolding and aggregation by stabilizing the unfolded 
monomers (Abe et al., 2007; El-Agnaf et al., 2004).  Missense mutations which reduce or 
remove fibril formation of AS are another approach to identify the critical aggregation motifs in 
AS. Six self fibrillation-defective mutants (V66S, V66P, T72P, V74E, V74G, and T75P) have 
been identified to block fibrillation of wild-type/PD-linked AS molecules completely. The 
flanking regions of these mutants can be used as peptide inhibitors to stabilize the unfolded 
monomers of AS (Choi et al., 2011; Kim et al., 2009; Koo et al., 2009). The disadvantage of 
these peptides is that they are hydrophobic. A strategy to overcome this limitation is to place 
hydrophilic residues at one or both termini to increase the solubility of them. For example 
hydrophilic residues, arginine and glycine, can be placed at the N-terminus and the C-terminus of 
the synthetic peptides (Amer et al., 2006; El-Agnaf et al., 2004). This strategy which produces 
positively-charged peptides is an efficient peptide design technique for nanopore studies. As the 
electrophoretic movement of positively-charged small peptides is away from the pore, they will 
not produce a significant signal during the experiment. Using this approach a library of β-sheet 
breaker peptides can be designed and their interaction with AS can be studied using nanopore 
analysis. The limitation of peptide drugs is that they are substrates for peptidase enzymes and 
will be degraded before reaching the target. To overcome this limitation, D-amino acids could be 
used instead of the L-amino acids to synthesize the peptides (Welch et al., 2007).  
AS is a natively unfolded protein and lacks any 3D binding pockets which are found in folded 
proteins with 3D structure. Interaction of a ligand with AS involves binding of the ligand to a 
group of neighboring or long-distanced residues and causing that region to make a loop around 
the ligand. The binding region is determined by the ligand biochemical properties such as 
polarity, hydrophobicity and structure. In 1996 a group of artificial receptors were designed with 
the ability to bind to specific moieties in a polymer (Klärner et al., 1996). As these horseshoe 
shaped molecules were able to enfold their specific target groups, they were called “molecular 
tweezers” (Fokkens et al., 2005; Klärner et al., 1996). Later in 2005 a lysine-specific molecular 
tweezer (CLR01) was synthesized (Figure 4.9, Figure 4.10a) which specifically binds to lysine 
residues with a Kd of 20 μM. This molecular tweezer features a rigid horseshoe shaped cavity 
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with two nonpolar wings and two rotatable peripheral anionic phosphates attached to the joint of 
the structure (Figure 4.9, Figure 4.10a) (Acharya et al., 2014; Attar et al., 2014; Attar et al., 
2012; Ferreira et al., 2014; Fokkens et al., 2005; Prabhudesai et al., 2012; Sinha et al., 2012a; 
Sinha et al., 2011a; Sinha et al., 2012b; Talbiersky et al., 2008).  
 
Figure 4.9 Structure of CLR01 bound to a lysine side-chain (blue) (Acharya et al., 2014). 
Copyright © 2014 American Society for Biochemistry and Molecular Biology. All rights 
reserved. 
Disordered proteins are mostly composed of disorder-promoting residues including polar and 
charged amino acids (glutamic acid, aspartic acid, lysine, arginine, glycine, glutamine, serine and 
proline) (Chiti and Dobson, 2006; Oldfield and Dunker, 2014; Theillet et al., 2013; Uversky, 
2011, 2013a, b). Among these residues, lysine has an important role in disordered proteins. For 
example, the “KKLVFF” motif in the central part of the β-amyloid peptide serves as the 
nucleation site which triggers the misfolding and aggregation (Fokkens et al., 2005; Sinha et al., 
2012b). Similarly, AS contains 7 repeats of 11-residue sequence, each containing a variant of the 
consensus 6-residue sequence “KTKEGV” (Auluck et al., 2010; Dikiy and Eliezer, 2012; Jo et 
al., 2000). These lysine residues also are involved in hydrophobic and electrostatic interactions 
which causes the misfolding and self-assembly of unfolded monomers (Sinha et al., 2012b). 
Targeting of these critical residues with lysine-specific molecular tweezers causes masking of 
lysine residues and stabilizes the unfolded conformation (Acharya et al., 2014; Attar et al., 2014; 
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Attar et al., 2012; Ferreira et al., 2014; Fokkens et al., 2005; Prabhudesai et al., 2012; Sinha et 
al., 2012a; Sinha et al., 2011a; Sinha et al., 2012b). Thus interaction of these groups of small 
molecules with lysine residues of unfolded proteins, may be an efficient strategy to target 
specific regions of unfolded proteins which lack regular cavity like binding sites (Acharya et al., 
2014; Attar et al., 2014; Attar et al., 2012; Ferreira et al., 2014; Fokkens et al., 2005; 
Prabhudesai et al., 2012; Sinha et al., 2012a; Sinha et al., 2011a; Sinha et al., 2012b; Talbiersky 
et al., 2008). These small molecules have been successfully used as anti-fibrillization agents to 
prevent the fibrillization of AS (Acharya et al., 2014; Attar and Bitan, 2014; Prabhudesai et al., 
2012), β2-Microglobulin (Attar and Bitan, 2014), islet Amyloid Polypeptide (IAPP) (Attar and 
Bitan, 2014), β-amyloid (Attar and Bitan, 2014; Attar et al., 2014; Attar et al., 2012; Sinha et al., 
2012a; Sinha et al., 2012b), insulin (Attar and Bitan, 2014), calcitonin (Attar and Bitan, 2014) 
and transthyretin (Ferreira et al., 2014) in both in vivo and in vitro systems. AS has 15 lysine 
residues which are distributed throughout the sequence as follow:  11 residues at the N-terminus, 
1 residue at the NAC region and 3 residues at the C-terminus. In vitro experiments using 
thioflavin T fluorescence, electron microscopy and in vivo experiments in a zebrafish model of 
AS have demonstrated that the CLR01 molecular tweezers prevents the misfolding of AS 
monomers into β-sheet-rich fibrils and also causes the disaggregation of pre-formed fibrils 
(Acharya et al., 2014; Prabhudesai et al., 2012). Mass-spectrometric analysis has revealed that 
CLR01 binds two lysine residues at the N-terminus (Lys-10 and/or Lys-12) (Acharya et al., 
2014). This molecular tweezers just masks two of the lysine residues at the N-terminus, while 
there are C-terminal lysine residues which can facilitate long range interaction of C- and N-
terminal and cause folding. Thus a possible strategy to increase the efficiency of CLR01 would 
be chemical modifications which increase its affinity for the C-terminus of AS. Our nanopore 
experiments with (-)-methamphetamine showed that this molecule binds to the C-terminal of AS 
(Figure 3.9b). The (l)-N-methyl-propan-2-amine moiety can be attached to the benzyl ring of one 
side of CLR01 in order to generate a (-)-methamphetamine analogue (Figure 4.10b). The (-)-
methamphetamine moiety attached to CLR01 might increase the affinity of the molecule for the 
C-terminal. Nanopore analysis, NMR spectroscopy, CD spectroscopy and ITC will be useful in 
assessing the efficacy of these new drugs.  
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Figure 4.10 Structure of CLR01 (a) and CLR01 with a (l)-N-methyl-propan-2-amine moiety 
attached to one of the side benzyl rings (b)  
From the above discussion it would appear that many lead compounds are available and that a 
suitable drug with high affinity and specificity will be available soon. Nanopore analysis will 
undoubtedly prove useful in evaluating the interactions of these drugs with AS.   
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